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Abstract  
The work reported in this thesis describes the characterisation of cell derived 
colonies from cancer cell lines and mechanisms of a key signalling pathway within 
these. PC3 cells were cultured at clonal density and resultant colony formation 
objectively described. Wnt signalling was investigated in colony types using a live 
[Ca2+]i assay. Exploratory work regarding ion channel gene and protein expression in 
3 prostate cancer cell lines was performed. Preliminary investigation on the effects of 
MPRC (membrane potential regulating compounds) was performed using a cell 
proliferation assay. PC3 prostate cancer cells form distinct colonies with different 
morphologies. These different colony types can be characterised using quantitative 
parameters such as cell density and percentage cellularity, unlike previously 
employed visual only characteristics. PC3 cells form two types of colonies from a 
single cell. In this thesis these are termed holo/meroclones and paraclones. Cells 
within both colony types respond to Wnt activation, demonstrated by a response in 
free intracellular calcium [Ca2+]i . In addition, there is a suggestion of increased 
expression of, and translocation into the nucleus of the transcription factor co-
activator β-catenin again in response to both Wnt 5A and Wnt 9B in both colony 
types. The characteristics of Wnt induced calcium release vary between different 
types of colonies. This is the first report of Wnt mediated [Ca2+]i release in response 
to both Wnt 5A and Wnt 9B in different PC3 colony types and the first report 
suggestive of β-catenin translocation following Wnt activation in colonies derived 
from stem-like cells. 
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Chapter 1: Introduction 
 
 
1.1 The Prostate  
 
The prostate is a small gland forming part of the male reproductive system. The 
function of the prostate gland is to produce secretions which form constituents of 
semen.  The prostate gland lies beneath the bladder and anterior to the rectum as 
shown in Figure 1. 
 
 
 
Figure 1. Anatomy of male reproductive system (From (http://www.salisbury.nhs.uk) 
 
 
The prostate gland has been divided into different anatomical lobes or zones 
(Griffiths, 1889; Walker, 1904). The former consists of the anterior lobe (or isthmus), 
posterior lobe, lateral lobes and median lobe. Zones include the peripheral zone, the 
central zone, the transition zone and the anterior zone (McNeal, 1988). As shown in 
Figure 2, the majority of prostate cancers are thought to occur in the peripheral zone, 
with cancers arising less commonly in the transition zone and very rarely in the 
central zone (De Marzo et al., 2007).  
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Pathology Prostate zone 
 Peripheral Transition Central 
    
Benign prostatic hyperplasia None High 
prevalence 
Low 
prevalence 
High grade intra-prostatic neoplasia Medium - 
high 
prevalence 
Medium 
prevalence 
Low 
prevalence 
Prostate carcinoma Medium - 
high 
prevalence 
Medium 
prevalence 
Absent  
 
 
Figure 2. Zones of the prostate gland and incidence of hyperplasia, high grade intra-prostatic 
neoplasia and cancer occurring within these zones. 
Modified from: (De Marzo et al., 2007). 
 
Ejaculatory 
duct a Central zone  
b  Fibromuscular zone 
c Transitional zone 
d  Peripheral zone 
e  Periurethral gland 
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1.2 Prostate cancer  
 
Prostate cancer is the most frequently diagnosed cancer in men in the UK with 1 in 8 
men receiving a diagnosis of prostate cancer at some point in their lives (Prostate 
cancer UK, 2015). In 2014 there were over 46 000 men diagnosed with prostate 
cancer in the UK and over 11 000 deaths from the disease (CRUK, 2014 ). 
Internationally, prostate cancer represents one fifth of all male cancer diagnoses with 
over 1,100,000 men around the world diagnosed in 2012 (Ferlay et al., 2010; WCRF, 
2015 
) A proportion of patients who initially received curative treatment will relapse and a 
further group have advanced metastatic disease at presentation.  
 
Standard initial treatment in this situation is hormone therapy with androgen 
deprivation therapy. This may be achieved either surgically with bilateral 
orchidectomy or more commonly medically with either luteinising hormone releasing 
hormone (LHRH) agonists or antagonists (Huggins, 1942; Klotz et al., 2008). 
Typically, after a 2 – 3 years of hormone treatment, prostate cancer becomes 
resistant to androgen deprivation therapy (Sharifi et al., 2010). Advances in past 
decade with new agents such as abiraterone and enzalutamide have meant more 
systemic treatments are available for patients with castrate resistant prostate cancer 
(Beer et al., 2014; Ryan et al., 2013). Recent trials such as the STAMPEDE  study 
have also demonstrated the benefit of augmentation of systemic therapy with the 
addition of abiraterone or docetaxel in the castrate sensitive setting in both 
progression free and overall survival (James et al., 2017; Sweeney et al., 2015). 
However, a clinical need remains for effective, non-toxic, targeted therapies to treat 
and improve outcomes for men with high risk and metastatic prostate cancer.  
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1.3 Stem cells and cancer stem cells  
1.3.1 Stem cells 
 
Stem cells are undifferentiated  cells which demonstrate an ability to undergo self-
renewal and potency (Perin and Silva, 2006). The former relates to repeated cell 
division producing the same undifferentiated cell type. Potency is the ability to 
produce terminally differentiated cells of different lineages. Stem cells have been 
divided into two types: embryonic stem cells (totipotent or pluripotent) are isolated 
from the inner cell mass of blastocysts and adult stem cells (multipotent) found in 
various adult tissues (Evans and Kaufman, 1981).  
 
1.3.2 Adult stem cells  
 
Adult stem cells demonstrate self-renewal and potency - the potential to differentiate 
to form all the functional cell types within a tissue (Mackillop et al., 1983; Pittenger et 
al., 1999). Stem cells are maintained by symmetrical cell division producing two 
identical stem cell daughters (Mackillop et al., 1983). Asymmetric division of stem 
cells may occur and this produces 2 cells with different characteristics: one cell 
identical to the original stem cell and a second cell programmed to differentiation 
(Miller et al., 2005; Pittenger et al., 1999). Adult stem cells maintain organ 
homeostasis that involves continuous replacement of differentiated cells (Mackillop 
et al., 1983). Stem cells differentiate into transit amplifying cells which then 
differentiate further into multiple cell types depending on this cascade of 
differentiation (Miller et al., 2005). As these cells progressively differentiate they 
become irreversibly committed to one of that particular tissue‟s cell type. This 
hierarchal process of stem cell maintenance and differentiation is described in Figure 
3.  
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Figure 3. Adult stem cell hierarchy and the process of self-renewal of a stem cell and the 
process of differentiation through cell division into cells of distinct lineage.  
Proliferating cells are indicated with a blue nucleus, differentiated cells with a red nucleus. 
Blue arrows represent cell damage and regeneration. Figure adapted from Tetteh et al (Tetteh 
et al., 2015).  
 
1.3.3 Prostate stem cells 
 
Stem cells and stem cell markers have been most extensively characterised in 
systems with active self - renewal and cell turnover, such as the haemopoietic 
system and gastrointestinal system (Scoville et al., 2008; Zon, 2008). However, 
since Professor Donald Coffey‟s important early work in the 1980s we now have a 
body of evidence for stem cells in the prostate.  
 
The prostate gland increases in size with age. One theory states that with increasing 
age there may be an increase in the number of prostatic stem cells or in the clonal 
expansion of stem cells into amplifying and transit cells (Isaacs and Coffey, 1989). 
Early work suggesting the prostate gland has a subpopulation of cells capable of 
self-renewal and differentiation was in the prostate of rats, where androgen 
20 
 
suppression induced apoptosis of secretory epithelial cells and androgen 
replenishment induced cell proliferation (Evans and Chandler, 1987). This cycle of 
prostate regression and regeneration can be repeated more than 30 times, indicating 
the existence of a population of surviving stem cells (Isaacs et al., 1987). 
 
Prostate stem cells are thought to differentiate into basal, luminal secretory and 
neuroendocrine distinct lineages (Kasper, 2008). Of these, prostate stem cells are 
thought to reside in the basal compartment (Rodgers CH, 1987). In human prostate 
tissue, the majority of proliferative cells are basal cells expressing Bcl-2 and cells 
where overexpressing of Bcl-2 gene protein had reduced levels of nuclear androgen 
receptor (Bonkhoff et al., 1998).  
 
De Marzo et al (De Marzo et al., 1998) investigated the role expression of p27Kip1 
may play in prostate carcinogenesis. In human benign epithelial prostate tissue 
widespread moderate to strong nuclear staining of p27Kip1 was observed whilst the 
potential stem cell harbouring basal cell compartment showed lower and more 
variable pattern of p27Kip1 expression. As well as basal cells, high-grade prostatic 
intraepithelial neoplasia and invasive carcinoma also demonstrated down-regulation 
of p27Kip1 compared with the surrounding normal secretory cells (De Marzo et al., 
1998).  
 
Shalken et al (Schalken and van Leenders, 2003) have described variability in 
expression of keratin (K) markers in the prostate based upon anatomical location as 
well as degree of cell differentiation. Basal cells strongly expressed K5, but only 
weakly expressed K18. Conversely, luminal cells strongly expressed K18. A 
proportion of basal cells coexpressed K5 and K14. Poorly differentiated stem cells in 
the basal layer were positive for K5 and K14, with weak expression for K18 whilst 
moderately differentiated cells expressed K5 and K18. The authors noted that 
prostate cancers demonstrated the same pattern of keratin expression as 
intermediate differentiated stem cells, potentially suggesting the role of these cells in 
prostate cancer carcinogenesis (Schalken and van Leenders, 2003).  
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In a mouse model, PTEN was found to regulate p63-positive prostatic basal cell 
proliferation without blocking differentiation (Wang et al., 2006). Basal cell 
proliferation was observed in this model with increased proliferation of a 
subpopulation of Sca-1 and Bcl-2-positive prostate stem/progenitor cells (Wang et 
al., 2006). 
 
Prostate stem cells are therefore thought to demonstrate distinctive expression of 
proliferation markers including telomerase, p63 and p27Kip1  
and  identification of these markers may therefore potentially be used to identify stem 
cells (Kasper, 2008).  
 
Prostate stem-like cells with increased prostate regenerative capacity have been 
identified with specific markers from mice (Xin et al., 2005). Using a single cell 
suspension derived from murine prostates, Sca-1+ cell fractions implanted under the  
kidney capsule of severe combined immunodeficient (SCID) mice produce much 
larger grafts with more prostatic structures than implantation of Sca-1- cell fractions 
(Xin et al., 2005). Other markers identifying cells with colony forming efficiency 
include α2β1, CK5 / CK14 with lack of expression of markers prostate specific 
antigen and prostatic acid phosphatase (Collins et al., 2001) and CD133 expression 
within a cell population expressing α2β1 (Richardson et al., 2004). Overexpression 
of the transcription factor NANOG in cancer cell lines Du145, LNCaP and MCF-7 
have led to increased drug resistance and other pro-tumorigenic effects associated 
with upregulation of CD133 (Jeter et al., 2011). 
 
Stem cell-like ability of self-renewal of murine prostate cells has been demonstrated 
in vitro using a sphere-forming assay as well as in mouse in vivo (Xin et al., 2007). 
Only a proportion of murine prostate epithelial cells were able to form spheroid 
structures when cultured in Matrigel, and when dissociated these cells were able to 
produce further spheres (Xin et al., 2007). Expression of CD24, CD49f, and Sca-1 
was present in sphere forming cells. These sphere forming cells were tested in an in 
vivo assay and were able to form prostate murine tissue when injected 
subcutaneously into SCID mice (Xin et al., 2007).    
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Further work undertaken by my group aimed to determine which of these markers 
were most associated with cells which demonstrated stem-cell like characteristics 
such as spheroid colony-forming ability (Yamamoto et al., 2012).  Subpopulations of 
cells positive for the previously noted markers: CD49f+, CD44+, and CD133+ 
differed in their propensity to behave as spheroid colony-forming cells . Expression 
of CD49f+ was highly accurate in identifying cells which were stem cell like in their 
spheroid colony-forming ability (Yamamoto et al., 2012).  
 
1.3.4 Cancer stem cells and prostate cancer stem cells  
 
The existence of cancer stem cells has also been proposed  as a theory to explain a 
population of cancer cells with stem cell-like characteristics (Lapidot et al., 1994; 
Mani et al., 2008; Tai et al., 2005). Cancer stem cells are described as being a 
subpopulation of cells within a tumour able to self-renew and form a heterogeneous 
population of cancer cells (Clarke et al., 2006). The heterogeneity of cancer cells 
produced from cancer stem cells results in the disparate biology of cells observed 
within a tumour (Clarke et al., 2006; Reya et al., 2001a). There are parallels in the 
capabilities of self-renewal in stem cells and cancer stem cells (Reya et al., 2001a). 
 
Putative prostate cancer stem cells have been sorted and enriched from a population 
of cells using their cell surface marker expression. Cells of primary human prostate 
cancers and prostate cancer cell lines isolated by  fluorescence-activated cell sorting 
(FACS) for the presence of CD44+/α2β1hi/CD133+ demonstrate increased colony 
forming and sphere forming efficiency (Collins et al., 2005; Gu et al., 2007). For 
example, in experiments using cell lines and cells derived from human prostate 
cancer xenograft tumours, Patrawala et al (2006), reported that prostate cancer cells 
which are CD44(+) demonstrate increased proliferation and clonogenic, tumorigenic, 
and metastatic characteristics compared with CD44(-). CD44(+)  cells also express 
elevated  mRNA levels of stem cell genes such as Oct-3/4, BMI, and β-catenin 
(Patrawala et al., 2006). In addition, CD44(+)  prostate cancer cells can produce 
CD44(-) cells in vitro and in vivo and CD44(+) cells which are AR(-) and can 
differentiate into AR(+) cells (Patrawala et al., 2006).  
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In experiments utilizing in vitro culturing techniques, the ability of a single cell to form 
a colony can be assessed (Puck and Marcus, 1955). Colony forming assays are 
commonly used to differentiate between cell types; it has been proposed that in cell 
culture cancer stem-like cells have the ability to form colonies derived from single 
cells (Pfeiffer and Schalken, 2010).  
 
1.3.5 Prostate cancer cell line colonies  
 
PC3 is a human prostate cancer cell line originating from a bone metastasis in a 
patient with advanced prostate cancer (Kaighn et al., 1979). The colony forming 
ability of PC3 cells and the differential behaviours of distinct colonies which are 
derived from single cells has been investigated (Li et al., 2008; Zhang and Waxman, 
2010). Upon culturing PC3 cells at low density (1 cell / 32mm2 clonal density), the 
emergence of distinctive colonies has been observed (Li et al., 2008; Zhang and 
Waxman, 2010). These colonies have been described to resemble colonies 
reminiscent of keratinocyte cultures that form holoclones, meroclones and 
paraclones (Barrandon and Green, 1987). Holoclones were colonies characterised 
as consisting of small tightly packed cells; paraclones were larger colonies 
comprised of less cells; meroclones were colonies in between in size and number of 
constituent cells (Li et al., 2008; Zhang and Waxman, 2010). Zhang et al (2010) 
reported appearances of these 3 colony types formed from single PC3 cells as 
shown in Figure 4.   
 
 
Figure 4. Image showing 3 morphologically different colony types formed from culture of 
single cell plated PC3 cells.  
Colony types were described as holoclones, meroclones and paraclones as shown (Zhang and 
Waxman, 2010).  
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Li et al (2008), describe and categorised colonies obtained from culturing PC3 cells 
at low density in  single wells of a culture dish: 10% were holoclones, 22% 
meroclones and 68% paraclones  (Li et al., 2008). As shown in table 1, cells of these 
3 different colony types demonstrated different biological properties. Clones were 
followed and after 8 weeks, proliferative ability varied between colony types: 6 of 7 
holoclones continued to proliferate well, 11 of 16 meroclones continued to proliferate 
well, but only 1 of 49 paraclones continued to proliferate well. Four weeks later, of 
these colonies investigated, only the 6 holoclones continued to proliferate and no 
meroclones or paraclones. In addition, cells of holoclones were able to produce 
colonies of all 3 types when re-plated at clonal density (Li et al., 2008). 
 
Table 1. Survival of PC3 cell colonies. 
Three colony types were described and cultured for 8 weeks by Li et al (2008). Holoclone 
colony type had the highest survival and paraclone colony type the lowest survival rate.  
 
Colony Type  Survival  Aborted 
   
Holoclone 6/7 (85.7%) 1/7 (14.3%) 
Meroclone 11/16 (68.8%) 5/16 (31.2%) 
Paraclone 1/49 (2.0%) 48/49 (98.0%) 
 
 
Colonies derived from PC3 cells have a differential ability to initiate tumours and 
sustain serial tumour transplantation (Li et al., 2008). PC3 and PC3-GFP cells 
initiated tumours in a manner dependent on number of cells injected. A high 
incidence of tumours was induced when cells derived from 3 holoclones were 
injected into NOD/SCID mice. Cell populations derived from 2 meroclones did not 
induce tumours, and for paraclones it was difficult to yield a sufficient number of 
cells, but these did not induce tumours. When tumours induced by holoclone injected 
were harvested, these were able to serially induce secondary and tertiary tumours. 
Furthermore, Li et al, 2008, suggest that upon re-plating tumour derived cells at 
clonal density, all 3 colony morphologies were observed (Li et al., 2008). As such the 
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PC3 holoclones exhibited some characteristics of cancer stem cells whilst PC3 cells 
derived paraclones did not.  
 
Plating cells at low density with the formation of distinct colonies has been used in in-
vitro work as a surrogate stem cell assay (Li et al., 2008; Locke et al., 2005; Pfeiffer 
and Schalken, 2010). In Li et al‟s (2008) work discussed above, holoclones 
expressed the stem cell and progenitor marker proteins CD44, A2b1 and β-catenin 
whilst paraclones did not express these markers (Li et al., 2008). 
  
The formation of 3 distinct colony types (holoclones, meroclones, and paraclones) 
has been demonstrated in other prostate cancer cell lines when plated at clonal 
density (Pfeiffer and Schalken, 2010). Cell lines DU145, 22Rv1, LAPC-4, DuCaP, 
and LNCaP form these morphologically distinct colony types.  Examples of colonies 
formed by DU145 and LNCaP cells are shown in Figure 5 (Pfeiffer and Schalken, 
2010).  
 
 Holoclone Meroclone Paraclone 
DU145 
 
  
LNCaP 
   
 
Figure 5. Colony morphologies observed in prostate cancer cell lines DU145 and LNCaP.  
Pfeiffer et al reported that both DU145 and LNCaP formed three morphologically different 
colonies: holoclones, meroclones and paraclones (Pfeiffer and Schalken, 2010). Scale: Bar 
measures 200 µm.   
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1.4 Wnt Signalling 
 
Wnts (a name derived from Drosophila wingless and int-1)(Siegfried and Perrimon, 
1994) are a family of secreted glycoprotein ligands that subsequent to binding to 
Frizzled (Fz) receptors activate a cascade of intracellular processes (Logan and 
Nusse, 2004; Niemann et al., 2004). The two major intracellular transducers of Wnt 
signalling are calcium (Ca2+) and a transcription factor co-activator protein called β-
catenin (CTNNB1). Wnt signalling is involved in the regulation of cellular processes 
such as proliferation, development and disease, including carcinogenesis (Boyden et 
al., 2002; Fearon and Vogelstein, 1990; Logan and Nusse, 2004; Niemann et al., 
2004). Wnt signalling comprises several signal transduction pathways subsequent to 
the binding of a Wnt glycoprotein to a Fz receptor, which via the intracellular protein 
Dishevelled, transmits a downstream signalling cascade.  
 
Wnt signalling plays an important role in stem cell functions such as self-renewal and 
differentiation (Reya and Clevers, 2005; Reya et al., 2003; Willert et al., 2003).  The 
particular interest of investigation in this project was the role Wnt signalling may play 
in carcinogenesis. An early idea was that if active, Wnt signalling may regulate 
cancer stem cells or population of cells with stem like characteristics in cancer cell 
lines, known as cancer stem-like cells (Kondo, 2007). 
 
1.4.1 Categorisation of Wnt pathways 
 
A number of Wnts have been identified and Wnt signalling is implicated in a range of 
biological processes. Wnts have historically been categorised according to the 
physiological functions they exert.  
 
Using a Xenopus embryo assay in which the expression of certain Wnts on the 
ventral aspect of the embryo induces the formation of a secondary dorsal body axis 
(Christian et al., 1991; McMahon and Moon, 1989). Injection of Xenopus embryo with 
murine Wnt 1 RNA was found to consistently produce a phenotype of embryonic axis 
duplication (McMahon and Moon, 1989). The same phenotype was observed in this 
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assay upon injection of ectopic mRNA encoding Xwnt 8 (Christian et al., 1991) and 
Xwnt3A  (Wolda et al., 1993). However, overexpression of Xwnt 5A in Xenopus 
embryos results in a different phenotype with altered cell movements, malformations 
in the head and tail, but no duplication of the embryonic axis (Moon et al., 1993). 
Subsequently, mRNA Xwnt 4 and Xwnt 11 were found to produce an identical 
phenotype to Xwnt 5A. As such, Xwnt 1, 3A, and 8 were placed in one functional 
class and Xwnt 4, 5A, and 11 in another (Du et al., 1995). 
 
Another important assay in the categorization of Wnts was based on their ability to 
induce transformation in a mammary epithelial cell line derived from normal mouse 
mammary tissue, C57MG (Wong et al., 1994). Expression constructs of murine Wnt 
genes were transfected into C57MG cells and transformation entailing cells 
becoming elongated and with disorganised growth pattern was assessed for each 
murine Wnt gene. Wnt 1, Wnt 3A, and Wnt 7A demonstrated frequent transformation 
to this morphology; Wnt 2, Wnt 5B, and Wnt 7B demonstrated a lower efficiency of 
transformation; Wnt 4 and Wnt 6 demonstrated little or no ability to induce 
transformation; and Wnt 5A demonstrated no ability at all to transform C57MG cells 
(Wong et al., 1994). As such, these findings were consistent with the observations in 
Xenopus embryos that Wnts may be categorised into functionally distinct groups, or 
“classes”. 
 
Some Wnt ligands are able to induce release of intracellular Ca2+ ([Ca2+]i). In 
zebrafish embryos, injection of Xwnt 5A mRNA induces [Ca2+]i release, whilst ectopic 
expression of Xwnt 8 does not (Slusarski et al., 1997b). Protein kinase C (PKC) 
isoforms respond to Ca2+ signalling and as such modulation of PKC by Wnts was 
investigated in Xenopus embryos, where again a differential effect is seen: Ectopic 
expression of Xwnt 5A was able to induce PKC localization and activity far more than 
Xwnt 8 (Sheldahl et al., 1999). 
 
Cellular responses induced by Wnts, such as those described above have been 
found to be influenced by other factors such as Frizzled (Fz, see 1.2.1.1 below) 
receptors. In the Xenopus embryos assay, co-injection of Xwnt 5A RNA and hFz5 
RNA induced secondary axis formation (He et al., 1997). In the early 1990s it was 
known that β-catenin played an important role in cell fate downstream of a Wnt 
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ligand receptor signal, and overexpression of β-catenin is also able to induce axis 
duplication (Guger and Gumbiner, 1995). 
 
In addition, certain Wnts have been shown to antagonise the function of others. The 
interaction between the Wnt 5A class and Wnt 1 class signalling pathways by co-
expressing members of both classes together was demonstrated in Xenopus 
embryos. Injection of RNAs encoding members of the Wnt 5A class antagonized the 
embryonic responses to ectopic expression of the Wnt  1 class (Torres et al., 1996).
  
This antagonistic effect of some Wnts on the functional effects of others supported 
the model of multiple Wnt signalling pathways responsible for disparate cellular 
responses. 
 
1.4.2 Pathways of Wnt Signalling - The canonical (β-catenin) Wnt pathway 
 
The key element of the canonical Wnt pathway is the regulation of β-catenin protein 
levels and thus regulation of transcription of β-catenin dependent target genes 
(Behrens et al., 1996) (Molenaar et al., 1996). 
 
Wnt proteins bind to Fz receptors; there are 7 members of the Fz family of integral 
cell membrane proteins. Each Wnt may bind to a number of Fz receptors and one 
receptor may bind to several Wnt proteins. (Bhanot et al., 1996) With Wnt - Fz 
binding there is co-operation with co-receptors of the low-density lipoprotein receptor 
(LDLR)-related protein (LRP) family i.e. LRP5 or LRP6.  
 
In the absence of Wnt ligand activation, levels of cytosolic and nuclear β-catenin are 
controlled via protein phosphorylation and ubiquitination. Essential to β-catenin 
degradation is a destruction complex composed of Axin / GSK-3 / APC. Scaffold 
proteins are often involved in the regulation of signalling pathways by interacting or 
binding with other members of a pathway and tethering them into complexes. Here, 
Axin is such a scaffold protein, interacting with GSK3, CK1 α and APC. CK1α 
phosphorylates β-catenin at serine 45, which then leads to GSK3-mediated β-
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catenin phosphorylation at threonine 41, serine 37 and serine 33 (Kimelman and Xu, 
2006). 
 
The S-phase kinase - associated protein 1 p19 (SKP1) / Cullin / F-box complex (SCF 
complex) is an ubiquitin ligase complex and the F-box component, B-TRCP, 
recognises phosphorylated β-catenin. This complex catalyses the ubiquitination of β-
catenin, following which β-catenin degradation occurs (Kimelman and Xu, 2006). 
APC may also play a role in the β-catenin ubiquitination as in a colon cancer cell line, 
a truncated form of APC is functional in β-catenin phosphorylation but inhibited β-
catenin ubiquitination and degradation (Yang et al., 2006).  
 
On Wnt signalling activation, Dsh (Dishevelled) a cytoplasmic phosphoprotein is 
activated and interaction between LRP5/6 and Axin, a process mediated by 
phosphorylation of LRP by Casein kinase 1γ (CK1γ) (Gary et al., 2005). A significant 
consequence of Axin binding with LRP and Dsh with Fz, is that the APC complex 
becomes unable to function as a kinase for β-catenin.   
 
As β-catenin is constitutively transcribed and translated, this inhibition in degradation 
leads to elevated cytosolic levels of unphosphorylated, stable β-catenin which may 
lead to its entry into the cell nucleus. Within the nucleus β-catenin binds to the N 
terminus of LEF/TCF (lymphoid enhancer factor/T cell factor) transcription factors 
resulting in expression of Wnt target genes (Behrens et al., 1996; Van de Wetering 
et al., 1997).  
 
Functional APC is critical in the regulation of β-catenin by the destruction complex. 
The colon cell line SW480 with mutant APC has high levels of β-catenin. 
Transfection of SW480 cells with wild-type APC, results in a decrease of β-catenin 
staining on immunofluorescence. The ability of several APC constructs to down-
regulate β-catenin was investigated and it was found that the presence of the central 
region of the protein was essential for the down regulation of β-catenin (Munemitsu 
et al., 1995). Consistent with these findings, mutant APC genes‟ protein products 
present in colorectal tumours have been found to be defective in their ability to 
reduce β-catenin activity (Morin et al., 1997). 
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The importance of the regulation of this pathway in cancer is critical as demonstrated 
by the fact that both Axin and APC are, likely, tumour suppressor genes and 
mutations in the latter are highly prevalent in colorectal carcinoma (He et al., 1998). 
 
 Translocation of β-catenin into nucleus 1.4.2.1
 
The mechanism by which stabilized β-catenin, a 92kDa protein, translocates from 
the cytoplasm to the nucleus is not yet fully understood (Thrasivoulou et al.). In 
general for eukaryotic cells, the size limit for molecules that can permeate the 
nuclear envelope through the nuclear pore complex (without a nuclear envelope 
specific translocation mechanism, e.g. expenditure of energy or receptor mediated 
translocation), is <10kDa (Mazzanti et al., 2001). Nuclear pore complexes are large 
proteins which span the nuclear envelope. The complex allows water soluble 
molecules such as metabolites and proteins with a diameter of ≤ 10 kDa to permeate 
through the nuclear membrane. However, proteins > 10kDa require a mediated 
mechanism for nuclear import (Gerace and Burke, 1988; Mazzanti et al., 2001). This 
process is dependent on nuclear location sequences (NLSs) - amino acid sequences 
- which are recognised by importins, or karyopherins proteins which dock the protein 
to the nuclear pore through which there is translocation of the protein into the 
nucleus in an energy dependent manner (Gerace and Burke, 1988), (Fagotto et al., 
1998). 
 
β-catenin has no NLS but shares functionally important Armadillo amino-acid repeats 
with importin / karyopherins. In colorectal cell lines, β-catenin has been shown to 
interact directly with nuclear pore complex components (Shitashige et al., 2008). The 
Armadillo sequence binds to specific regions of the NPC, and silencing of these 
regions of the NPC reduces the rate of both β-catenin import and export (Sharma et 
al., 2012). Nuclear import can be inhibited by importin (Fagotto et al., 1998; Kim et 
al., 2000). Through binding to β-catenin, cadherins have been found to inhibit β-
catenin/TCF signalling (Fagotto et al., 1996; Gottardi et al., 2001). There may be 
inhibition of the transcriptionally active signalling pool of β-catenin without 
significantly reducing the protein‟s total levels in the cytosol or nucleus. In SW480, a 
colorectal cancer cell line, E-cadherin inhibits β-catenin/TCF signalling and SW480 
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tumour cell growth (Gottardi et al., 2001). In Drosophila, as well as its role in the 
destruction complex, axin has been found to retain β-catenin in the cytoplasm 
(Tolwinski and Wieschaus, 2001).  
 
 β-catenin mediated gene transcription 1.4.2.2
 
When there is a lack of nuclear β-catenin, TCF/LEF proteins act as inhibitors to 
transcription and bind to members of the Groucho/TLE family (Brantjes et al., 2001; 
Chen and Courey, 2000). In man there are for four TCF transcription factors; TCF1, 
LEF1, TCF3 and TCF4 (Galceran et al., 2000; Kim et al., 2000; Korinek et al., 1998; 
Verbeek et al., 1995). There are four full-length human Groucho homologues: TLE -
1, -2, -3 and -4 (transducin-like enhancer of split) and one truncated variant: hAES 
(for amino-terminal enhancer of split) (Palaparti et al., 1997; Stifani et al., 1992). β-
catenin accumulation in the nucleus results in its interaction with DNA-bound 
TCF/LEF transcription factors as a co-activator. In a number of benign and malignant 
cell lines, several TLE and TCF family members are expressed but there is no 
suggestion of specificity in the interaction between them (Brantjes et al., 2001). In 
fact, β-catenin and TLE appear to directly compete for LEF-1 binding and β-catenin 
is able to displace Groucho/TLE from TCF/LEF (Daniels and Weis, 2005).  
 
Phosphorylation may also play an important role in mediating TCF transcriptional 
activity. NLK (NEMO-like kinase), through TAK1 (TGF-β-activated kinase) activation, 
phosphorylates TCF and represses activation of β-catenin mediated transcriptional 
activation in human embryonic kidney 293 cells (Ishitani et al., 1999). The kinase 
CK1 binds to and phosphorylates LEF-1 resulting in structural changes in the 
LEF1/DNA complex and disruption of the association of LEF1 with β-catenin, whilst 
not diminishing LEF1 DNA binding.  Using reporter gene assays, in HEK293 cells, 
CK1e is found to have repressor and CK2 activator effects on the transcriptional 
activity of the LEF1/β-catenin complex (Hämmerlein et al., 2005). 
 
TCF/LEF may also be subject to ubiquination. NARF, (a Nemo-like Kinase (NLK)-
associated Ring Finger Protein) induces the ubiquination of TCF/LEF and this is 
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enhanced by NLK. In 293 cells, NARF negatively regulates TCF/LEF-dependent 
transcriptional activity (Yamada et al., 2006). 
 
Nuclear co-factors may also play a role in mediating Wnt transcription. In Drosophila, 
legless (lgs) and pygopus (pygo) mediate Wnt transcription, with lgs as a recruiter of 
pygo to β-catenin (Kramps et al., 2002). In man the human homolog of lgs is BCL9. 
In cell lines, BCL9 may act independently of pygo, and its effects are cell type 
speciﬁc; for example in lymphoid cells BCL9 enhances transcriptional activity 
significantly compared with its effect in ﬁbroblastic cells (Sustmann et al., 2008). 
 
 Wnt-β-catenin target genes 1.4.2.3
 
There are numerous known target genes of Wnt / β-catenin mediated gene 
transcription. These are most notably and typically described as being functionally 
important in stem cell maintenance, terminal differentiation and carcinogenesis (Fevr 
et al., 2007; He et al., 1998; Kinzler et al., 1991; Nusse, 2008).  
 
Wnt signalling target genes implicated in the aetiology of cancer are of particular 
research interest; understanding these processes may lead to the development of 
new therapies in the management or possibly prevention of the disease.   
The literature regarding Wnt / β-catenin signalling target genes is summarised in 
table 2 and figure 6 below. 
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Table 2. Putative target genes under the transcriptional regulation of the β-catenin co-transcription factor. 
The table below describes these genes, the system they have been studied in, and the mechanism by which their effect occurs. 
 
 
Gene 
 
 
System studied in 
 
Effect 
 
 
Up / down 
Regulated 
 
 
Reference 
c-myc 
 
 
 
 
Human colon cancer 
 
 
 
 
In colorectal cancer cell line HT29 (in which 
wild-type APC can be induced), APC mutations 
increase β-catenin / TCF 4 activity and lead to 
overexpression of c-myc. Wild type APC and a 
dominant-negative TCF 4 reduced c-myc 
expression.  
up 
 
 
 
 
(He et al., 
1998) 
 
 
 
n-myc Vertebrate limb 
development 
In mouse limb buds, n-myc expression is co-
localized to the zone of proliferating cells in the 
limb; when n-myc is absent, cell division in this 
region decreases. Wnt 3a induces a proliferative 
effect in the forelimb bud of wild-type but not n-
myc-/- limb buds. 
up (ten Berge et 
al., 2008a) 
 
Cyclin D1 
 
Human colon cancer 
 
Cyclin D-1 is elevated in a third of human colon 
cancers. Cyclin D1 promoter has a LEF1 
up (Shtutman et 
al., 1999) 
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binding site. In colorectal cancer cell line 
SW480, cyclin D1 is repressed by wild type 
APC. 
 
HELA cells and human 
colon cancer 
In HELA cells, β-catenin activates transcription 
from the cyclin D1 promoter, and transcription is 
augmented by p21ras. Mutant β-catenin cells 
constitutively produce elevated cyclin D1 mRNA 
and protein. Colorectal cancer cell line HCT116, 
dominant-negative TCF 4 inhibits cyclin D1 
expression and arrests cells in G1 cell cycle 
phase, which is rescued by cyclin D1 
expression.  
up (Tetsu and 
McCormick, 
1999) 
TCF 1 
 
 
 
Human colon cancer In colorectal cancer cell line HT29, APC 
expression decreases TCF 1. TCF 1 −/− mice 
develop intestinal and mammary adenomas. 
TCF 1 may provide negative feedback to 
regulate β-catenin / TCF target genes. 
up (Roose et al., 
1999) 
 
LEF1 Human colon cancer 
 
LEF 1 is activated in colon cancer but not 
expressed in normal colonic tissue. 
 
β-catenin / TCF induces transcription from the 
up Hovanes et 
al., 2001 
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LEF 1 promoter. 
Human embryonic 
kidney cells  
β-catenin / TCF induces transcription from the 
LEF 1 promoter. 
up (Filali et al., 
2002) 
PPARdelta Human colon cancer APC induction inhibits β-catenin / TCF 4 
regulated transcription of PPARδ. 
up (He et al., 
1999) 
c-jun Human colon cancer Colorectal cancer cell lines transfected with β-
catenin increases gene expression of c-jun, fra-
1 and urokinase-type plasminogen activator 
receptor (uPAR). c-jun is a component of the 
AP-1 transcription factor complex.  
up (Mann et al., 
1999) 
Fra 1 Human colon cancer Colorectal cancer cell lines transfected with β-
catenin increases gene expression of c-jun, fra-
1 and urokinase-type plasminogen activator 
receptor (uPAR). 
Fra 1 is a component of the AP 1 transcription 
factor complex.  
up (Mann et al., 
1999) 
uPAR Human colon cancer Colorectal cancer cell lines transfected with β-
catenin increases gene expression of c-jun, fra-
1 and urokinase-type plasminogen activator 
receptor (uPAR). uPAR‟s transcription is 
activated by AP 1. 
up (Mann et al., 
1999) 
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In patients with primary colorectal cancer and 
liver metastases, uPAR and β-catenin 
expression levels are concomitantly increased 
in tissue from both sites. 
matrix metalloproteinase 
MMP-7 
Human colon cancer The promoter of the human invasion associated 
gene, MMP-7 has 2 TCF binding sites.  The 
Human MMP-7 Promoter is activated by β-
catenin / TCF 4 and suppressed by a dominant-
negative TCF 4 mutant in colon cancer cells. 
MMP-7 expression correlates with that of β-
catenin in tissue from patients with hereditary 
and sporadic colon cancer. 
up (Brabletz et 
al., 1999) 
Human colon cancer In colon cancer cell lines, MMP-7 promoter 
activity is up-regulated by β-catenin, particularly 
in those cell lines with a low level of 
endogenous β-catenin /TCF, and is dependent 
on an optimal TCF 4 recognition site. Co-
expression of E-cadherin (thought to be an 
inhibitor of Wnt signalling) reduces MMP-7 
promoter activity. 
up (Crawford et 
al., 1999) 
Axin-2 / Hnkd  Human colon cancer In a colon cancer cell line with stabilised β- up (Yan et al., 
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catenin due to truncated APC, reducing 
cytosolic β-catenin reduces levels of axin 2 and 
human naked cuticle (hnkd) mRNAs. Compared 
with benign colon cells, >60% of human colon 
cancers cells demonstrate elevated levels of 
axin 2 and hnkd mRNA.  
In cancer cells where expression of axin2 and 
hnkd mRNA was increased, mutations in APC 
were present. 
2001) 
 
 
 
 
 
 
 
Nr-CAM Various cell lines 
including human 
malignant melanoma 
and human colon 
cancer  
Nr-CAM is induced by β-catenin in various cell 
types and LEF/TCF binding sites in the Nr-CAM 
promoter are required for this activation. Nr-
CAM and β-catenin target gene, LEF 1 
expression is increased in human colon cancer 
tissue and cell lines and malignant melanoma 
cell lines, but not in benign melanocyte cell lines 
or benign colon tissue.  
up (Conacci-
Sorrell et al., 
2002) 
ITF-2 RK3E cell line 
(epithelial rat kidney), 
human ovarian cancer 
tissue 
Mutant β-catenin promotes malignant 
transformation in the RK3E cell line. Class I 
bHLH protein ITF-2 is activated in these cells 
but not in cells transformed through other 
up (Kolligs et al., 
2002) 
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pathways. β-catenin mediated induction of ITF-2 
is inhibited by a mutant dominant negative TCF 
4.  
In a colorectal cell line, APC activity suppresses 
ITF-2 expression. In human ovarian cancer 
tissue with defects in β-catenin regulation, there 
are increased levels of ITF-2A and ITF-2B 
transcripts compared to ovarian cancer without 
aberrant β-catenin regulation.  ITF-2B induces 
neoplastic transformation in RK3E cells.  
Gastrin Human colon cancer In colorectal cell lines induction of wild-type 
APC reduces gastrin mRNA expression. In 
HELA cells, co-transfection of a constitutively 
active β-catenin expression construct 
increases gastrin promoter activity; this activity 
can be inhibited by a dominant-negative TCF 4 
expression construct.  In APC (min-/+) mice, an 
increase in colonic polyps is observed in those 
which overexpress a form of gastrin, whilst in 
mice lacking gastrin, a reduced number of 
polyps is observed.  
up (Koh et al., 
2000) 
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CD44 Human and mouse 
benign and cancerous 
colon  
CD44 is overexpressed in human adenomas 
and carcinomas. In APC mutant mice, CD44 is 
expressed in the crypt epithelium of normal 
intestine, in adenomas and in invasive 
carcinomas. In APC-mutant mice, aberrant crypt 
foci with dysplasia overexpress CD44 and the 
same is observed in humans with familial 
adenomatous polyposis. In TCF 4−/− mutant 
mice there is no expression of CD44 in the 
small intestine epithelium.  
up (Wielenga et 
al., 1999) 
EphB/ephrin-B Human colon cancer EphB2/EphB3 are receptor tyrosine kinases. 
Gene expression of the ligand Ephrin-B1 is 
upregulated upon inhibition of β-catenin / TCF. 
down (van de 
Wetering et 
al., 2002) 
BMP4 Human colon cancer In a colorectal cell line, gene expression of 
BMP4 is lower in clones lacking β-catenin than 
in parental cells. In APC mutant colon cancer 
cell lines, BMP4 levels are high. BMP4 
expression is elevated in colon cancer cell lines 
compared with benign colonic tissue. 
up (Kim et al., 
2002) 
claudin-1 Human colon cancer In colon cancer cell lines, when β-catenin is 
reduced through introduction of wild-type APC 
up (Miwa et al., 
2001) 
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in APC-deficient cells, expression of CLDN1 is 
in turn reduced. CLDN1 transcription occurs 
through TCF 4 binding sites. There is increased 
expression of CLDN1 in human colorectal 
cancer compared with benign tissue.   
Survivin Human colon cancer In a colorectal cell line, induction of wild-type 
reduces survivin mRNA and protein expression. 
Dominant-negative TCF 4 reduces survivin 
expression. 
up (Zhang et al., 
2001)  
VEGF Human colon cancer A VEGF-pGL2-basic luciferase vector construct 
is active in colon cancer cell lines with 
endogenously activated Wnt signalling. In the 
same cell lines, dominant negative TCF 4 co-
transfection reduces VEGF promoter activity. A 
similar suppression of VEGF is not observed in 
293 kidney cells.  
up (Zhang et al., 
2001) 
FGF18 Human colon cancer FGF18 gene expression is elevated in human 
colorectal cancer tissue compared with benign 
tissue. In colon cancer cell line SW480, FGF18 
expression is reduced by dominant negative 
TCF 4. 
up (Shimokawa 
et al., 2003) 
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Hath1 Human colon cancer Hath1 expression is relatively high in benign 
colon and small intestinal tissue but is down-
regulated in cancers arising from these sites.  
Hath1 expression is low in colon cancer cell 
lines. In a colon cancer cell line, inhibition of 
Wnt signalling through transient expression of 
wild-type APC and dominant negative LEF 1 
increases Hath1 expression.  
down (Leow et al., 
2004) 
Met Human colon cancer The receptor tyrosine kinase, met, is 
overexpressed in human dysplastic aberrant 
crypt foci, adenoma and in carcinoma of the 
colon. In colorectal cancer cell lines, dominant-
negative TCF reduces met expression. 
up (Boon et al., 
2002) 
endothelin-1 Human colon cancer In a colorectal cell line, when APC is induced, 
EDN1 mRNA levels are reduced. In another 
colorectal cancer cell line (HCT116), lithium 
treatment which inhibits GSK3B and stabilizes 
β-catenin increases EDN1 mRNA. Dominant-
negative TCF 4 or β-catenin reduce EDN1 
peptide secretion. EDN1 is overexpressed in 
human colon cancers. 
up (Jung and 
Kim, 2005) 
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c-myc binding protein Human colon cancer, 
human corneal 
epithelial cell 
In a colon carcinoma cell line (DLD-1) and a 
corneal epithelial cell line (HCE), LEF 1 
overexpression up-regulates c-myc binding 
protein gene.  
up (Jung and 
Kim, 2005) 
L1  Human colon cancer L1, transmembrane cell adhesion molecule, is 
expressed in SW480 and HCT116 colorectal 
cell lines; sparsely growing cells express higher 
levels of L1 than densely growing cells. In 293 
cells, L1 promoter activation is increased by 
mutant stabilized β-catenin and is inhibited by 
dominant negative LEF 1. In a colorectal cell 
line, β-catenin suppression results in reduction 
in L1. 
up (Gavert et al., 
2005) 
Id2 Human colon cancer Id2 is expressed in human colonic adenomas 
but not in normal colonic tissue. There is a 
concordance in Id2 β-catenin expression in 
crypts.  Colon cancer cell lines with TCF 
reporter TOPFLASH activity express Id2. Over-
expression of β-catenin in HEK-293 cells 
increases expression of Id2.  
In colorectal cell line SW480 which has an APC 
up (Rockman et 
al., 2001) 
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mutation and high nuclear β-catenin, 
reintroduction of wild type APC protein reduces 
Id2 promoter activity.  
Jagged  Human colon cancer Notch is a family of transmembrane receptors. 
Wnt and notch inhibition in CRC cell line Ls174T 
down–regulate a number of genes. The Notch 
ligand, jagged, is highly expressed in Ls174T 
but dominant negative TCF 4 reduces jagged 
mRNA and protein, and activated Notch1. 
Jagged1 mRNA levels is elevated in human 
adenomas in those with FAP, compared with 
normal intestinal tissue. Pattern of expression 
correlates with regions also demonstrating 
nuclear β-catenin staining, together with Notch 1 
and Notch2.  
up (Rodilla et al., 
2009) 
Msl1 
translation inhibitor 
protein, Musashi1 (MSI1) 
Human colon cancer In colorectal cancer cell line HCT116 with wild-
type allele of β-catenin (HCT116βw), reducing 
APC mRNA and protein levels results in an 
increase in MSI1 mRNA and protein. 
APC mRNA is a target of translational inhibition 
by MSI1. Knockdown of MSI1in HCT116βw 
up (Spears and 
Neufeld, 
2011) 
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cells result in an increase in APC protein, and 
so in a negative feedback loop overexpression 
of wild-type Msi1 in HCT116βw cells decreases 
APC protein. 
Tiam1 Human colon cancer Tiam1 is a selective Rac GTPase activator 
expressed in cells at the base of small intestine 
crypts in wild type mice but uniformly in both 
polyps of APC mutant mice and in human colon 
adenomas.  In human CRC cell line, DLD1, 
inhibition of TCF reduces Tiam1 mRNA and 
protein. Exogenous expression of both Wnt 1 
and β-catenin in RIE (a rat intestinal epithelial 
cell line) cells increases Tiam1 protein. 
 (Malliri et al., 
2006) 
Nitric Oxide Synthase 2 Human colorectal 
cancer cell lines and a 
liver cancer cell line 
 
Hepg2 cells 
There are 2 TCF 4-binding elements (TBE1 and 
TBE2) in the promoter of human inducible NO 
synthase 2 (NOS2). In human colorectal cancer 
cell lines and a liver cancer cell line, β-catenin 
/TCF 4 specifically binds to these TBEs. 
Overexpression of β-catenin and TCF 4 
expression plasmids increase NOS2 promoter 
activity. In colorectal cancer cell line HCT116, 
up (Du et al., 
2006) 
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overexpression of TCF 4 or β-catenin increases 
NOS2 mRNA and protein whilst dominant-
negative TCF 4 decreases NOS2 mRNA and 
protein expression. Similarly, LiCl inhibition of 
GSK-3β increases NOS2 protein expression in 
primary human hepatocytes.  
Telomerase Mouse ES cells TERT is part of the telomerase complex which 
controls telomere length. Tert mRNA and 
protein is reduced in β-catenin–deficient mouse 
ES cells. Wnt 3a stimulation of wild-type ES 
cells increases Tert expression. Reduction in 
Tert expression and telomerase activity 
produces shortened telomeres in β-catenin–
deficient cells.  
up (Hoffmeyer et 
al., 2012) 
Dickkopf Various cells, tumours DKK1 is known to be an inhibitor of Wnt 
signalling. There are 9 nine putative TCF-
binding sites on the DKK1 promoter. In various 
cell lines (MCF-7, MDA-MB-453, HeLa) 
activation of canonical signalling by Wnt 1 or 
ectopic β-catenin or TCF 4 induces transcription 
of DKK-1. Non-canonical Wnt 5a does not 
up (Gonzalez-
Sancho et al., 
2005) 
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activate DKK1. Inactivation of TCF4 suppresses 
DKK-1 promoter activation. However, DKK-1 is 
down-regulated in human colon tumours as 
compared to normal tissue.  
FGF9 Ovarian endometrioid 
adenocarcinoma 
A proportion of primary ovarian endometrioid 
adenocarcinomas (OEA) have constitutive 
activation of Wnt signalling. FGF20 and FGF9 
are up-regulated in OEAs with deregulated β-
catenin / TCF signalling compared with those 
with intact signalling. Two OEA-derived cell 
lines demonstrate increased expression of 
FGF9. FGF9 is overexpressed by Wnt 1, β-
catenin and LiCl GSK3β inhibition, whilst 
dominant-negative TCF 4 reduces expression.  
up (Hendrix et 
al., 2006) 
FGF20 293 cells, ovarian 
endometrioid 
adenocarcinoma,  
Xenopus 
FGF20 RNA is normally only present in the 
adult central nervous, but is also present in 
several human colon cancers and in a β-catenin 
mutant ovarian endometrioid cell line. In 293 
cells and primary ovarian endometrioid 
adenocarcinomas, stabilised β-catenin leads to 
overexpression of FGF20 and DKK1. 
up (Chamorro et 
al., 2005) 
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LBH 293 cells, breast cancer 
cells 
 
In human 293T embryonic kidney epithelial 
cells, Wnt 3a induces Lbh and Dkk1 expression 
and is abrogated by depletion of β-catenin. Wnt 
5a and Wnt 7a treatment reduce Lbh and Dkk1 
expression. Mammary tumours from MMTV-Wnt 
1 mice have elevated Lbh expression compared 
with normal mammary cells and HC11 mouse 
mammary epithelial cell line.  
up (Rieger et al., 
2010) 
LGR5 (Leucine-rich-
repeat-containing G-
protein-coupled receptor 
5); Gpr49 
Intestine Dominant-negative TCF 4 suppresses 
expression of LGR5. There is some expression 
of LGR5 in the crypts of mouse small intestine.  
up (Barker et al., 
2007) 
Sox9 Intestine SOX proteins are a family of high mobility group 
box transcription factors. In mouse neonate and 
adult intestine, of these SOX9 is over-expressed 
particularly in proliferative regions. SOX9 mRNA 
and protein are expressed in CRC cell lines.  
In colorectal cancer cell line LS174T, dominant 
negative TCF 4 suppresses SOX9 mRNA and 
protein expression.  Additionally, SOX9 
suppresses the intestinal differentiation genes 
up (Blache et al., 
2004) 
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CDX2 and MUC2. 
Sox17 Gastric and colonic 
tumours  
Gan mice develop gastric tumours via Wnt / β-
catenin signalling and such tumours express 
several Wnt target genes including Sox17.  
Sox17 is expressed in human gastric adenomas 
but less so in carcinomas. Similar findings are 
observed in colon polyps and carcinomas. 
Sox17 inhibits β-catenin / TCF activity in a 
human gastric cancer cell line. Wnt signalling 
induces Sox17 in early tumourigenesis. 
up (Du et al., 
2009) 
Runx2 Chick chondrocytes In chick chondrocytes, Wnt 8c, Wnt 9a, and β-
catenin overexpression up-regulates RunX2 
mRNA and produces chondrocyte hypertrophy. 
β-catenin and LEF 1 over-expression induce 
Runx2 promoter activation whilst a mutation in 
the TCF / LEF binding site of Runx2 inactivates 
its response to β-catenin. 
up (Dong et al., 
2006) 
 
 
Gremlin  Human and mouse 
fibroblasts 
In Wnt responsive human lung fibroblasts, Wnt 
3a increases expression of GREMLIN2, the 
gene for secreted bone morphogenetic protein 
(BMP) antagonist. 
up (Klapholz-
Brown et al., 
2007) 
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SALL4 Check cell lines  
 
2102 EP embryonal 
carcinoma cells and 
epithelial ovarian 
cancer OVCAR-3 cells. 
HEK293 cells  
The product of SALL4 is thought to be a 
transcription factor, and mutations of the gene 
cause a rare syndrome (Okihiro/Duane-Radial 
Ray syndrome) associated with various 
malformations. In 2102 EP embryonal 
carcinoma cells and epithelial ovarian cancer 
OVCAR-3 cells, LEF 1 and TCF 4E activate the 
SALL4 promoter, whilst mutation of the TCF / 
LEF-binding site reduces activation. 
up (Böhm et al., 
2006) 
Osteoprotegerin Mouse Osteoblasts Osteoprotegerin (Opg), encodes a TNFα 
receptor which inhibits osteoclast differentiation. 
In mice with constitutively active canonical 
signalling in osteoblasts, osteoblastic 
expression of Opg is elevated in developing 
long bones. Opg expression is decreased 
in bones and osteoblasts of mutant mice 
deficient in β-catenin signalling. 
up (Glass Ii et 
al., 2005) 
CCN1/Cyr61 Mouse mesenchymal 
stem cells 
 
In a mouse mesenchymal progenitor line, 
CCN1/Cyr61, CCN2/connective tissue growth 
factor (CTGF), and CCN5/WISP2, are up-
regulated in response to Wnt 3a.  
up (Si et al., 
2006) 
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Pituitary tumour 
transforming gene 
(PTTG) 
Human oesophageal 
squamous cell 
carcinoma 
PTTG mRNA is overexpressed in human 
oesophageal squamous cell carcinoma (ESCC), 
as well as human ESCC and other malignant 
cell lines. β-catenin is localised in the cytoplasm 
in malignant ESCC compared to on the 
membrane in benign tissue. Most ESCCs 
exhibiting cytoplasmic accumulation of β-catenin 
also demonstrate overexpression of PTTG.   
Mutant constitutively active β-catenin activates 
PTTG promoters, which are inhibited by 
dominant-negative TCF 4. Corresponding 
elevation and inhibition of PTTG mRNA and 
protein are observed.  
up (Zhou et al., 
2005) 
Delta-like 1 Somites The Notch ligand Delta-like 1(Dll1) is a gene of 
the Notch-Delta signalling pathway, downstream 
of Wnt signalling. LEF 1 mutant mice exhibit a 
lowered expression of Mesp2, Notch 1 and Dll1. 
LEF 1 binding sites are present in Dll1. In a 
fibroblastic cell line, a LEF1–β-catenin fusion 
protein induces an elevation in the expression of 
Dll1.  
up (Galceran et 
al., 2004) 
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FoxN1 Thymus Proper development of the thymus requires 
expression of transcription factor FoxN1. Co-
culture of TEC cell lines transfected with a 
reporter with thymocytes, activates TCF / LEF1 
dependent transcription. Wnt 4 up-regulates 
FoxN1. Dominant-negative TCF 4 inhibits 
FoxN1 transcription.  
up (Balciunaite 
et al., 2002) 
matrix 
metalloproteinase-26 
Human lung cancer and 
fibrosarcoma cell lines 
Matrix metalloproteinases (MMPs) are important 
in remodelling and motility and their expression 
is usually well regulated. MMP-26 is expressed 
in common human epithelial cancers including 
lung, breast, endometrium, prostate cancer and 
their cell lines. A TCF 4 site was identified in the 
MMP-26 promoter. In human lung cancer and 
fibrosarcoma cell lines, mutation in the TCF 4-
binding site reduces transcriptional activity of 
the MMP-26 promoter. 
up (Marchenko 
et al., 2002) 
nanog ES  TCF 3 is highly expressed in murine ES cells 
where on TCF 3 knockdown there is increased 
expression of Oct4, Sox2, and Nanog. On 
treatment with Wnt 3a, Oct4 and Nanog gene 
up (Cole et al., 
2008) 
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expression increase. As such TCF 3 normally 
represses its target genes, with increased gene 
expression on Wnt stimulation.  
Oct 4 ES As above  up (Cole et al., 
2008) 
Snail Embryoid bodies of 
mouse ESCs 
In a Wnt reporter construct of embryoid bodies 
(aggregates of pluripotent stem cells), Wnt 3a 
up-regulates snail and fibronectin expression. 
Treatment with Wnt inhibitor Dkk1 reduces snail 
and fibronectin expression. 
up (ten Berge et 
al., 2008b) 
Fibronectin As above As above  up (ten Berge et 
al., 2008b) 
Follistatin Human embryonic 
carcinoma 
On treating human teratocarcinoma cells with 
Wnt 3a, several genes including follistatin are 
up-regulated. In NCCIT cells, Wnt 3a activates 
the follistatin promoter. Activation does not 
occur in the presence of a mutation in the TCF 
binding site on the Follistatin promoter.  
up (Willert et al., 
2002) 
receptor activator of 
NFkappaB ligand 
(RANKL or TNFSF11)  
Human and mouse 
osteoblastic cells  
Treatment of osteoblastic cells with 
LiCl (increasing β-catenin signalling) inhibits 
RANKL mRNA and protein expression. Wnt 3a 
down (Spencer et 
al., 2006) 
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produces the same response whilst non-
canonical Wnt 5A has no effect of RANKL 
expression. Similarly, β-catenin overexpression 
reduces RANKL promoter activity. 
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Figure 6. Figure summarising inactive canonical signalling (left) and active canonical 
signalling with target genes under the transcriptional regulation of the β-catenin (right). 
Modified from: (MacDonald et al., 2009). 
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1.4.3 Pathways of Wnt signalling: The non - β-catenin mediated pathways 
 
The most well described non-canonical pathway is the Wnt / Ca2+ pathway; a further 
non-canonical pathway is the Planar Cell Polarity (PCP) (Wnt – JNK) pathway. 
Ligands which activate the non-canonical pathways are: Wnt 4, Wnt 5a, and Wnt 11 
(Sheldahl et al., 1999; Slusarski et al., 1997a; Slusarski et al., 1997b).  
 
 Wnt / Calcium pathway 1.4.3.1
 
As discussed earlier in section 1.41, it was proposed that activation by some Wnts 
can induce free intracellular Ca2+ ([Ca2+]i) release, whilst other Wnts were only 
thought to mediate their effects through β-catenin signalling. Hence the designation 
of canonical and non-canonical pathways (Gonzalez-Sancho et al., 2005; Molenaar 
et al., 1996). 
 
The ability of a Wnt protein to produce a cellular response mediated by a Ca2+ 
response was originally studied in zebrafish embryos and Xenopus laevis. 
Expression of Rfz-2 (rat protein Frizzled-2), but not Rfz-1 increased Ca2+ release 
above basal levels from internal stores in zebrafish embryos. [Ca2+]i release has 
been shown to be elevated in response to Xwnt 5A (Slusarski et al., 1997a) but not 
Xwnt 8 (Slusarski et al., 1997b). Rfz-2 and Wnt 5A modulate Ca2+ flux through G 
proteins and phosphatidylinositol cycling, and their ability to induce Ca2+ release is 
sensitive to inhibition by G protein inhibitor pertussis toxin (Slusarski et al., 1997a).  
With regard to frizzled receptors, certain Fzs are associated with activation of either 
the canonical or non-canonical pathways. In Xenopus, ectopic expression of the 
homologs Rfz2, mouse Frizzled 3, mouse Frizzled 4 and mouse Frizzled 6 induced 
PKC membrane translocation in Xenopus but did not induce expression of β-catenin 
target genes siamois and Xnr3.  Ectopic expression of mouse Frizzled 7 and 
mouse Frizzled 8, and Rfz1, did not induce PKC translocation, but did induce 
expression of siamois and Xnr3 (Sheldahl et al., 1999). 
 
Wnt 5A interacts with its Fz receptors and also with receptor tyrosine kinase-like 
orphan receptor 2 (Ror2). The latter possess an extracellular cysteine rich domain 
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(CRD) similar to the Wnt binding site of Fz receptors. As such Ror2 is also a receptor 
for Wnt 5A through this CRD (Oishi et al., 2003).  Interestingly, Ror2−/− and Wnt 
5a−/− mice exhibit similar developmental abnormalities including dwarfism, facial 
abnormalities, and lung and genital dysplasia (Oishi et al., 2003). In NIH3T3 cells, 
both Wnt 5A and Ror2 increase activity of non-canonical mediator JNK. Co-
expression of both Wnt 5A and Ror2 produces a further increase in JNK activity 
(Oishi et al., 2003). 
 
Dishevelled is required for transduction of both canonical and non-canonical 
signalling (Theisen et al., 1994). Dsh‟s role in Ca2+ signalling has been demonstrated 
in Xenopus where a Dsh construct which is inactive in β-catenin signalling activates 
PKC, intracellular Ca2+ flux and Ca2+ / calmodulin-dependent protein kinase II. In 
Xenopus embryos, PKC activity enhanced by XFz-7 is inhibited by a domain of Dsh 
(Sheldahl et al., 2003). In the C-terminal DEP domain of the dsh1 allele, there is a 
single amino acid point mutation required for JNK and planar cell polarity signalling 
but not required for β-catenin dependent signalling. As such, Wnt / Fz signalling 
employs Dsh, after which intracellular signalling may have divergent downstream 
pathways (Boutros et al., 1998). 
 
In terms of Ca2+ signalling activating protein kinase C (PKC), Wnt and frizzled 
homologs have been found to differentially induce translocation of PKC to the 
plasma membrane and total PKC activity. For example, Xwnt 5A and Rfz2 induce 
PKC translocation with an increase in total PKC activity more than Xwnt 8 or Xwnt 
3A or Rfz1 (Sheldahl et al., 1999). 
 
Despite no direct measurement (e.g. the conventional approach of adding a ligand 
and measuring free cytosolic calcium release) of investigating this phenomenon, it 
was proposed that ability of certain Wnts and their Frizzled receptors to produce 
[Ca2+]i release and activation of PKC led to the proposition that the non-canonical 
Wnts may activate other Ca2+ sensitive kinases such as Ca2+ / calmodulin-dependent 
protein kinase II (CamKII), a serine /threonine protein kinase. In man, CamKII activity 
is described in a range of biological processes including malignancy which will be 
discussed later. However, it is most abundantly present in the neuronal system 
where it is involved in long-term potentiation signalling between neurones (Hudmon 
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and Schulman, 2002) and is also described in arrhythmia in cardiac disease (Mohler 
and Hund, 2011). In Xenopus embryos Xwnt 5A, Xwnt 11and Rfz2 induce CamKII 
activity. Conversely, Xwnt 8 and Rfz1, which signal through the β-catenin-dependent 
canonical pathway do not stimulate CamKII activity. Dominant negative Xwnt 11 
inhibits CamKII activity. As discussed, Rfz2 and Xwnt 5a induction of Ca2+ release is 
sensitive to pertussis (Slusarski et al., 1997a) and as expected, activity of CamKII in 
response to Xwnt 5A is also sensitive to pertussis. CamKII autophosphorylates upon 
activation and elevated autophosphorylation is observed with Xwnt 5A and Rfz2. 
CamKII activity is elevated on the ventral aspect of the Xenopus embryo and also 
functions in axis formation (Kühl et al., 2000). 
 
 Wnt/planar cell polarity pathway and Wnt / jun N-terminal kinase (JNK) 1.4.3.2
pathways 
 
Planar cell polarity describes the feature many cells possess of being arranged in a 
polarized fashion in the plane of a tissue. Though initially studied in Drosophila 
(Gubb and Garcia, 1982; Wong and Adler, 1993), planar cell polarity occurs within 
both epithelial and mesenchymal human tissue. 
 
The planar cell polarity pathway involves 2 sets of factors which are evolutionarily 
conserved: Frizzled (Fz) / Flamingo (Fmi) and Fat / Dachsous (Ds). In drosophila, 
planar cell polarity activation involves asymmetric redistribution of its core proteins - 
frizzled, flamingo, dishevelled, Stbm/Vang and prickle. In drosophila pupal wings, 
Dsh localization follows a particular pattern. Prickle acts to antagonize Fz and Dsh 
localization and magnifies the differences in  Fz / Dsh activity between adjacent cell 
surfaces.(Tree et al., 2002) 
 
In the drosophila wing, Fat provides directional information to the Fz-associated 
polarity alignment mechanism (Ma et al., 2003). Fat is a large (> 5000 amino 
acids) transmembrane cadherin receptor protein (Mahoney et al., 1991). Dachsous 
(Ds) is also a large (> 3500 amino acids), transmembrane protein that binds to Ft 
and the two proteins stabilize one another other on the cell surface (Matakatsu and 
Blair, 2004). In Drosophila, the gene four-jointed (Fj) encodes a protein kinase which 
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phosphorylates serine or threonine residues within extracellular cadherin domains of 
Fat and Dachsous, as such performing as a regulator of Fat signalling (Ishikawa et 
al., 2008).  
 
1.4.4 Pathways of Wnt signalling - A convergent Wnt pathway 
 
As discussed in section 1.4.2.1, the mechanism by which β-catenin, a negatively 
charged 92kDa protein, moves from the cytoplasm to the nucleus is not yet fully 
understood. Nuclear pore complexes are large proteins which span the nuclear 
envelope. The complex allows water soluble molecules such as metabolites and 
proteins with a diameter of ≤ 10 kDa to permeate through the nuclear membrane. 
However, proteins > 10 kDa require a mediated mechanism for nuclear import 
(Gerace and Burke, 1988; Mazzanti et al., 2001).   
 
Recently, a new, convergent pathway of Wnt signalling has been proposed in 
prostate, breast and urothelial cancer cell lines (Thrasivoulou et al., 2013) that 
proposes a convergent Wnt signalling pathway in mammalian cells and may also 
explain how a large protein such as β-catenin may enter the nucleus through the 
nuclear envelope. The ratio of Fluo4 / FuraRed dyes was used to quantify [Ca2+]i. 
The addition of Wnts of different classes – Wnt 3A; Wnt 4; Wnt 5A; Wnt 7A; Wnt 9B 
and Wnt 10B all induced [Ca2+]i release in whole populations of PC3 prostate cancer 
cell line.  A similar response was seen in breast cell line MCF7 and urothelial cell line 
253J and also COS7 (simian kidney cell line). Further to this, the “waveform” 
describing the rise, duration and fall of [Ca2+]i could be measured. For example, at 
the same concentration, Wnt 9B induced a longer period of elevated [Ca2+]i than Wnt 
5a did.  This [Ca2+]i response to Wnts 5A, 9B and 10B was not observed when cells 
were prior treated with thapsigargin, an inhibitor of endoplasmic reticulum Ca2+ -
ATPase which inhibits intracellular Ca2+ stores.  An increase in [Ca2+]i further 
resulted in elevated intranuclear Ca2+ concentration. Immunocytochemistry 
demonstrated increased expression of β-catenin in PC3 cells treated with Wnt 3A, 
Wnt 4, Wnt 5A, Wnt 9B, and Wnt 10B compared with untreated cells (Thrasivoulou 
et al., 2013).  
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Based on the above observations of [Ca2+]i response to Wnts, Thrasivoulou et al 
proposed a novel convergent, electrogenic model for Wnt signalling and an 
explanation for β-catenin protein may traverse the nuclear envelope (Thrasivoulou et 
al., 2013).  Wnt signalling induces an increase in intranuclear Ca2+ and 
depoloraisation of the nuclear membrane and is associated with elevated expression 
of nuclear β-catenin (Thrasivoulou et al., 2013). Conversely, incubation of cells with 
thapsigargin reduced the translocation of β-catenin into the nucleus. This suggests 
that the regulation of the nuclear membrane potential regulation of through ions such 
as Ca2+ may control the translocation of β-catenin into the nucleus and Wnt 
signalling (Thrasivoulou et al., 2013).  Patent (New British Patent Application no. 
1318659.8).  
 
1.5 Wnt signalling and cancer  
 
Of all malignancies, the role of the Wnt pathway in the aetiology of colon cancer has 
been most researched and through mechanisms outlined below, significant numbers 
of colon cancers are initiated due to aberrant Wnt signalling. Much of our 
understanding of Wnt signalling and the consequences of deregulated signalling on 
tumourigenesis is derived from this system.  However, Wnt signalling has now been 
implicated in a range of other solid tumours including lung, breast, head and neck, 
pancreas, ovarian, central nervous system, penile and prostate cancer. 
  
1.5.1 De-regulated Wnt signalling and cancer 
 
In 1925, Lockhart-Mummery, a surgeon at St Mark‟s hospital, London described the 
clinical features and family histories of 3 of his patients between the ages of 20-31 
presenting with extensive benign adenomatosis polyposis of the large bowel, each of 
whom had multiple family members who had died from colorectal cancer at a young 
age (Lockhart-Mummery, 1925). We now understand that this condition of familial 
adenomatous polyposis (FAP) is characterised by the development of multiple, 
benign, colonic polyps which develop into adenocarcinoma at an early age and is 
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caused by an autosomal dominant germline mutation of the APC gene on 
chromosome 5q21 (Kinzler et al., 1991; Nishisho et al., 1991).  
 
The effects of mutant APC have been studied in colon cancer cell line SW480 which 
has mutant APC and high levels of β-catenin throughout the cell. Transfection of 
SW480 cells with wild-type APC, results in a decrease of β-catenin staining on 
immunofluorescence. The ability of several APC constructs to down-regulate β-
catenin was investigated and it was found the presence of the central region of the 
protein was essential for the down regulation of β-catenin (Munemitsu et al., 1995). 
Consistent with these findings, mutant APC genes‟ protein products present in 
colorectal tumours have been found to be defective in their ability to reduce β-
catenin activity (Morin et al., 1997). 
 
As well as APC mutations, de-regulated β-catenin signalling may also occur from 
mutations in β-catenin itself (Morin et al., 1997). In 2 colorectal cell lines with full 
length APC, HCT116 and SW48, β-catenin / TCF–mediated transcription remains 
constitutively active, and is unaffected by wild-type APC.  However, these cells were 
found to have mutations in the β-catenin gene: HCT116 a 3-bp deletion removing 
amino acid Ser45 and SW48 a missense mutation that changing Ser33 to Tyr. In a 
series of primary colorectal cancers without APC mutations, over half the cancers 
were found to have β-catenin mutations thought to affect their ability to become 
phosphorylated (Morin et al., 1997). β-catenin mutants are highly inductive of β-
catenin / TCF mediated transcription (Morin et al., 1997).  
 
β-catenin stabilization and resultant activation of TCF-dependent transcription can 
also, though less commonly, occur as a result of mutation in Axin 2. This functional 
effect of mutant Axin 2 has been demonstrated in cell lines. A series of human 
colorectal tumours demonstrated Axin 2 mutations in a third of tumours with 
defective DNA mismatch repair. These tumours had β-catenin accumulation, whilst 
not possessing mutations in APC or CTNNB (Liu et al., 2000). 
 
The effect of APC in regulating β-catenin / TCF-mediated transcriptional activity has 
been investigated in colon cancer cell lines and several other systems. As discussed 
above in the description of Wnt target gene research, manipulation of the Wnt 
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signalling system by reducing APC function or treating with ectopic Wnts has led to 
the discovery of many Wnt target genes.  
 
1.5.2  Wnt and solid cancers other than colorectal cancer  
 
Wnt signalling has been investigated in prostate, colorectal, breast, lung, pancreatic, 
ovarian, gastric and penile cancer. Several studies have investigated Wnt signalling 
in prostate cancer tissue. Compared to benign prostate tissue, there is up-regulation 
of certain genes (SFRP4, Fz4, Fz6, DVL1, TCF4, and MYC) and down regulation of 
others (WNT2, WIF1, PPP2CB, CCND2, CD44) in prostate cancer. (Wissmann et 
al., 2003). Further work found Wnt 5a expression is elevated in prostate cancer 
tissue compared to benign tissue (Wang et al., 2010). Expression of Wnt 5A mRNA 
and Wnt5A protein was also increased in a prostate cancer cell line compared with a 
benign cell line. (Wang et al., 2010). Wnt 5A expression is greater in high grade 
cancers compared to cancers of lower grade Gleason 7 cancers or below. Wnt5a 
expression has been found to be prognostic and an independent predictor for 
prostate cancer relapse following radical prostatectomy (Yamamoto et al., 2010).  
 
Table 3 below lists our current understanding of the role of Wnt signalling in cancer.  
 
 
62 
 
 
Table 3. Wnt signalling in solid cancers. 
 
Tumour  
 
Investigated in 
 
Mechanism  
 
Wnt abnormality  
Prostate Human prostate 
cancer and benign 
tissue 
 
Cancer tissue 
demonstrates a differential 
in RNA expression of Wnt 
gene genes  
 
 
 
 
Comparison of Wnt genes expressed in prostate cancer tissue 
compared with benign tissue demonstrated up-regulation of certain 
genes (SFRP4, Fz4, Fz6, DVL1, TCF4, and MYC) and down 
regulation of others (WNT2, WIF1, PPP2CB, CCND2, CD44).  The 
most marked aberrant RNA expression in cancer were of 
Wnt inhibitory factor 1 (WIF1) and secreted frizzled related protein 
(SFRP4). SFRP4 was up-regulated in 81% of the tissues it was 
expressed in, whilst WIF1 was down regulated in 64%. There is also 
reduced expression of WIF1 protein in 23% of the prostate cancers 
analysed (Wissmann et al., 2003). 
Prostate cancer 
mouse model; 
human prostate 
cancer and benign 
tissue 
 
 
Wnt 5A acts as an 
activator carcinogenesis, 
potentially via AR 
signalling 
 
 
Using a mouse model, a mutation in the androgen receptor – AR 
T887A mutation – led to the formation of prostate cancer 
development. In such tumours, Wnt 5A was an activator for 
carcinogenesis. In human benign prostatic hyperplasia, Wnt 5A 
expression is normal whilst in prostate cancer tissue Wnt 5A levels 
are elevated. Co-localisation of AR proteins and Wnt 5A was 
specifically seen in in cancerous tissue (Takahashi et al., 2011). 
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Human prostate 
cancer and benign 
tissue 
Prostate cancer cell 
lines and benign cell 
line 
 
Wnt 5A is overexpressed 
in a prostate cancer cell 
line and prostate cancer 
tissue. mRNA of Wnt/β-
catenin target genes 
mRNA is reduced in 
prostate cancer; Wnt5A 
induces a Ca2+ release in 
the PC3 cell line.  
Wnt 5A protein is expressed in benign and malignant human 
prostate cancer tissue and semi-automated analysis demonstrates 
expression is significantly elevated in malignant compared to benign 
prostate tissue. Expression of Wnt 5A mRNA and Wnt 5A protein 
was increased in a prostate cancer cell line compared with a benign 
cell line. Wnt/β-catenin mediated TCF transcription target genes‟ 
mRNA is reduced in prostate cancer cells compared with benign 
cells, suggesting Wnt/β-catenin mediated TCF transcription may be 
of less significance in prostate cancer than other Wnt mechanisms 
such the Wnt / Ca2+ pathway. Wnt5A peptide induces  Ca2+ release 
of up to 100s duration in prostate cancer cell line PC3 (Wang et al., 
2010). 
Human prostate 
cancer and benign 
tissue 
Prostate cancer cell 
lines and benign cell 
line 
Wnt5a expression is 
increased in prostate 
cancer tissue; Wnt 5A is 
associated with invasion 
in prostate cancer cell 
lines; Wnt 5A expression 
is a prognostic factor for 
clinical relapse. 
On immunohistochemistry of prostate cancer tissue, Wnt 5A 
expression is elevated in cancer tissue compared to benign tissue. A 
greater proportion of high grade cancers expressed Wnt 5A 
compared to cancers of lower grade Gleason 7 or below. On multi-
variate analysis, Wnt 5A staining was found to be an independent 
predictor for prostate cancer relapse following radical prostatectomy. 
Knockdown Wnt 5A in a prostate cancer cell line DU145 reduces 
invasion whilst Wnt 5A overexpression in prostate cancer cell line 
PC3 stimulates invasion. (Yamamoto et al., 2010) 
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Colorectal  
 
 
Human colorectal 
cancer; mouse 
model  
Mutation in APC leads to loss 
of function and unregulated  
β-catenin causing aberrant 
Wnt signalling 
As discussed earlier, most human colorectal cancers have a loss of 
function of APC, (Kinzler and Vogelstein, 1996) which usually 
functions as a tumour suppressor through its regulation of  β-
catenin. This regulation is required for both prevention of 
tumourigenesis as well as normal embryonic development (Smits 
et al., 1999). 
Colorectal cancer 
cell lines, human 
colorectal cancer 
As well as APC mutations, 
de-regulated β-catenin 
signalling may also occur 
from mutations in β-catenin 
itself 
In certain colorectal cancer cell lines, β-catenin / TCF-mediated 
transcription is constitutively active, and is unaffected by wild-type 
APC.  However, these cells were found to have mutations in the β-
catenin gene: HCT116 a 3-bp deletion. In a series of primary 
colorectal cancers without APC mutations, over half the cancers 
were found to have β-catenin mutations thought to affect their 
ability to become phosphorylated. β-catenin mutants are inductive 
of β-catenin / TCF mediated transcription (Morin et al., 1997). 
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Breast 
 
 
 
Breast cancer cell 
lines  
 
 
Upregulated β-catenin from autocrine 
expression of Wnt ligands  
Breast and ovarian cancer cells lines with transcriptionally 
active β-catenin do not have mutations in β-catenin or 
APC, but express Wnt ligands in an autocrine fashion. 
Wnt antagonists FRP1 and DKK1 inhibit the upregulation 
of β-catenin in these cells (Bafico et al., 2004). 
Human breast 
cancer, breast 
cancer cell lines, 
breast cancer 
mouse model  
LRP6 co-receptor activates Wnt 
signalling and its inhibition reduces 
carcinogenesis 
The co-receptor LRP6 is upregulated in a proportion of 
breast cancer tissues and cell lines, particularly those 
which are receptor negative. Knockdown of LRP6 results 
in a reduction of β-catenin and Wnt gene transcription as 
measured by quantification of target genes as well as a 
TCF-dependent TOP Flash reporter. Overexpression of 
LRP6 increases cancer cell proliferation in a cell line and 
suppression of LRP6 reduces cancer growth in a breast 
cancer mouse model (Liu et al., 2010). 
Human breast 
tissue 
Cytoplasmic and nuclear β-catenin is 
elevated in in-situ and invasive 
cancers and is indicative of poorer 
prognosis 
Membrane β-catenin is found in normal tissue, but less 
frequently in in-situ and invasive carcinoma. Cytosolic 
and nuclear β-catenin is scarce / absent in benign breast 
tissue but seen in in-situ and invasive cancers.  Elevated 
cytosolic or nuclear β-catenin expression is associated 
with poorer prognosis (Khramtsov et al., 2010). 
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Lung Human lung 
cancer tissue and 
lung cancer cell 
lines 
Dishevelled overexpression is 
important in Wnt signalling activation 
and colony formation in NSCLC 
Dishevelled 3 is overexpressed in lung cancer. 
Transfection of siRNA results in selective inhibition of 
human dishevelled -1, -2 and -3 in non-small cell lung 
cancer (NSCLC) cell line H1703. This reduced β-catenin 
expression and TCF-dependent transcriptional activity 
and colony formation in H1703 (Uematsu et al., 2003).  
Pancreas Human pancreas 
cancer tissue 
Elevated total β-catenin is found in 
adenocarcinoma of the pancreas, 
whilst mutation in β-catenin is rare 
Analysis of human adenocarcinoma of the pancreas 
tissue and benign pancreatic tissue demonstrated 
elevated total β-catenin in malignant tissue. However, 
very few of these tumours demonstrated a β-catenin 
mutation.  
Ovarian 
 
Ovarian cancer 
cell lines  
 
 
Upregulated β-catenin from autocrine 
expression of Wnt ligands  
Breast and ovarian cancer cells lines with transcriptionally 
active β-catenin do not have mutations in β-catenin or 
APC, but express Wnt ligands in an autocrine fashion. 
Wnt antagonists FRP1 and DKK1 are able to inhibit the 
upregulation of β-catenin in these cells (Bafico et al., 
2004). 
Gastric 
 
 
Human Gastric 
cancer  
 
 
Nuclear β-catenin detected in 
proportion of gastric cancers, with 
frequent mutation in exon 3 
Nuclear β-catenin was found in almost 30% of gastric 
cancers, and 26% had a mutation in exon 3 of β-catenin. 
In tumours where there was no nuclear β-catenin, none 
the cancers tested were found to have a mutation in β-
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catenin. This mutation in β-catenin may be important in 
carcinogenesis in gastric malignancy (Clements et al., 
2002). 
Gastric cancer cell 
lines, human 
gastric cancer, in 
vivo mouse model 
HMGA1 is a target of Wnt and is 
associated with nuclear β-catenin and 
increased proliferation of gastric 
cancer cells 
High-mobility group A (HMGA) proteins are expressed in 
several cancers, including gastric cancer. Knockdown of 
cmyc or β-catenin in gastric cancer cell lines results in 
reduced HMGA1. Knockdown of HMGA1 with siRNAs 
results in reduced proliferation of gastric cancer cells. In 
gastric cancer tissue, increased detection of HMGA1 was 
associated with nuclear β-catenin in 30% of studied 
samples (Akaboshi et al., 2009). 
Penile   Human penile 
cancer tissue and 
benign penile 
tissue 
There is increased expression of Wnt 
protein in squamous cell carcinoma of 
the penis and benign / malignant 
tissue may be characterised by Wnt 
protein co-localisation   
Protein expression of Wnt4 and of several downstream 
targets of β-catenin transcription activation - MMP7, 
cyclinD1 and c-MYC - are significantly increased in 
squamous cell carcinoma of the penis in comparison to 
non-malignant penile tissue. In addition, when protein co-
localisation was analysed in control benign / grade 1 
malignant / grade 2 malignant tissues, differences in co-
localisation between certain proteins, such as 
MMP7/Wnt4, was between different tissues. These 
differences in Wnt protein expression may in the future be 
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used as a biomarker in diagnosis or prognosis of 
squamous cell carcinoma of the penis.  
(Arya et al., 2015) 
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1.6 Wnt signalling in stem and cancer stem cells 
  
Wnt signalling is involved in both the self-renewal and differentiation of stem cells 
and may play an important role in the behaviour of cancer stem cells. This is 
discussed below. 
 
1.6.1 Wnt in stem cells  
 
Crypts of the small intestine provide a physiological example of the importance of 
Wnt signalling and stem cell function. The epithelium of the small bowel epithelium is 
continuously undergoing self–renewal with the maintenance of several differentiated 
cell types. Stem cells reside towards the base of the crypts and produce progenitor 
cells (sometimes called transit amplifying cells), which differentiate as they move 
away from the crypt base towards the villi (Barker et al., 2012; Potten and Loeffler, 
1990). 
 
The key role of β-catenin / TCF transcription in maintaining stem cell function in the 
small intestine crypt has been demonstrated by studying TCF 7l2 -/- mice which lack 
TCF 4 activity. In the small intestine of control mouse embryo, various differences 
are observed in the morphology of cells on the villi compared with the inter-villi 
regions which were not found in TCF 7l2 -/- mice where cells of different 
compartments appeared the same. In normal mice, proliferation measured by Ki 67 
staining was noted but restricted to the inter-villus regions whilst Tcf7l2 -/- mice 
demonstrated no Ki67 staining. Once neonatal, the intestinal epithelium of Tcf7l2 -/- 
mice consisted only of differentiated villus cells (Korinek et al., 1998). Similarly, in 
transgenic mice which ectopically express Wnt inhibitor Dickkopf1 (Dkk1), crypt and 
villus formation is greatly reduced and staining for β-catenin and proliferation 
markers is absent from crypt regions. Mutant mice also fail to produce secretory cell 
lineages in the intestine (Pinto et al., 2003). 
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In a study investigating Wnt target genes in colorectal cancer, nuclear β-catenin 
expression correlated with Wnt target gene expression in both cancer and the 
proliferative region of benign colon crypts using immunohistochemistry (van de 
Wetering et al., 2002). In addition, cells at the base of crypts demonstrate nuclear β-
catenin staining which decreases in cells ascending up the crypt towards the 
surface. In colorectal cancer cell line Ls174T, genes down-regulated by dominant-
negative TCF are those expressed by proliferating cells of the crypts, whilst 
differentiated epithelial cells express genes that were up-regulated when β-catenin / 
TCF transcription was suppressed (van de Wetering et al., 2002). Expression of the 
ligand ephrin-B1 and receptors EphB2/EphB3 are controlled by β-catenin / TCF 
transcription (Batlle et al., 2002; van de Wetering et al., 2002). In vivo, histological 
structure of crypts and villi in EphB2 /EphB3 mutant mice has been studied. Double 
mutant mice lack a clear boundary between proliferative and differentiated regions 
usually observed when proliferative cells are present in regions normally composed 
of differentiated cells (Batlle et al., 2002). 
 
 Wnt signalling in breast tumour initiating cells 1.6.1.1
 
The importance of Wnt β-catenin signalling has been demonstrated in breast tumour 
initiating cells, and further to this, the effect of inhibition of Wnt / β-catenin signalling 
on effectively suppressing tumourigenicity (Hallett et al., 2012). 
 
In one such study, microarray analyses with global gene expression profiling were 
performed on tumourspheres (breast tumour inducing cells), mammospheres 
(mammary epithelial stem / progenitor cells), and mammospheres induced to 
differentiate in vitro (differentiated mammary epithelial cells). This demonstrated 
tumourspheres highly expressed transcripts of Wnt / β-catenin pathway genes 
compared with mammospheres or mammospheres induced to differentiate. 
Tumourspheres also highly expressed certain Wnt / β-catenin target genes such as 
Axin2, cyclinD1 and CD44. Mammospheres induced to differentiate express 
transcripts of inhibitors of Wnt / β-catenin signalling, such as Sfrp1, Srfp2 and Dkk2. 
This pattern of expression between the three types of cells was confirmed with 
quantitative RT-PCR, which also demonstrated elevated expression of Wnt 7A, Wnt 
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7B, and Fz 4 and Fz 6 receptors in tumourspheres. In terms of clinical application of 
these findings, a Wnt breast tumour inducing cell gene signature of genes 
differentially expressed between tumourspheres and mammospheres induced to 
differentiate in vitro was used to categorise human tumour tissue into 2 groups.  The 
group with expression of tumoursphere-related Wnt / β-catenin pathway gene 
expression had poorer overall and metastasis free survival when compared with the 
group with gene expression related to that of mammospheres induced to differentiate 
in vitro (Hallett et al., 2012). 
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1.7 Experimental aims  
 
There is clear evidence of Wnt signalling being involved in carcinogenesis of many 
cancers including prostate cancer (section 1.5); the role of Wnt signalling is also well 
characterized in the maintenance of stem cells (section 1.6). Cancer is often 
suggested to be a disease of stem cells (Clarke et al., 2006; Reya et al., 2001a) and 
therefore I decided to establish an experimental system in which to investigate this 
notion. Ideally the role of Wnt signalling in prostate cancer would be studied in vitro 
models of human prostate cancer stem cells isolated from fresh tissue. There are 
numerous difficulties in executing such a plan, the primary one being the availability 
of human tissue and also the identification of putative stem (let alone cancer stem 
cells). Cell lines are thought to contain a fraction of cells that behave like stem cells 
(termed stem-like cells in cell lines).  
 
The aim of this study was to characterise colonies formed from PC3 prostate cancer 
cells and investigate the properties of Wnt signalling in the cells of these colonies. 
 
 
1.7.1 Hypothesis  
 
PC3 cells at clonal density will form colonies with distinct morphology upon which 
they can be categorised. These colony types respond differently to Wnt signalling. 
Wnt signalling occurs in the cancer stem-like cells of holoclones, but not paraclones. 
Cells within these colonies will express β-catenin. Cells within these colonies will 
demonstrate an intracellular Ca2+ release following Wnt treatment which may make 
these amenable to compounds and mechanisms (e.g. regulation of cell membrane 
potential) that regulate Ca2+ homeostasis.  
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1.7.2 Key objectives 
 
The following objectives test the hypothesis:  
 
 To assess if PC3 prostate cancer cells form distinct colony types when 
cultured from single cells. 
 To develop an objective, quantitative method for the assessment of these 
colonies. 
 To characterize Wnt signalling with regards to intracellular Ca2+ release and 
expression and location of β-catenin in these colonies.  
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Chapter 2: Materials and methods 
 
 
2.1 Cell culture  
 
 
The PC3 cell line was used to study colonies formed from clonal expansion, in live 
cell imaging experiments and for immunocytochemistry. This cell line originated from 
a prostate cancer bone metastasis (Kaighn et al., 1979). Other cells used in this 
research project included prostate cancer cell lines LNCaP derived from a 
supraclavicular lymph node metastasis (Horoszewicz et al., 1983) and DU145 
derived from a brain metastasis (Stone et al., 1978). Cell culture was performed as 
described below for all cell lines. 
 
Cells were cultured in 75 cm2 culture flasks (Nunc) in RPMI1640 (Invitrogen) 
supplemented with 2 mM L-Glutamine (Invitrogen) and 10% foetal bovine serum 
(FBS) (PAA, UK #A10409-1608); this will be referred as culture medium, henceforth. 
Cells were incubated at 37°C 5% CO2. As a general practice cells were grown in 
culture to approximately 70% confluency. To passage cells, medium was aspirated 
from the culture flask using a glass pipette and suction device. Two millilitres of 
trypsin 0.25% (Invitrogen) was added to the empty flask, ensuring coverage of the 
base of the flask, and the flask then placed in an incubator at 37°C for 3-4 min.  
Following this period cells were inspected for detachment from the surface of the 
flask, and the cell suspension was transferred using a pipette into a 7ml Bijou bottle 
containing 2 ml culture medium. The number of cells / ml in this cell suspension was 
determined as outlined below. The cell suspension was used to set up fresh culture 
flasks or used in experiments.  
 
2.1.1 Cell counting using a haemocytometer 
 
The haemocytometer was to determine the number of cells / ml in a cell suspension 
following trypsinisation. The cell suspension was gently mixed by pipetting and 100 
µL cell suspension added to 100 µL trypan blue (Sigma-Aldrich) in an Eppendorf 
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tube. 100 µL of this blue cell suspension was loaded into the haemocytometer 
chambers. Using the 10X objective of the microscope, the number of viable cells in 
each of the 4 peripheral cells and the central square were counted.  
The number of cells / ml = total counted cells / 5 x 10 000 x 2. 
 
2.2 Clonal expansion 
2.2.1 Clonal expansion in 6 well plates 
 
Colonies formed from single cells were studied in a clonogenic assay (McCulloch et 
al., 1981; Pellegrini et al., 1999). A cell suspension was made through trypsinisation 
of a culture flask (not >70% confluent as described above). A cell count using trypan 
blue and a haemocytometer was used to determine the concentration of cells / ml in 
the cell solution. Serial dilution of the cell suspension was performed by diluting a 
small volume of cell suspension into a larger volume of supplemented RPMI 
medium, to achieve a final cell suspension of 40 cells / ml.   
 
Six well plates (Nunc) were used to study colony formation. Cells were plated at 
clonal density, defined as 60 cells / well in 3 ml of culture medium (60 cells / 9.6cm2). 
Some plates were placed in the IncuCyte™ (Essen Bioscience), a live cell imaging 
apparatus, for cell division and colony formation studies.  Cell culture medium was 
changed at day 5 with a fresh 3 ml of culture medium and colonies imaged and 
colony size measured at day 10.  
 
2.2.2 Clonal expansion with cells grown on FluoroDishes  
 
In order to study Wnt induced [Ca2+]i release (Wang et al., 2010) and protein 
expression in colonies, further colonies were grown in 35-mm FluoroDishes (catalog 
no. FD35-100, World Precision Instruments). FluoroDishes were placed on a plastic 
surface to facilitate their handling and transfer. Cells were plated at clonal density on 
FluoroDishes defined as 40 cells in 1 ml culture medium / dish. After 1 day, once 
cells had become adherent, a further 1 ml RPMI was added to each dish. Culture 
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medium was changed on day 7. Colonies were used for live cell Ca2+ imaging or 
immunostaining at day 12. 
 
 
 
2.3 Live cell free intracellular calcium ([Ca2+]i) imaging of colonies  
Live cell Ca2+ imaging was performed based upon previous work from our group 
(Wang et al., 2010) An Olympus FluoView FV 1000 confocal microscope (Olympus 
KeyMed) with x10 and x20 dry objectives (numerical aperture = 0.75) was used. 
Ca2+ dyes Fluo-4 and FuraRed (Invitrogen) were used: Fluo4 binds free calcium and 
FuraRed detects bounds calcium within the cells; in live calcium measurement 
assays, as the Ca2+ is released from the stores in response to a stimulus (e.g. Wnt 
ligand) the Fluo4 signal should increase while the FuraRed signal should 
simultaneously decrease. The ratio of the signal between Fluo4 and FuraRed 
represent the free intracellular calcium release (Thrasivoulou et al., 2013) (Wang et 
al., 2010).  . PC3 cells were plated at low density and cultured as described above 
for experiments. On day 12 after plating, FluoroDishes were carefully transported to 
the UCL core facility for confocal imaging where the Olympus system resides. For 
each dish, culture medium was discarded and replaced with just 1ml culture medium. 
2 µl Fluo-4 and 2 µl FuraRed each at concentration 1ng / ml was added to the 
FluoroDish for 15 min.   
 
The culture medium was then discarded, the dish washed with 2ml PBS and a 
further 1 ml of fresh culture medium added to the dish. The FluoroDish was placed 
into the chamber of an Olympus microscope with incubator set at 37°C. All live 
intracellular Ca2+ experiments were performed at 37°C. 
 
Cells were viewed using x10 objective to identify an individual colony of cells. This 
colony was then observed at x20 and 20 cells were contoured (sampled) as separate 
regions of interest for further analysis. On Olympus settings, imaging was performed 
using excitation from an argon laser (488nm) with emissions recorded in green (510–
580 nm) and red channels (600–700 nm) for Fluo-4 and FuraRed respectively (Wang 
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et al., 2010). The microscope was set at x20 objective; zoom x1; 512x512. Gain was 
appropriately adjusted so as the signal would have scope to potentially increase or 
decrease in intensity before being saturated or disappearing. Images were taken at 
intervals of 450ms. Excitation of Fluo-4 and FuraRed was recorded and exported 
into an excel file for analysis.  Cells were imaged for a “run in” period of at least 30-
60s before proceeding with the experiment. During this run-in period a plateau of 
intensity was observed. At this time, either 2 µl of PBS control, 2 µl of 100 ng/ml Wnt 
5A (R&D Systems) or 2 µl of 100 ng/ml Wnt 9B (R&D Systems) was very carefully 
and gently pipetted onto the surface of the medium in the dish, at a distance of 
approximately 1cm from the colony being imaged. Imaging continued until no further 
response or change in plotted intensity was observed. Data from each experiment 
was saved as an OIF movie file and exported as an excel datasheet. Analysis of live 
cell imaging data is detailed in chapter 3. 
 
 
2.4 Cell proliferation assays  
 
Using PC3 cell line, ceIl culture, trypsinisation and cell counting was performed as 
described in sections 2.1.1. 50 000 cells were plated into each well of a 6 well plate 
(Nunc) with or without experimental compounds (see below). Plates were placed in 
an IncuCyte™ programmed to image a selection of areas of each well at a 4 hour 
time interval. Following 24 hours, once cells had become adherent, the control and 
experimental wells were treated with the appropriate agents and placed back in the 
IncuCyte™ for further imaging of cell proliferation.  Compounds used, and details of 
this assay are described in section 4.2. 
 
 
  
78 
 
2.5 Immunocytochemistry 
 
2.5.1 Cell fixation  
 
Cells were washed with PBS and fixed with 1ml 4% paraformaldehyde (PFA) at 
room temperature for 20 min. Cells were then washed 3x with PBS for 5 min. Plates 
were sealed and stored at 4°C for up to 1 month. 
 
2.5.2 Cell staining  
 
A permeabilisation buffer of 0.2% bovine serum albumin (BSA) in PBS with 0.2% 
Triton x 100 (Sigma) was prepared.1ml permeabilisation buffer was added to each 
dish and incubated for 40 min.  
 
The permeabilisation buffer was removed and cells blocked with 10% normal goat 
serum (NGS) (PAA) in PBS for 30 minutes at room temperature to prevent non-
specific binding. Primary antibody dilutions were prepared in 1% NGS in PBS and 
the blocking buffer was removed and replaced with the primary antibody and 
incubated overnight at 4°C in a humidity box, to prevent drying (see sections 3.2.4 
and 4.2.2). For negative control, antibody diluent containing no antibody was added 
to the target well. Following an overnight incubation, the primary antibody was 
removed, and the wells were washed 4 times with PBS containing 1% NGS.  
 
Secondary Ab was prepared at dilution 1:500 in 2% BSA in PBS and added to the 
dishes. The vessels were again placed upon a tray which was wrapped in foil and 
placed on a rocker at medium speed in a dark room for 60 min. Following this time, 
cells were washed in PBS for 3 x 5 min.  
 
At the final wash extra care was taken to remove as much PBS as possible. A small 
drop of Vectorshield mounting medium with DAPI (vector laboratories) was placed 
on a glass round coverslip diameter 22 mm.  The coverslip was gently placed onto 
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the surface of the Fluorodish using forceps. Care was taken to lower the coverslip 
onto the dish so as to avoid disruption of cells and formation of air bubbles.  
Dishes were placed on a tray and wrapped in foil and left at 4°C until imaging.  
 
 
2.5.3 Imaging using confocal microscopy 
 
Imaging of fixed and stained cells was performed using an Olympus confocal 
microscope. Cells were focussed upon and serial sections were imaged through the 
cells forming a Z-stack. Slices were imaged at 0.63 µm intervals such that each 
stack was formed of approximately 15 images. Images were taken using x10; x20; 
x40 objectives and sometimes with the combination of a zoom function. Z stack 
images are presented in subsequent chapters. Further details are described in 
section 3.3. 
 
 
2.6 Polymerase Chain Reaction (PCR) 
2.6.1 Primer design 
 
Primer design was the first step in investigating gene expression in cells of interest. 
Several websites were used in the primer design process. http://www.genecards.org/ 
was used in determining the correct nomenclature for genes and the NCBI/Primer-
BLAST website was used for primer design. Primer lengths of 20 base pairs and 
product size 400-600 base pairs were requested parameters. Of those primer pairs 
suggested by the website, those with an appropriate GC content of 55%, and similar 
annealing temperatures of approximately 50°C were selected.   
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2.6.2 RNA extraction 
 
RNA extraction from harvested cells was performed using Qiagen RNeasy Mini Kit 
(Qiagen, Manchester). The kit protocol was followed as detailed in the 06/2012 
handbook. http://www.qiagen.com/us/products/catalog/sample-technologies/rna-
sample-technologies/total-rna/rneasy-mini-kit/. As per the protocol, RNA was eluted 
using 50 µl RNase-free water. RNA concentration was measured using a 
spectrophotometer at 260 and 280 nm wavelengths. RNA extraction from cells of 
colonies and PCR of stem cell genes is detailed in chapter 3. 
 
2.6.3 Reverse transcription of RNA into cDNA 
 
RNA was synthesised to cDNA using a Qiagen Omniscript RT kit as per the 10/2010 
handbook protocol: http://www.qiagen.com/us/products/catalog/assay-
technologies/end-point-pcr-and-rt-pcr-reagents/omniscript-rt-kit/. For sufficient yield 
of cDNA for subsequent PCR, constituents were scaled up x 2 so that 4 µg template 
RNA was used and made up to a volume of 24 µl with RNase free water as indicated 
in table 4. Once the protocol was completed, the cDNA was frozen at -20C if for later 
use in PCR.  
 
Table 4. Mixture composition used for reverse transcription reactions.  
In each reaction 4 µg template RNA was used and made up to a volume of 24 µl with RNase 
free water as indicated. The reaction mixture was made up with the constituents as shown to a 
volume of 40 µl. 
 
Reaction Component Volume (µl) 
  
10x Buffer RT  4 
dNTP Mix 4 
Oligo dT primer (8.4 µM) 4 
RNase inhibitor 2 
Omniscript reverse transcriptase 2 
RNase free water + 
Template RNA 
24 
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Total Volume  40 
 
 
2.6.4 PCR 
 
PCR was performed using Qiagen Taq PCR Master Mix kit and following the 
protocol handbook 10/2010. http://www.qiagen.com/us/products/catalog/assay-
technologies/end-point-pcr-and-rt-pcr-reagents/taq-pcr-master-mix-kit. Prior to 
commencing PCR cDNA was thawed on ice and quantified using a spectrometer 
giving a concentration in µg/ml. 0.5 µg template cDNA was used in all PCR reactions 
per reaction tube. The volume of cDNA required for 0.5 µg was calculated and the 
volume of RNase free water to make a cDNA solution up to 12 µl was calculated as 
indicated in table 5. Reaction tubes were placed in a thermal cycler programmed as 
indicated in table 6. Following amplification, PCR product samples were stored at 
4°C until agarose gel electrophoresis. 
  
PCR of ion channel genes is detailed in section 4.2.1.  
 
 
Table 5. Reaction mixture made up in each tube for PCR reaction.  
For all PCR reactions 0.5 µg template cDNA was used in each reaction tube. The volume of 
cDNA required for 0.5 µg was calculated and the volume of RNase free water to make a cDNA 
solution up to 12 µl was calculated as indicated in table 5. The other constituents were added 
as in the table to a total volume of 30 µl. 
 
Reaction Component  Volume (µl) 
Taq PCR mastermix solution 15 
Primer A (forward) 8.4 µM 1.5 
Primer A (reverse) 8.4 µM 1.5 
RNase-free water + 
Template DNA 0.5 µg 
made up to 12  
Total volume  30 
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Table 6. Programme for thermal cycler. 
PCR reaction tubes were placed in a thermal cycler programmed as indicated below. Following 
amplification, PCR product samples were stored at 4°C until agarose gel electrophoresis. 
 
Initial denaturation 3 min  94°C  
 
3-step cycling 
 
Denaturation: 
 
 
Annealing: 
 
 
 
 
 
Extension: 
 
 
 
Number of cycles: 
35 
 
 
 
0.5–1 min  
 
 
0.5–1 min  
 
 
 
 
 
1 min  
 
 
94°C 
 
 
55°C 
 
 
 
 
 
72°C 
 
 
Approximately 5°C 
below Tm of 
primers 
 
 
Final extension 10 mins 72°C  
 
Following end of 
programme 
 4°C  
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2.6.5 Agarose gel electrophoresis 
 
A concentrated stock solution of TAEx50 was diluted x50 using de-ionized water to 
TAEx1. Agarose gel 1.1% was made up using 150 ml TAEx1 with 1.65 g agarose in 
a conical flask. This mixture was heated at high power in a microwave for 
approximately 3 min, with swirling in between, until boiling and all agarose had 
dissolved. The flask was left to cool for approximately 10 min after which 10 µl 0.5 
μg/ml ethidium bromide (Sigma-Aldrich) was added. The mixture was then gently 
poured in to an electrophoresis gel tray (Bio Rad) and 2 combs placed in the tray to 
create wells. The gel was left to set for approximately 20 min. Once set the combs 
were removed and the gel and tray placed in a bath of TAEx1 in an electrophoresis 
machine. Care was taken to ensure TAEx1 covered the surface of the gel. A 
template was created mapping which product was to be pipetted into which well. 10 
µl of each PCR product was pipetted into wells with 1μl 10x Blue Juice loading dye 
(Sigma-Aldrich). 2 µl of 1K base pair DNA ladder (ThermoFisher Scientific 10787-
018) was also pipetted into a well in each column with <1μl 10x Blue Juice loading 
dye. 
 
For gel electrophoresis a current was applied at 110V for duration of 70 min. 
Following this time, the gel was imaged under UV light analysed for the presence of 
product bands at the expected sizes to be indicative of expression of that specific 
gene.  
 
 
2.6.6 Sequencing 
 
To confirm products visualised at the expected band size were amplified products of 
the genes being characterised, positive bands genes of interest were sent to for 
sequencing. Immediately after imaging a gel, a clean scalpel was used to carefully 
cut out a band from the gel. Each PCR product band was placed in an Eppendorf 
tube. DNA extraction from the gel was performed using a QIAquick® Gel Extraction 
Kit (Qiagen). The protocol handbook 10/2010 was followed: 
https://www.qiagen.com/gb/resources/resourcedetail?id=f4ba2d24-8218-452c-ad6f-
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1b6f43194425&lang=en. The DNA was sent for sequencing to Beckman Coulter 
Genomics (now known as Genewiz Europe (Takeley, UK). The resultant sequences 
were read using Finch TV software and cross-referenced for the gene on the NCBI 
website.   
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Chapter 3: PC3 prostate cancer colony formation 
and characterisation  
 
 
3.1 Introduction  
 
The colony forming ability of PC3 cells and the differential behaviours of distinct 
colonies which are derived from single cells have been investigated (Li et al., 2008; 
Zhang and Waxman, 2010). Distinctive colonies - holoclones, meroclones and 
paraclones  - have  been observed when PC3 cells are cultured at low density (1 cell 
/ 32mm2 clonal density) (Li et al., 2008; Zhang and Waxman, 2010). Holoclones 
were colonies characterised as consisting of small tightly packed cells; paraclones 
were larger colonies comprised of fewer cells; meroclones were colonies in between 
in size and number of constituent cells (Li et al., 2008; Zhang and Waxman, 2010).  
 
Cells of these different colony types have distinct biological properties. On serial 
passage, cells of the holoclone colony type had the highest survival and paraclone 
colony type the lowest survival rate (Li et al., 2008). Cells of holoclones are 
considered cancer stem cell-like in their properties and unlike cells of paraclones, 
are able to induce tumour in a xenograft model (Li et al., 2008; Locke et al., 2005; 
Pfeiffer and Schalken, 2010).  
 
Wnt signalling occurs in stem-like cells (Reya and Clevers, 2005; (Reya et al., 2003; 
Willert et al., 2003). A physiological example of Wnt signalling in stem cell function is 
in the crypts of the small intestine of the human gastrointestinal tract (Barker et al., 
2012; Potten and Loeffler, 1990). Wnt signalling occurs in cancer stem-like cells 
(Hallett et al., 2012; Holland et al., 2013; Reya and Clevers, 2005; Reya et al., 
2001b). The importance of Wnt β-catenin signalling has been demonstrated in breast 
tumour initiating cells where inhibition of Wnt / β-catenin signalling suppressed 
tumourigenecity (Hallett et al., 2012). 
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Aim 
 
The aim of the work described in this chapter was to assess if colonies are formed 
by a prostate cancer cell line (PC3) and if so, to characterise Wnt signalling by 
determining intracellular Ca2+ activation and β-catenin expression in different PC3 
colonies.  
 
3.1.1 Hypothesis 
3.1.1.1 PC3 cells plated and cultured at clonal density, defined as 60 cells / well in 
3 ml of culture medium (60 cells / 9.6cm2), will form distinct colonies of 
cells. 
3.1.1.2 The colony types formed will resemble holoclones, meroclones and 
paraclones morphologically, but will also have objective features upon 
which they can be categorised. 
3.1.1.3 Wnt signalling occurs in cells of PC3 colonies, but cells of different 
colonies will demonstrate differences in Wnt signalling with regards to Wnt 
induced intracellular Ca2+ release and expression of β-catenin, the two key 
transducers of Wnt signalling. 
 
3.1.2 Objectives 
3.1.2.1 To assess if PC3 prostate cancer cells form distinct colony types when 
cultured from single cells at clonal density. 
3.1.2.2 To determine an objective, quantitative technique to describe these 
colonies formed from PC3 cells. 
3.1.2.3 To characterise Wnt signalling with regards to intracellular Ca2+ release 
and expression and location of β-catenin in these colonies.    
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3.2 Materials and methods 
3.2.1 Characterisation of colonies 
  
The culturing of colonies was performed as outlined in section 2.3. Colonies were 
imaged at day 10 and exported as „joint photographic expert group‟ (jpeg or jpg) files 
for further analysis. In order to calculate the cellularity of a colony, each image was 
processed using the Image J software (Murphy, 2012; Rasband, 2015) as follows: 
 
- Image opened in Image J 
- Imaged cropped so as to include colony only 
- Image type converted to 8 bit greyscale 
- Image thresholding applied to show cells; this is automated by processing and 
making the image binary 
- Particles are analysed in image J 
- Summary of area fraction of colony consisting of cells is given  
 
3.2.2 Expression of stem cell genes in different populations of PC3 cells  
 
PC3 cells in a single cell suspension were plated at clonal density (60 cells / well) in 
Nunc 6 well plates. Cells were cultured in 3 ml culture medium which was replaced 
after 5 days. For colonies grown for RNA extraction, 3 plates of cells were seeded for 
each experiment. Colonies were viewed using a microscope at x10 magnification 
and categorised as holo/meroclones or paraclones, initially, based upon the 
characteristics described previously (Li et al., 2008; Zhang and Waxman, 2010) and 
section 1.1.5. Cells were washed in PBS and replaced in 1 ml PBS/well. A 200 µl 
pipette was used to disrupt individual colonies and aspirate cells from individual 
colonies in a small volume of PBS. One centrifuge tube was used to collect cells 
aspirated from holo/meroclone colonies and another centrifuge tube used to collect 
cells from paraclone colonies. Cell suspensions were centrifuged at 350 x g for 5 min 
to obtain a cell pellet. RNeasy (Qiagen, Manchester) protocol was followed to extract 
RNA from pelleted cells. RNA was eluted into 50µl RNase-free water. The quantity 
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(µg/ml) of isolated RNA was determined using a spectrometer machine. RNA was 
stored at -80oC until further use. 
 
3.2.3 Live cell calcium imaging and data analysis 
 
For methods of culture of PC3 colonies on FluoroDishes and intracellular calcium 
imaging on treatment with Wnt ligands see sections 2.2.2 and 2.3. For each cell, 
data points of intensity of signal were determined at 0.45s time intervals using 
Olympus FluoView 1000 software. Data from each experiment (after drawing regions 
of interest on cells within a colony) was saved as an Olympus (OIF) video file and 
also exported as an excel spreadsheet. Waveform graphs were created of Fluo-4 
intensity: FuraRed intensity (y axis) against time (x axis) using Origin software. 
Graphs were used to determine the kinetics of [Ca2+]i by calculating the rise, fall and 
dwell times of wave form for each cell. 
 
A baseline (resting intensity) and maximum intensity reached for each waveform 
were determined and set as 0% and 100% excitation values for each specific cell. 
Using these values, 10% and 90% threshold values between the baseline and 
maximum were calculated and plotted on the waveform, and the time taken to reach 
these thresholds read from the graphs. The time interval between where the 
waveform rose intersected the 10% threshold until when it intersected with the 90% 
threshold was the rise time. The time the waveform was maintained above the 90% 
threshold was the dwell time. The time interval between the waveform falling from 
90% to 10% threshold was the fall time. The time interval between the waveform 
rising above 10% to the initial fall to the 10% threshold was the duration of the 
primary response. The time interval between the waveform rising above 10% to the 
final fall to the 10% threshold was the duration of the total response. In many cases, 
where only a primary response was observed, the duration of the primary response 
was the same as the duration of the total response. These intervals of rise time, 
dwell time, fall time and duration primary and total response are as indicated in 
Figure 7 which shows a plotted waveform of intensity ratio against time obtained for 
one cell taken as a region of interest. Origin software was used to create graphs and 
test for statistical significance using the Mann-Whitney U test. 
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Figure 7. Plotted waveform of intensity ratio against time obtained for one cell taken as a 
region of interest. 
For each cell, data points of intensity of signal were determined at 0.45 s time intervals using 
Olympus FluoView 1000 software. Data from each experiment (after drawing regions of interest 
on cells within a colony) was saved as an Olympus (OIF) video file and also exported as an 
excel spreadsheet. Waveform graphs were created of Fluo-4 intensity: FuraRed intensity (y 
axis) against time (x axis) using Origin software. The time interval between where the 
waveform rose intersected the 10% threshold until when it intersected with the 90% threshold 
was the rise time. The time the waveform was maintained above the 90% threshold was the 
dwell time. The time interval between the waveform falling from 90% to 10% threshold was the 
fall time. The time interval between the waveform rising above 10% to the initial fall to the 10% 
threshold was the duration of the primary response. The time interval between the waveform 
rising above 10% to the final fall to the 10% threshold was the duration of the total response. 
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3.2.4 Immunocytochemistry for β-catenin 
 
Colonies of PC3 cells were cultured on FluoroDishes and live cell Ca2+ imaging 
experiments performed as detailed in section 2.4. At the end of an experiment, the 
FluoroDish was left in the incubator at 37oC for 20 minutes. Medium was removed 
from the FluoroDish and cells fixed with 2ml paraformaldehyde (PFA) 4%. Following 
20 minutes, PFA was removed from the FluoroDish and cells were washed in PBS 
3x 5min. For each experiment day, 2 dishes were not treated with Wnt and the 
colonies cultured on these dishes were fixed as above.  
 
Fluorodishes were labelled according to date, Wnt ligand, experiment number, and 
1° and 2° antibody. Immunocytochemistry was performed as outlined in section 
2.5.1. Primary mouse monoclonal antibody to beta catenin (abcam; ab22656) was 
prepared as indicated in Table 7. The permeabilisation buffer was removed and cells 
blocked with 10% normal goat serum (NGS) (PAA) in PBS for 30 minutes at room 
temperature to prevent non-specific binding. Primary antibody dilutions (Table 7) 
were prepared in 1% NGS in PBS and the blocking buffer was removed and 
replaced with the primary antibody and incubated overnight at 4°C in a humidity box, 
to prevent drying. For negative control, antibody diluent containing no antibody was 
added to the target well. Following an overnight incubation, the primary antibody was 
removed and the wells were washed 4 times with PBS containing 1% NGS.  
Secondary Ab was prepared at dilution 1:500 in 2% BSA in PBS and added to the 
dishes. The vessels were again placed upon a tray which was wrapped in foil and 
placed on a rocker at medium speed in a dark room for 60 min. Following this time, 
cells were washed in PBS for 3 x 5 min.  
 
At the final wash extra care was taken to remove as much PBS as possible. A small 
drop of Vectorshield mounting medium with DAPI (vector laboratories) was placed 
on a glass round coverslip diameter 22 mm.  The coverslip was gently placed onto 
the surface of the Fluorodish using forceps. Care was taken to lower the coverslip 
onto the dish so as to avoid disruption of cells and formation of air bubbles.  
Dishes were placed on a tray and wrapped in foil and left at 4°C until imaging.  
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Table 7. Antibodies and dilution used for β-catenin immunocytochemistry. 
 
 Antibody  Dilution Total Volume 
per Fluorodish 
Primary 
 
Mouse monoclonal to β-catenin 
(abcam ab22656) 
1:250 in PBS 
BSA 2% 
750 µl 
Secondary 
 
Cy 5 Goat anti-mouse IgG  
(SouthernBiotech-1030-15) 
1:500 in PBS 
BSA 2%  
750 µl 
 
3.2.5 Imaging and analysis of β-catenin immunostaining 
 
Colonies were imaged using an Olympus microscope system. The specific colony 
imaged in the live cell Ca2+ experiment was identified using 10x objective. Cells of 
this colony were then imaged using x40 objective at x3 zoom excited with a 647 nm 
wavelength. Serial images were taken at 0.63 µm intervals forming a Z stack. Z-
stacks were visually assessed to explore differences in β-catenin expression 
following Wnt treatment and amongst cells in different colony types.  
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3.3 Results 
3.3.1 Colony formation   
 
Cells plated at clonal density (see section 2.2.1) in 6 well plates (Nunc), were 
cultured for 10 days and during this period formed clusters, or colonies that could be 
visually categorised into 2 types as shown in Figure 8. One type of colony consisted 
of tightly clustered, rounded cells and with a colony outline which could be well 
demarcated. Examples of the two types of colonies observed at day 10 are as shown 
in Figure8. 
 
This was consistent with holoclones or meroclone colonies previously described (Li 
et al., 2008; Pfeiffer and Schalken, 2010; Zhang and Waxman, 2010). A further type 
of colony was formed of cells with a greater inter-cellular distance, flattened in 
appearance and with a colony outline which was difficult to demarcate. The 
holoclone/meroclone packed colony is shown in figure 8A and the sparser, less 
distinct paraclone colony type shown in figure 8B. 
 
PC3 cells plated on 6 well plates at 60 cells / well were incubated in an IncuCyte™ 
and imaged every 6 hours for 10 days as described in materials and methods 
(section 2.2.1). IncuCyte™ images around 25% of the well, which decreases the 
probability of focussing upon a single cell. Nonetheless, several single cells were 
captured at the start of imaging which went on to form colonies. Figure 9 shows 
representative images from IncuCyte™ at given time intervals which demonstrate 
the formation of a colony from a single cell. The images presented are representative 
of at least four independent experiments. 
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Figure 8. Image of 2 distinct PC3 cell colonies formed after 10 days culture at clonal density.  
PC3 cells were plated on Nunc 6 well plates at clonal density, defined as 60 cells / well in 3 ml 
of culture medium (60 cells / 9.6cm
2
). Colonies were imaged, and colony size measured at day 
10. Colony on the left (A) morphologically a holoclone or meroclone with tightly clustered cells 
and colony on the right (B) a paraclone with the appearance of more dispersed cells. Scale bar 
as shown. Representative image of experiments performed at least 10 times. 
 
 
 
(A)                                                   (B) 
 
                                                                          100 µm 
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Figure 9. Sequential imaging using IncuCyte™ live image acquisition system showing colony formation by a single cell over a 10 period.  
PC3 cells plated on 6 well plates (Nunc) at 60 cells / well in 3 ml of culture medium (60 cells / 9.6cm
2
). Plates were incubated in an IncuCyte™ and 
imaged every 6 hours for 10 days. Row (A) shows a single cell at day 1. This forms a colony of tightly clustered cells. (B) shows a single cell at day 
1. This forms a colony of dispersed cells. Therefore, 2 morphologically distinct colony types are observed: (A) holo/meroclone and (B) paraclone. 
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Colony formation by PC3 cells in 6 well plates was analysed. The experiment was 
repeated 4 times and data from 24 wells was obtained. A total of 198 colonies were 
observed at day 10 were and subjectively, morphologically categorised into 2 colony 
types: holo/meroclones or paraclones. Each colony was measured for diameter as 
shown in Figure 10A. This was defined as the greatest distance between 2 cells of a 
colony.  
 
Figure 10B shows the automated conversion of an imaged colony into black and 
white for the calculation of an objective measure of how closely packed cells were in 
a colony, i.e. inter-cellular distance. This measure was defined as the “mean cell 
density” within each colony. Details regarding the processing of images and 
calculation of mean cell density are described in section 3.2.1.  
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Figure 10. Representative colony imaged using a bright field microscope.  
(A) Shows a measurement made of the longest dimension of the colony. (B) Shows the image 
converted to a black and white 8 bit image by ImageJ for subsequent calculation of the % 
cellularity. PC3 cells were plated at cell density 60 cells / well in 3 ml of culture medium (60 
cells / 9.6cm
2
) in 6 well plates (Nunc). Colony formation by PC3 cells was analysed. 
 
 
(A) An example of a colony 
and the measured length as 
shown with a line. The 
length of the line is  the 
colony diammeter (434 µm) 
 
 
 
 
(B) Image converted to 8-bit 
and proportion of total 
colony area covered by cells 
calculated (as described in 
section 3.2.5) 
  
 
 
 
 
                                       100 µM 
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Two, morphologically distinct, types of colonies were formed: holo/meroclones and 
paraclones. Table 8 describes parameters of almost 200 colonies analysed when 
PC3 cells were plated at clonal density. In a total of 24 wells, 102 colonies were 
formed and identified, morphologically, as holo/meroclones and 96 colonies as 
paraclones. Of the holo/meroclones, a mean number of 4.3 ± 0.4 colonies were 
formed with a mean diameter of 837.7 ± 21.6 µm. Of the paraclones, a mean number 
of 4.0 ± 0.4 colonies were formed with a mean diameter of 1191.3 ± 28.3 µm. Figure 
10 shows the distribution of PC3 colony diameters. The diameters of all colonies 
formed are presented in Figure 11A and the distribution of colony diameter according 
to morphological type of colony (holo/meroclone or paraclone) is shown in Figure 
11B. 
 
There was no difference in the number of holo/meroclones formed and number of 
paraclones formed. An independent t-test performed for equality of means found that 
the diameter of paraclones was greater than the diameter of holo/meroclones 
(p<0.05).  
 
Thirteen colonies out of 120, comprising of both holo/meroclones and paraclones, 
were randomly selected and imaged at day 10 of culture and analysed for their % 
cellularity (summarized in Table 9). The mean cell density of holo/meroclones was 
27.3 ± 3.2 (n=8, mean ± SE) and the mean cell density of paraclones was 4.7 ± 0.4 
(n=5). To enable valid statistical testing, mean cell densities (which were proportions 
ranging from 0-1.0) were transformed using an arcsine transformation. A Mann-
Whitney U test was applied to transformed measurements. The mean cell density in 
holo/meroclones was significantly greater than in paraclones (p<0.05). 
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Table 8. Characteristics of colonies formed by PC3 cells. 
Two, morphologically distinct, types of colonies are formed: holo/meroclones and paraclones. 
PC3 cells were plated at cell density 60 cells / well in 3 ml of culture medium (60 cells / 9.6cm
2
) 
in 6 well plates (Nunc). Colony formation by PC3 cells was analysed. The experiment was 
repeated 4 times and data from 24 wells was obtained. A total of 198 colonies were observed at 
day 10 and subjectively, morphologically categorised into 2 colony types: holo/meroclones or 
paraclones. Each colony was measured for diameter. The table shows numbers of colonies 
formed in a total of 24 wells; mean number of colonies formed per well and diameter of 
individual colony (data is presented as mean ± SE). 
 
 
 
 
Morphological 
holo/meroclones 
 
Morphological paraclones 
 
 
Number of colonies in 4 
experiments (24 wells) 
 
 
102 
 
96 
 
Mean number of colonies 
formed per well 
 
 
4.3 ± 0.4 
 
4.0 ± 0.4 
 
Mean diameter of each 
colony (µm) 
 
 
837.7 ± 21.6 
 
1191.3 ± 28.3 
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Figure 11. Histogram showing the distribution of PC 3 colony diameters. 
PC3 cells were plated at cell density 60 cells / well in 3 ml of culture medium (60 cells / 9.6cm
2
) 
in 6 well plates (Nunc). Colony formation by PC3 cells was analysed. 198 colonies were 
observed at day 10 were and subjectively, morphologically categorised into 2 colony types: 
holo/meroclones or paraclones. Each colony was measured for diameter. (A) Shows colony 
diameters of all colonies formed. (B) Shows colony diameter according to type of colony 
(holo/meroclone or paraclone). 
 
 
 
10A 
 
 
 
  
0
10
20
30
40
50
60
F
re
q
u
e
n
c
y
 (
N
u
m
b
e
r 
o
f 
c
o
lo
n
ie
s
) 
Colony diameter (µm) 
100 
 
10B 
 
 
 
 
 
 
  
0
5
10
15
20
25
30
35
40
Holo/meroclones Paraclones
Colony diameter (µm) 
F
re
q
u
e
n
c
y
 (
N
u
m
b
e
r 
o
f 
c
o
lo
n
ie
s
) 
101 
 
Table 9. Colony diameter; subjective morphology; % cellularity and the arc sin of these values 
for a random selection of 13 colonies observed and analysed at day 10 of culture. 
PC3 cells were plated at cell density 60 cells / well in 3 ml of culture medium (60 cells / 9.6cm
2
) 
in 6 well plates (Nunc). Colony formation by PC3 cells was analysed. % cellularity describes 
the proportion of total colony area covered by cells and these values were transformed using 
an arc sin function for valid statistical analysis. 
 
 
Colony 
diameter 
 
Categorisation by 
morphology 
 
% 
cellularity 
 
arc sin of % 
cellularity 
    
356 Holo/meroclone 36 37 
434 Holo/meroclone 17 24 
625 Holo/meroclone 31 34 
650 Holo/meroclone 30 33 
739 Holo/meroclone 41 40 
896 Holo/meroclone 17 24 
1086 Holo/meroclone 25 30 
1124 Holo/meroclone 21 28 
1108 Paraclone 5 12 
1431 Paraclone 4 11 
1664 Paraclone 4 12 
1761 Paraclone 6 14 
1868 Paraclone 5 12 
 
 
3.3.2 Expression of stem cell genes in different populations of PC3 cells  
 
As described in section 2.7, RNA was extracted from colonies and following reverse 
transcription, cDNA PCR was performed to test for expression of stem cell genes. 
PCR was performed on 3 separate passages of colonies formed. Results for gene 
expression in holo/meroclones and paraclones are shown in Table 10. The results 
show that there was a differential expression of the 4 stem cell genes between 
102 
 
holo/meroclones and paraclones. Whilst both holo/meroclones and paraclones 
expressed BMI1, only holo/meroclones expressed Oct 4 whilst paraclones did not 
express Oct 4. These results were consistent in 3 passages of experimental repeats. 
Expression of two stem cell genes was not detected in cells of either colony type – 
these were BCRP and hSOX. Example agarose gel images of product 
electrophoresis are shown in Figure 12. 
 
 
Table 10. Summary of expression of 4 stem cell genes: BM1, Oct 4, BCRP and hSOX in cells of 
holo/meroclones and paraclones with 3 experimental repeats.  
PC3 cells in a single cell suspension were plated at clonal density (60 cells / well) in Nunc 6 
well plates. Cells were cultured in 3ml culture medium which was replaced after 5 days. 
Colonies were viewed using a microscope at x10 magnification and categorised as 
holo/meroclones or paraclones, based upon morphology. Cells were washed in PBS and 
replaced in 1ml PBS/well. A 200µl pipette was used to disrupt individual colonies and aspirate 
cells from individual colonies in a small volume of PBS. One centrifuge tube was used to 
collect cells aspirated from holo/meroclone colonies and another centrifuge tube used to 
collect cells from paraclone colonies. Cell suspensions were centrifuged at 350 x g for 5 min to 
obtain a cell pellet. RNA was extracted from colonies and following reverse transcription, 
cDNA PCR was performed to test for expression of stem cell genes. 
 
   
Holo/meroclones 
 
Paraclones 
 
(1) 
 
BMI 1 
 
Positive 
 
Positive 
 
(2) 
 
Oct 4 
 
Positive 
 
Absent 
 
(3) 
 
BCRP 
 
Absent 
 
Absent 
 
(4) 
 
hSOX 
 
Absent 
 
Absent 
 
(5) 
 
GAPDH 
 
Positive 
 
Positive 
 
(6)  
 
GAPDH - control 
(no cDNA) 
 
Absent 
 
Absent 
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Figure 12. Agarose gel electrophoresis of PCR products from holo/meroclones (A) and 
paraclones (B).  
0.5 µg template cDNA was used in all PCR reactions per reaction tube. The volume of cDNA 
required for 0.5 µg was calculated and made up to a volume of 12 µl with RNase free water. A 
reaction mixture of Taq PCR mastermix solution, Primer A (forward) 8.4 µM, Primer A (reverse) 
8.4 µM, RNase-free water + Template DNA 0.5 µg was made up to a total volume of 30 µl. 
Agarose gel 1.1% was made up using 150 ml TAEx1 with 1.65g agarose and  10 µl 0.5 μg/ml 
ethidium bromide (Sigma-Aldrich) for visualisation. 10 µl of each PCR product was pipetted 
into wells with 1μl 10x Blue Juice loading dye (Sigma-Aldrich). 2 µl of 1K base pair DNA ladder 
(ThermoFisher Scientific 10787-018) was also pipetted into a well in each column with <1 μl 
10x Blue Juice loading dye. Gel electrophoresis was performed using a current was applied at 
110V for 70 min followed by the gel imaging under UV light. Presence of product bands at the 
expected sizes is indicative of expression of that specific gene.1=BMI 1; 2=Oct 4; 3=BCRP; 
4=hSOX; 5=GAPDH; 6=GAPDH negative control (no cDNA); L=ladder. 
 
(A)  
         
 
  
(B) 
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3.3.3 Wnt induced [Ca2+]i release in PC3 cell line derived colonies  
 
As described in section 3.2.3, intensity ratio of Fluo-4 : FuraRed was measured in 
cells defined as regions of interest (ROI). An example of a view of cells defined as 
regions of interest following staining with Fluo-4 and FuraRed is shown in Figure 13. 
Intensity ratios were observed and analysed from over a period of up to 15min during 
which cells were treated with PBS control or Wnt. There was no change in intensity 
ratios of the stained cells following treatment with PBS control. There was a change 
in intensity ratios following the addition of Wnt ligands to the plate. A representative 
example of changing Fluo-4 intensity in cells of a colony over time following 
treatment with Wnt5A is shown in Figure 14.  
 
Waveform graphs were created of intensity ratio of Fluo-4 : FuraRed against time 
indicating changes in [Ca2+]I. As described in section 3.2.3, the kinetics of [Ca
2+]i 
within each cell analysed was determined using graphs to calculate rise, fall and 
dwell times of [Ca2+]i (Thrasivoulou et al., 2013).  
 
There was no change in intensity ratios of the stained cells following treatment with 
PBS control on 3 experimental repeats. A total of 104 cells within holo/meroclones 
and a total of 109 cells within paraclones were analysed for intracellular response to 
Wnts. These cells were in colonies cultured and tested in 3 experimental repeats. All 
holo/meroclone colonies demonstrated an [Ca2+]i response to treatment with Wnt5A 
and to treatment with Wnt 9B. The majority of paraclones tested demonstrated an 
[Ca2+]i response to both Wnt 5A and Wnt 9B. A representative waveform of intensity 
ratio of Fluo-4 : FuraRed in a single cell region of interest against time following Wnt 
treatment with a Gaussian fit curve is shown in Figure 15A. 
 
Following an initial (primary) [Ca2+]i response and a return to baseline, a number of 
cells of holo/meroclones, particularly those treated with Wnt 9B, demonstrated a 
second rise in [Ca2+]i. An example of such a waveform with a primary and secondary 
response is shown in Figure 15B. 
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Figure 13. A holo/meroclone imaged for intensities of (A) Fluo-4 and (B) FuraRed with a 
selection of cells sampled as regions of interest for analysis. 
Cells were plated at clonal density (40 cells in 1 ml culture medium / dish) on 35-mm 
FluoroDishes (see methods). After 1 day, once cells had become adherent, a further 1 ml RPMI 
was added to each dish. Culture medium was changed on day 7. Colonies were used for live 
cell Ca
2+
 imaging at day 12. Intensity ratio of Fluo-4 : FuraRed was measured in cells defined 
as regions of interest (ROI).  
 
(A)                                                            (B) 
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Figure 14. Changing intensity of Fluo-4 in cells of a holo/meroclone colony over time following treatment with Wnt5A. 
Cells were plated at clonal density (40 cells in 1 ml culture medium / dish) on 35-mm FluoroDishes (see methods). After 1 day, a further 1 ml RPMI was 
added to each dish. Culture medium was changed on day 7. Colonies were used for live cell Ca
2+
 imaging at day 12.  Cells of colonies cultured on a 
Fluorodish were treated with 100 ng/ml Wnt 5A, 100 ng/ml Wnt 9B or control. Intensity in cells demarcated as regions of interest. Intensity ratios of Fluo-4 
and FuraRed were measured for up to 15 min during which cells were treated with PBS control or Wnt. 
 
 
 
 
 
 
 
Baseline  
 
50 seconds 
 
 
85 seconds 
 
 
110 seconds 
 
 
140 seconds 
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Figure 15. Intensity ratio of Fluo-4 : FuraRed in a single cell region of interest against time 
following Wnt treatment with a Gaussian fit curve. 
Cells were plated at clonal density (1 cell / 32mm
2
) on 35-mm FluoroDishes. Colonies were 
used for live cell [Ca
2+
]i  imaging at day 12.  Cells of colonies cultured on a Fluorodish were 
treated with Wnt 5A, Wnt 9B or control. Intensity in cells was demarcated as regions of 
interest. Intensity ratios of Fluo-4 and FuraRed were observed and analysed from over a period 
of up to 15 min during which cells were treated with PBS control or Wnt. Intensity ratio of Fluo-
4 : FuraRed in single cell regions of interest when imaged using live cell imaging were 
calculated and plotted against time following treatment with Wnt. (A) shows a representative 
waveform of intensity ratio of Fluo-4 : FuraRed in a single cell region of interest when imaged 
using live cell imaging against time following treatment with Wnt. (B) shows a representative 
waveform of intensity ratio of Fluo-4 : FuraRed in a single cell region of interest against time 
following treatment with Wnt with an initial rise followed by a second rise in intensity ratio. In 
(B) a primary response is observed and a longer total response time.  
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Table 11 summaries the numbers of cells within holo/meroclones and cells within 
paraclones in which Wnt 5A and Wnt 9B induced [Ca2+]i was observed and the 
numbers in which either response single waveform only or a primary or secondary 
waveform was observed. Figure 16 shows these results graphically. In paraclone 
colonies Wnts (5A or 9B) did not induce [Ca2+]i  in some cells; as a control, other 
cells within the same colonies were observed to have Wnt induced [Ca2+]i release. A 
smaller proportion of cells within paraclones showed a secondary waveform to Wnt 
9B and Wnt 5A. Chi squared statistical tests were performed on the data using IBM 
SPSS. With regards to [Ca2+]i release observed with Wnt 5A treatment (n=103), this 
was more likely to occur in cells of holo/meroclones than in paraclones (p<0.05). 
[Ca2+]i release was also more likely to occur in cells of holo/meroclones than in cells 
of paraclones following treatment with Wnt 9B (n=110). Cells of holo/meroclones 
were also more likely than cells of paraclones to demonstrate a secondary response 
in [Ca2+]i release (n= 213, p<0.05). Amongst all cells, Wnt 9B was more likely to 
produce a secondary response in [Ca2+]i release than Wnt 5A (n=213, p<0.05).  
 
 
  
In
te
n
s
it
y
 R
a
ti
o
 
Time (seconds) 
109 
 
Table 11. Response of cells within holo/meroclones and paraclones to Wnt 5A and Wnt 9B. 
Cells of colonies cultured on a Fluorodish were treated with Wnt 5A, Wnt 9B or control. 
Intensity in cells were demarcated as regions of interest. Intensity ratios of Fluo-4 and 
FuraRed were observed and analysed from over a period of up to 15 min during which cells 
were treated with PBS control or Wnt. Intensity ratio of Fluo-4 : FuraRed in single cell regions 
of interest when imaged using live cell imaging were calculated and plotted against time 
following treatment with Wnt. Either no response, primary response only or both primary and 
secondary response waveforms were observed as shown below. 
 
 
 
Wnt and colony type 
 
 
No response 
 
 
Primary response 
only 
 
Primary and 
secondary response 
 
5A Holo/meroclones 
 
 
0 
 
44 
 
8 
 
9B Holo/meroclones 
 
 
0 
 
30 
 
22 
 
 
5A Paraclones 
 
11 
 
42 
 
5 
 
 
9B Paraclones 
 
11 
 
32 
 
8 
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Figure 16. Numbers of cells within holo/meroclones and paraclones demonstrating a Wnt 
induced free intracellular calcium release [Ca
2+
]i following treatment with Wnt 5A and Wnt 9B.  
Intensity ratio of Fluo-4 : FuraRed in single cell regions of interest when imaged using live cell 
imaging were calculated and plotted against time following treatment with Wnt. For [Ca
2+
]i 
release, either no response, primary response only or both primary and secondary response 
waveforms were observed. All analysed cells in holo/meroclones responded to Wnt 5A with a 
proportion of cells demonstrating a primary response and others a primary and secondary 
response; All analysed cells in holo/meroclones responded to Wnt 9B with a proportion of 
cells demonstrating a primary response and others a primary and secondary response; not all 
cells in paraclones responded to Wnt 5A but a proportion demonstrated a primary response 
and others a primary and secondary response; not all cells in paraclones responded to Wnt 9B 
but a proportion demonstrated a primary response and others a primary and secondary 
response. With regards to [Ca
2+
]i release observed with Wnt 5A treatment (n=103), this was 
more likely to occur in cells of holo/meroclones than in paraclones (p<0.05). [Ca
2+
]i release 
was also more likely to occur in cells of holo/meroclones than in cells of paraclones following 
treatment with Wnt 9B (n=110). Cells of holo/meroclones were also more likely than cells of 
paraclones to demonstrate a secondary response in [Ca
2+
]i release (n= 213, p<0.05). (see 
asterisk below). 
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Primary and secondary response 
Primary response only 
No response  
* p<0.05 [Ca2+]i occurs more frequently in holo/meroclones  
 
* p<0.05 [Ca2+]i I occurs  more frequently in holo/meroclones 
  
*                   * 
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Rise, dwell, fall and total duration of response times of cells within holo/meroclones 
and cells within paraclones in response to Wnt 5A and Wnt 9B were calculated. 
Table 12 summarises these results. The duration of the 1° responses and the 
duration of the entire responses, taking into account the duration of any 2° 
responses observed are presented in Table 12. Results are presented as mean ± 
standard error. Significance tests are presented in text below using the Mann-
Whitney Test.  
 
Table 12. Summary of the rise, dwell and fall times for [Ca
2+
]i of cells within holo/meroclones 
and paraclones in response to Wnt 5A and Wnt 9B presented as mean ± SE.  
Intensity ratio of Fluo-4 : FuraRed in single cell regions of interest when imaged using live cell 
imaging were calculated and plotted against time following treatment with Wnt. Either no 
response, primary response only or both primary and secondary response waveforms were 
observed. The table below summarises findings by colony type and Wnt. 
 
  
Holo/meroclones 
 
 
Paraclones 
 
Wnt 
 
 
5A 
 
9B 
 
5A 
 
9B 
 
n 
 
 
52 
 
52 
 
47 
 
40 
 
Rise time seconds 
 
13.8 ± 1.8* 
 
 
32.3 ±4.2 
 
23.5 ± 4.0* 
 
45.8 ± 10.6 
5A: rise time for paraclones longer than holo/meroclones 
p<0.05 
9B: no difference in rise times between colony types p=0.08 
 
Holo/meroclones: rise time with Wnt 5A shorter than Wnt 9B 
p<0.05 
Paraclones: rise time with Wnt 5A shorter than Wnt 9B p<0.05 
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Dwell time 
seconds 
 
38.0 ± 4.3* 
 
45.3 ± 2.6 
 
93.9 ± 8.6* 
 
84.3 ± 10.5 
5A: dwell time for paraclones longer than holo/meroclones 
p<0.05 
9B: dwell time for paraclones longer than holo/meroclones 
p<0.05 
 
Holo/meroclones: dwell time with Wnt 5A shorter than Wnt 9B 
p<0.05 
Paraclones: no difference in dwell time between Wnt type 
p=0.23 
 
Fall time seconds 
 
96.5 ± 7.0 
 
85.5 ± 7.4 
 
114.8 ± 10.2* 
 
179.8 ± 17.7* 
5A: no difference in fall times between colony types  
9B: fall time for paraclones was longer than holo/meroclones 
<0.05  
 
Holo/meroclones: no difference in fall time between Wnt type 
p=0.10 
Paraclones: fall time with Wnt 5A shorter than Wnt 9B p<0.05 
 
Duration primary 
response 
 
148.2 ± 8.6 
 
146.5 ± 6.4 
 
232.3 ± 20.3* 
 
309.9 ± 23.3* 
5A: duration of primary response longer in paraclones than 
holo/meroclones p<0.05 
9B: duration of primary response longer in paraclones than 
holo/meroclones p<0.05 
 
Holo/meroclones: no difference in duration of primary response 
between Wnt type p=0.90  
Paraclones: duration of primary response with Wnt 5A shorter 
than Wnt 9B p<0.05 
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Duration total 
response 
 
185.2 ± 17.7* 
 
405.7 ± 40.2 
 
272.2 ± 27.1* 
 
350.4 ± 25.7 
5A: duration total response longer in paraclones than 
holo/meroclones p<0.05 
9B: no difference in duration of total response between colony 
types p=0.68 
 
Holo/meroclones: duration total response shorter with Wnt 5A 
than Wnt9B p<0.05 
Paraclones: duration total response shorter with Wnt 5A than 
Wnt9B p<0.05 
 
 
This data was further analysed to ascertain if there were any differences in how cells 
of holo/meroclones compared to cells of paraclones responded to Wnts, in terms of 
rise time, dwell time, fall time, duration of primary response or the duration of total 
response. As shown below, Mann Whitney U tests were performed on the data for 
any differences in these Ca2+ responses with regards to colony type (Figure 17).   
 
A similar analysis was performed to establish if there were differences in rise time, 
dwell time, fall time, duration of primary response or the duration of total response for 
free [Ca2+]i when cells of the same colony type were treated either Wnt 5A or Wnt 
9B. I.e., if cells of holo/meroclones demonstrated a different response when treated 
with Wnt 5A compared to Wnt 9B, and similarly if cells of paraclones demonstrated a 
different response when treated with Wnt 5A compared to Wnt 9B. These analyses 
are summarised in Figure 18.  
 
When comparing [Ca2+]i following Wnt 5A treatment by colony type, significant 
differences between cells of holo/meroclones and cells of paraclones were observed. 
Both rise time and dwell times for paraclones (n=47) were longer than 
holo/meroclones (n=52) p<0.05. In addition, durations of both primary and total 
response were longer than in cells of paraclones (n=47) than holo/meroclones 
(n=52) p<0.05. Following treatment with Wnt 9B, dwell time and fall time in cells of 
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paraclones (n=40) were longer than in cells of holo/meroclones (n=52) p<0.05. 
Duration of primary response in cells of paraclones (n=40) was also longer than in 
cells of holo/meroclones (n=52) p<0.05. 
 
When comparing responses of the same cell type to Wnts, both cells of 
holo/meroclones (n=52) and cells of paraclones (n=47) had a shorter rise time 
following treatment with Wnt 5A than with Wnt 9B (n=52; n=40) p<0.05. Compared 
with Wnt 9B (n=52), Wnt 5A (n=52) induced a shorter dwell time in holo/meroclones. 
p<0.05. In cells of holo/meroclones, the durations of dwell time and total response 
following treatment were shorter with Wnt 5A (n=52) than following treatment with 
Wnt9B (n=52) p<0.05. Similarly, in cells of paraclones, the duration of the total 
response following treatment with Wnt 5A (n=47) was shorter than following 
treatment with Wnt9B (n=40) p<0.05. 
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Figure 17. [Ca
2+
]i response rise time (A), dwell time (B), fall time (C), duration primary response (D), and duration total response (E) in 
holo/meroclones compared to in paraclones following treatment with Wnt 5A (left column) and Wnt 9B (right column). 
Intensity ratio of Fluo-4 : FuraRed in single cell regions of interest when imaged using live cell imaging were calculated and plotted against time 
following treatment with Wnt. Either no response, primary response only or both primary and secondary response waveforms were observed. 
Each waveform was analysed for the duration, in seconds, of rise time, dwell time, fall time the duration of the initial (primary response) and the 
duration of the total response when intensity ratios were plotted against time. The figure below summarises findings by colony type and Wnt. 
 
 
 
 
 Wnt 5A treatment 
 
 Wnt 9B treatment 
(A) 
Rise time  
 
 
 
Figure shows rise time of [Ca2+]i in holo/meroclones 
compared to in paraclones following treatment with Wnt 
5A. Rise time for paraclones (n=47) was longer than for 
cells of holo/meroclones (n=52) p<0.05 designated by 
an asterisk.  
 
 
 
 
Figure shows rise time of [Ca2+]i in holo/meroclones 
compared to in paraclones following treatment with Wnt 
9B. There was no difference in rise times between 
holo/meroclones (n=52) and paraclones (n=40) p=0.08. 
* p<0.05 n.s. 
116 
 
 
  
 Wnt 5A treatment 
 
 Wnt 9B treatment 
(B) 
Dwell time  
 
 
 
 
Figure shows dwell time of [Ca2+]i in holo/meroclones 
compared to in paraclones following treatment with Wnt 
5A. Dwell time for paraclones (n=47) was longer than for 
cells of holo/meroclones (n=52) p<0.05 designated by 
an asterisk.  
 
 
 
 
 
Figure shows dwell time of [Ca2+]i in holo/meroclones 
compared to in paraclones following treatment with 
Wnt 9B. Following treatment with Wnt 9B, dwell time 
for paraclones (n=40) was longer than for cells of 
holo/meroclones (n=52) p<0.05 designated by an 
asterisk.  
 
 
 
 
* p<0.05 * p<0.05 
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Wnt 5A treatment 
 
Wnt 9B treatment 
(C) 
Fall time  
 
 
 
 
 
Figure shows fall time of [Ca2+]i in holo/meroclones 
compared to in paraclones following treatment with Wnt 
5A. Fall time in cells of holo/meroclones (n=52) is no 
different than cells of paraclones (n=47).  
 
 
 
 
 
 
Figure shows fall time of [Ca2+]i in holo/meroclones 
compared to in paraclones following treatment with 
Wnt 9B. Following treatment with Wnt 9B, fall time for 
paraclones (n=40) was longer than for cells of 
holo/meroclones (n=52) p<0.05 designated by an 
asterisk.  
 
 
 
  
n.s. * p<0.05 
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Wnt 5A treatment 
 
Wnt 9B treatment 
(D) 
Duration 
primary 
response 
 
 
 
Figure shows duration of primary response, as defined 
by time from rising above the 10% intensity threshold to 
the first fall back to the 10% intensity threshold. 
Following treatment with Wnt 5A, duration of primary 
response in cells of paraclones (n=47) is longer than in 
cells of holo/meroclones (n=52) p<0.05 designated by 
an asterisk.  
 
 
 
 
Figure shows duration of primary response, as defined 
by time from rising above the 10% intensity threshold to 
the first fall back to the 10% intensity threshold. 
Following treatment with Wnt 9B, duration of primary 
response in cells of paraclones (n=40) is longer than in 
cells of holo/meroclones (n=52) p<0.05 designated by 
an asterisk.  
 
 
 
* p<0.05 * p<0.05 
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Wnt 5A treatment 
 
Wnt 9B treatment 
(E) 
Duration total 
response 
 
 
 
Figure shows duration of total response, as defined by 
time from rising above the 10% intensity threshold to the 
final fall back to the 10% intensity threshold. Following 
treatment with Wnt 5A, duration of total response in cells 
of paraclones (n=47) is longer than in cells of 
holo/meroclones (n=52) p<0.05 designated by an asterisk.  
 
 
 
 
 
Figure shows duration of total response, as defined 
by time from rising above the 10% intensity threshold 
to the final fall back to the 10% intensity threshold. 
Following treatment with Wnt 9B, there is no 
difference in duration of total response between cells 
of holo/meroclones (n=52) and cells of paraclones 
(n=40) p=0.68.  
 
 
  
n.s. * p<0.05 
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Figure 18. Calcium response rise time (A), dwell time (B), fall time (C), duration primary response (D), and duration total response (E) following 
treatment with Wnt 5A compared to Wnt 9B in holo/meroclones (left) and paraclones (right). 
 
 
 
 
 
 
 
Holo/meroclone 
 
Paraclone 
 
Rise time 
 
 
 
 
 
Figure shows rise time in holo/meroclones following 
treatment with Wnt 5A compared to Wnt 9B.  
In cells of holo/meroclones duration of rise time with Wnt 
5A (n=52) treatment is shorter than with Wnt 9B (n=52) 
p<0.05 designated by an asterisk.  
 
 
 
 
 
Figure shows rise time in paraclones following 
treatment with Wnt 5A compared to Wnt 9B. In cells 
of paraclones, duration of rise time with Wnt 5A 
(n=47) treatment is shorter than with Wnt 9B (n=40) 
p<0.05 designated by an asterisk.  
 
* p<0.05 * p<0.05 
Wnt ligand Wnt ligand 
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Holo/meroclone 
 
Paraclone 
 
Dwell time  
 
 
 
 
 
 
Figure shows dwell time in holo/meroclones following 
treatment with Wnt 5A compared to Wnt 9B. In cells within 
holo/meroclones, dwell time of following treatment with 
Wnt 5A (n=52) is shorter than compared with Wnt 9B 
(n=52) (p=<0.05). 
 
 
 
 
 
 
Figure shows dwell time in paraclones following 
treatment with Wnt 5A compared to Wnt 9B. In 
cells of paraclones, there is no difference in dwell 
time following treatment with Wnt 5A (n=40) or 9B 
(n=47) (p=0.23). 
 
 
 
n.s. * p<0.05 
Wnt ligand Wnt ligand 
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Holo/meroclone 
 
Paraclone 
 
Fall time  
 
 
 
 
 
Figure shows fall time in holo/meroclones following 
treatment with Wnt 5A compared to Wnt 9B. In cells of 
holo/meroclones, there is no difference in fall time 
following treatment with Wnt 5A (n=52) compared with Wnt 
9B (n=52) (p=0.10). 
 
 
 
 
 
Figure shows fall time in paraclones following 
treatment with Wnt 5A compared to Wnt 9B. In cells 
of paraclones, duration of fall time following 
treatment with Wnt 5A (n=47) is shorter than with 
Wnt 9B (n=40) (p<0.05). 
 
n.s. 
Wnt ligand Wnt ligand 
* p<0.05 
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Holo/meroclone 
 
Paraclone 
 
Duration 
primary 
response 
 
 
 
 
 
Figure shows duration of primary response in 
holo/meroclones following treatment with Wnt 5A 
compared to Wnt 9B. In cells of holo/meroclones, there is 
no difference in duration of the primary response following 
treatment with Wnt 5A (n=52) or with Wnt 9B (n=52) 
(p=0.90).  
 
 
 
 
 
Figure shows duration of primary response in 
paraclones following treatment with Wnt 5A 
compared to Wnt 9B. In cells of paraclones, duration 
of primary response following treatment with Wnt 5A 
(n=47) is shorter than following treatment with Wnt 
9B (n=40) (p<0.05). 
 
 
 
n.s. 
Wnt ligand 
Wnt ligand 
* p<0.05 
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Holo/meroclone 
 
Paraclone 
 
Duration total 
response 
 
 
 
 
 
Figure shows duration of total response in holo/meroclones 
following treatment with Wnt 5A compared to Wnt 9B. In 
cells of holo/meroclones, the duration of the total response 
following treatment with Wnt 5A (n=52) is shorter than 
following treatment with Wnt 9B (n=52) (p<0.05) 
designated by an asterisk.  
 
 
 
 
 
 
Figure shows duration of total response in 
paraclones following treatment with Wnt 5A 
compared to Wnt 9B. In cells of paraclones, the 
duration of the total response following treatment 
with Wnt 5A (n=47) is shorter than following 
treatment with Wnt 9B (n=40) (p<0.05) designated 
by an asterisk.  
 
Wnt ligand Wnt ligand 
* p<0.05 * p<0.05 
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3.3.4 Expression of β-catenin in colonies with and without Wnt treatment and 
co-localisation of β-catenin in the nucleus 
 
Negative controls for immunostaining were performed using no primary antibody 
(section 3.2.4). With no primary antibody to bind the secondary antibody, lack of 
signal in negative controls demonstrates specificity of the primary antibody in 
subsequent experiments. Negative controls demonstrated no secondary antibody 
signal as shown in Figure19 below. 
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Figure 19. Experiments conducted as negative controls using no primary antibody and a 
flurophore secondary antibody (Cy 5 Goat anti-mouse IgG) counter stained with DAPI (blue) 
show that there was no non-specific binding of the secondary antibody. 
A-L show signal observed at excitation 647 nm, emission 667 nm.  A-C show the same whole 
colony: A shows DAPI staining, B signal observed for flurophore secondary antibody Cy 5, C 
shows A+B merge. D,E,F,G,H,I,J,K,L show higher magnification of cells within this colony. 
D,G,J show DAPI staining, E,H,K show signal observed for flurophore secondary antibody Cy 
5; F,J,L show respective merge images. Z-stacks obtained using an Olympus confocal system 
are shown. Representative image following at least 10 repeats. Scale Bar A,B,C: 180 µm; 
D,E,F,G,H,I,J,K,L: 15 µm. 
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As outlined in section 3.2.4, PC3 cells in holo/meroclones were tested for Wnt 5A 
and Wnt 9B induced [Ca2+]i release and then underwent immunostaining for 
expression of β-catenin. As a control for the expression of β-catenin in cells of 
holo/meroclones without Wnt ligand treatment, cells were treated with PBS control 
and then fixed and stained for β-catenin (section 3.2). Figures 20-22 below show the 
expression of β-catenin by immunocytochemistry in cells of holo/meroclones in the 
experiments as indicated: figure 20 shows cells of a holo/meroclone treated with 
PBS control; figure 21 shows cells of a holo/meroclone treated with Wnt 5A and 
Figure 22 shows cells of a holo/meroclone treated with Wnt 9B. Figure 20 shows all 
imaged cells of holo/meroclones treated with PBS control expressed β-catenin. 
However, comparatively, Figures 21 and 22 show cells of holo/meroclones treated 
with Wnt 5A or Wnt 9B respectively have markedly stronger staining for β-catenin 
than control cells treated with PBS. Cells of both holo/meroclones and paraclones 
treated with Wnt 5A and with Wnt 9B demonstrate strong nuclear staining for β-
catenin. This can particularly be observed in images in figure 21 F,I,L 
(holo/meroclone) and figure 22 F,I, L (paraclone). These results indicate that in cells 
of holo/meroclones and cells of paraclones, Wnt signal activation via Wnt 5A and 
Wnt 9B is associated with apparent increased β-catenin expression, and suggestive 
of translocation of β-catenin into the nucleus.  
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Figure 20. Immunocytochemistry shows presence of β-catenin in PBS treated cells of PC3 
holo/meroclones.  
Primary antibody mouse monoclonal to β-catenin concentration 1:250 detected with a 
flurophore secondary antibody (Cy 5 Goat anti-mouse IgG) concentration 1:500 (red) and 
counter stained with DAPI (blue). A-L show signal observed at excitation 647 nm, emission 667 
nm.  A-C show the same whole colony: A shows DAPI staining, B signal observed for 
flurophore secondary antibody Cy 5, C shows A+B merge. D,E,F,G,H,I,J,K,L show higher 
magnification of cells within this colony. D,G,J show DAPI staining, E,H,K show signal 
observed for flurophore secondary antibody Cy 5; F,J,L show respective merge images. 
Images F,I,L show a relatively moderate level of β-catenin staining. Z-stacks obtained using an 
Olympus confocal system are shown. Representative images following at least 10 repeats. 
Scale Bar A,B,C:180 µm; D,E,F,G,H,I,J,K,L:15 µm. 
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Figure 21. Immunocytochemistry on cells of PC3 holo/meroclones shows strong staining of β-
catenin, and suggests increased nuclear β-catenin following treatment with Wnt 5A. 
Images suggest there is increased nuclear β-catenin following treatment with Wnt 5A ligand 
(100 ng/ml) compared with cells treated with PBS control. Primary antibody mouse monoclonal 
to β-catenin concentration 1:250 detected with a flurophore secondary antibody (Cy 5 Goat 
anti-mouse IgG) concentration 1:500 (red) and counter stained with DAPI (blue). Signal 
observed at excitation 647 nm, emission 667 nm.  A-C show the same whole colony: A shows 
DAPI staining, B signal observed for flurophore secondary antibody Cy 5, C shows A+B 
merge. D,E,F,G,H,I,J,K,L show higher magnification of cells within this colony. D,G,J show 
DAPI staining, E,H,K show signal observed for flurophore secondary antibody Cy 5; F,J,L 
show respective merge images. Images F,I,L show the suggestion of increased β-catenin 
staining relative to control images in figure 20, as well as punctate staining over the nucleus. 
Z-stacks obtained using an Olympus confocal system are shown. Representative images 
following at least 10 repeats. Scale Bar A,B,C:180 µm; D,E,F,G,H,I,J,K,L:15 µm.  
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Figure 22. Immunocytochemistry on cells of PC3 holo/meroclones shows strong staining of β-
catenin and suggests increased nuclear β-catenin following treatment with Wnt 9B ligand. 
Images suggest there is increased nuclear β-catenin following treatment with Wnt 9B ligand 
(100 ng/ml) compared with cells treated with PBS control. Primary antibody mouse monoclonal 
to β-catenin concentration 1:250 detected with a flurophore secondary antibody (Cy 5 Goat 
anti-mouse IgG) concentration 1:500 (red) and counter stained with DAPI (blue). Signal 
observed at excitation 647 nm, emission 667 nm.  A-C show the same whole colony: A shows 
DAPI staining, B signal observed for flurophore secondary antibody Cy 5, C shows A+B 
merge. D,E,F,G,H,I,J,K,L show higher magnification of cells within this colony. D,G,J show 
DAPI staining, E,H,K show signal observed for flurophore secondary antibody Cy 5; F,J,L 
show respective merge images. Images F,I,L show the suggestion of increased β-catenin 
staining relative to control images in figure 20, as well as punctate staining over the nucleus. 
Z-stacks obtained using an Olympus confocal system are shown. Representative images 
following at least 10 repeats. Scale Bar A,B,C:180 µm; D,E,F,G,H,I,J,K,L:15 µm. 
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Paraclones were cultured for 10 days, treated with PBS control and stained for β-
catenin as outlined in section 3.2.4. Figures 23-25 below show the expression of β-
catenin by immunocytochemistry in cells of paraclones in the experiments as 
indicated: figure 23 shows cells of a paraclone treated with PBS control; figure 24 
shows cells of a paraclone treated with Wnt 5A and Figure 25 shows cells of a 
paraclone treated with Wnt 9B. Expression of β-catenin PC3 cells of paraclones 
treated with PBS control was compared with staining observed in Wnt 5A and Wnt 
9B treated cells. Figure 23 shows β-catenin is expressed in cells of paraclones 
treated with PBS control (no Wnt ligand). The staining observed is similar to staining 
observed in cells of holo/meroclones treated with PBS control. Figures 24 D-L and 
24 D-L demonstrate that compared to control cells, there is increased staining for β-
catenin following Wnt 5A and Wnt 9B treatment in paraclone cells and increased 
staining over the nucleus. This suggests that just as in cells of holo/meroclones, Wnt 
activation via Wnt 5A and 9B appears to result in increased expression of β-catenin 
and nuclear translocation.  
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Figure 23. Immunocytochemistry shows presence of β-catenin in PBS treated control cells of 
PC3 paraclones. 
 
Immunocytochemistry shows presence of β-catenin in control cells though staining is less 
than in paraclone cells treated with Wnts 5A or 9B (see figures 24 D-L and 25 D-L for 
comparison). Primary antibody mouse monoclonal to β-catenin concentration 1:250 detected 
with a flurophore secondary antibody (Cy 5 Goat anti-mouse IgG) concentration 1:500 (red) 
and counter stained with DAPI (blue). A-L show signal observed at excitation 647 nm, emission 
667 nm.  A-C show the same whole colony: A shows DAPI staining, B signal observed for 
flurophore secondary antibody Cy 5, C shows A+B merge. D,E,F,G,H,I,J,K,L show higher 
magnification of cells within this colony. D,G,J show DAPI staining, E,H,K show signal 
observed for flurophore secondary antibody Cy 5; F,J,L show respective merge images. 
Images F,I,L relatively moderate level of β-catenin staining . Z-stacks obtained using an 
Olympus confocal system are shown. Representative images following at least 10 repeats. 
Scale Bar A,B,C:180 µm; D,E,F,G,H,I,J,K,L:15 µm. 
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Figure 24. Immunocytochemistry on cells of PC3 paraclones shows strong staining of β-
catenin, and suggests increased nuclear β-catenin following treatment with Wnt 5A.  
Images suggest there is increased nuclear β-catenin following treatment with Wnt 5A ligand 
(100 ng/ml) compared with PBS treated control cells in figure 23. Primary antibody mouse 
monoclonal to β-catenin concentration 1:250 detected with a flurophore secondary antibody 
(Cy 5 Goat anti-mouse IgG) concentration 1:500 (red) and counter stained with DAPI (blue). 
Signal observed at excitation 647 nm, emission 667 nm.  A-C show the same whole colony: A 
shows DAPI staining, B signal observed for flurophore secondary antibody Cy 5, C shows A+B 
merge. D,E,F,G,H,I,J,K,L show higher magnification of cells within this colony. D,G,J show 
DAPI staining, E,H,K show signal observed for flurophore secondary antibody Cy 5; F,J,L 
show respective merge images. Images F,I,L are suggestive of increased β-catenin staining, as 
well as punctate staining over the nucleus relative to control images in figure 23. Z-stacks 
obtained using an Olympus confocal system are shown. Representative images following at 
least 10 repeats. Scale Bar A,B,C:180 µm; D,E,F,G,H,I,J,K,L:15 µm. 
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Figure 25. Immunocytochemistry on cells of PC3 paraclones shows significant staining of β-
catenin, and suggests increased nuclear β-catenin following treatment with Wnt 9B ligand. 
Images suggest there is increased nuclear β-catenin following treatment with Wnt 9B ligand 
(100 ng/ml) compared with PBS treated control cells in figure 23. Primary antibody mouse 
monoclonal to β-catenin concentration 1:250 detected with a flurophore secondary antibody 
(Cy 5 Goat anti-mouse IgG) concentration 1:500 (red) and counter stained with DAPI (blue). 
Signal observed at excitation 647 nm, emission 667 nm.  A-C show the same whole colony: A 
shows DAPI staining, B signal observed for flurophore secondary antibody Cy 5, C shows A+B 
merge. D,E,F,G,H,I,J,K,L show higher magnification of cells within this colony. D,G,J show 
DAPI staining, E,H,K show signal observed for flurophore secondary antibody Cy 5; F,J,L 
show respective merge images. Images F,I,L are suggestive of increased β-catenin staining, as 
well as punctate staining over the nucleus compared to holo/meroclones untreated with Wnt 
as shown in figure 20. Z-stacks obtained using an Olympus confocal system are shown. 
Representative images following at least 10 repeats. Scale Bar A,B,C: 180 µm; 
D,E,F,G,H,I,J,K,L: 15 µm. 
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3.4 Discussion  
 
The first aim of the work described in this chapter was to assess if colonies are 
formed by a prostate cancer cell line (PC3). A further aim was to characterize Wnt 
signalling as measured by a live cell imaging Ca2+ assay for [Ca2+]i response in these 
colonies. 
 
3.4.1 Colony formation by PC3 cells 
 
The first hypothesis in this study was that cultured from single cells at clonal density., 
defined as 60 cells / well in 3 ml of culture medium (60 cells / 9.6cm2), will form 
distinct colonies of cells. I formed a hypothesis that the colony types formed will 
resemble holoclones, meroclones and paraclones morphologically, as has been 
described previously in keratinocytes, and a number of cancer cell lines including 
prostate, breast, pancreatic and head and neck (Barrandon and Green, 1987; Harper 
et al., 2007; Liu et al., 2013; Pfeiffer and Schalken, 2010). In addition, the colony 
types formed by PC3 cells will also have objective features upon which they can be 
categorised. 
 
In this study, cells plated at clonal density formed colonies that could be categorised 
into 2 types, visually (Davda et al., 2015). One type of colony consisted of tightly 
clustered, rounded cells and with a colony outline which could be well demarcated. 
This was similar to two colony types - holoclones and meroclones - previously 
described (Li et al., 2008; Pfeiffer and Schalken, 2010; Zhang and Waxman, 2010). 
A further type of colony was formed of cells with a greater inter-cellular distance, 
flattened in appearance and with a colony outline which was difficult to demarcate. 
This colony type was morphologically consistent with paraclones previously reported 
by Li et al and others (Li et al., 2008; Pfeiffer and Schalken, 2010; Zhang and 
Waxman, 2010). 
 
Unlike findings in this study, Li et al and Zhang and Waxman (Li et al., 2008; Zhang 
and Waxman, 2010) reported 3 distinct colony types formed by single cell culture of 
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PC3 cells - holoclones, meroclones and paraclones (see Figure 4). However, in my 
work presented here, holoclones and meroclones were not clearly identified as two 
distinct colony types, morphologically. Paraclones were identified as a distinct colony 
type, morphologically. Similar to the observations presented in this thesis, the 
formation of just 2 rather than 3 colony types from single cell plating of PC3 cells in 
this study was also reported by Pfeiffer and Schalken as shown in figure 26 below. 
  
 
Meroclone Paraclone 
  
Figure 26. Two PC3 colonies in a colony forming assay.  
Pfeiffer and Schalken reported that with a PC3 colony forming assay, typical holoclone 
phenotype was not observed, only 2 colony types : meroclones and paraclones (Pfeiffer and 
Schalken, 2010). Scale: Bar measures 200 µm.  
 
 
Morphological segregation, as employed by Li et al 2008, (Li et al., 2008) appears to 
hold visually, for holo- and paraclones, but does not appear to hold for meroclones 
(section 1.3.5 Figure 4).   For visual only classification of biological  phenomenon, 
the differences need to be obvious (e.g. holo- and para-clones) and anything that is 
in between is difficult to categorize and subject to inaccuracy of observer 
interpretation (Motoyoshi et al., 2007). Such classification is not a quantitative 
measure. One specific issue that I attempted to address in this thesis was to develop 
some quantitative measure of analysis for the observed colonies. Surprisingly, 
previous studies (Barrandon and Green, 1987; Harper et al., 2007; Liu et al., 2013; 
Pfeiffer and Schalken, 2010) did not provide any quantitative analysis. At day 10 
post-plating, colonies with morphological appearances of holoclones and meroclones 
consisted of tightly clustered cells and colonies with morphological appearances of 
paraclones consisted of dispersedly spread cells. In addition to a morphological 
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description alone, this study aimed to describe disparate colony types by quantifiable 
measurements. At a specified time point of 10 days post cell plating, colonies were 
imaged and the longest diameter measured. Colonies with the morphological 
appearances of holo/meroclones had a mean diameter of 837 ± 21 µm. Those 
morphologically paraclones had a mean diameter of 1191.3 ± 28.3 µm. The diameter 
of paraclones was greater than that of holo/meroclones (p<0.05). 
 
A further difference between the colony types was the how closely cells were packed 
together within the colonies. Publications using prostate (Li et al., 2008; Pfeiffer and 
Schalken, 2010) and breast (Liu et al., 2013) cancer cell lines , as well as murine 
keratinocytes (Tudor et al., 2006) have described holoclones to consist of “closely 
packed cells”. This again has been a subjective description not quantified in studies. 
Analysis of colony images in my study found colonies mean cell density of colonies 
could be quantified, and mean cell density of holo/meroclones was greater than 
mean cell density of paraclones p<0.05 (27.3 ± 3.2 vs 4.7 ± 0.4). This manner in 
which cells of holoclones grow densely adjacent to each other may represent a 
function of their characteristics. For example, there may be altered intercellular 
communication between cells of holoclones which enhances their stem cell-like 
characteristics compared with intercellular communication between more dispersed 
cells of paraclones. 
 
3.4.2 Stem cell gene expression in prostate cancer cell line colonies 
 
The colony types have previously been associated with their possible identity as 
stem cells (Li et al., 2008; Pfeiffer and Schalken, 2010; Zhang and Waxman, 2010). I 
measured the expression of four putative stem cell genes was assessed in the 2 
colony types formed by PC3 cells. There was a differential expression in the stem 
cell gene Oct 4 between the 2 types of colonies formed as shown in section 3.3.2 
(Fig 10). In this study holo/meroclones expressed the stem cell gene Oct 4, but 
paraclones did not. However, BMI 1 was expressed by cells of both holo/meroclones 
and cells of paraclones in this study. A limitation of this work was that the PCR 
products were not sequenced and therefore lack absolute confirmation of being the 
expected products.  Zhang and Waxman tested expression of stem cell markers 
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CD44+ and α2β1+ using flow cytometry and found that expression of these 2 
markers was prevalent in the majority of PC3 cells, regardless of colony type. 
Through microarray and qPCR analysis to determine genes differentially expressed 
in cells of holoclones, Zhang and Waxman identified FAM65B was strongly up 
regulated in holoclones compared to paraclones and MFI2, LEF1 and IL18R1 were 
down regulated in holoclones compared to paraclones. The expression of these 
genes was not investigated in my study (Zhang and Waxman, 2010).  
 
Expression of stem cell markers has also been investigated in DU145 cell line 
derived colonies. Beaver et al, (2014) used immunocytochemistry to determine 
expression of four stem cell markers CD44, α2β1 integrin, Oct4 and BMI-1 in DU145 
colonies (Beaver et al., 2014). Most cells within holoclones stained for all these 
markers whilst paraclones were negative for α2β1 integrin, BMI-1 and Oct-4 and had 
fewer CD44 expressing cells than the holoclones and meroclones (Beaver et al., 
2014). Pfeiffer and Schalken investigated the expression of stem cell markers by 
immunocytochemistry in DU145 holoclones and paraclones (Pfeiffer and Schalken, 
2010) . Converse to finding by Beaver et al (2014) α2-integrin and BRCP staining 
was observed in both holoclones and paraclones (Pfeiffer and Schalken, 2010). 
These results suggest that stem cell markers may be expressed in both holoclone 
and paraclone colony types, in colonies derived from prostate cancer cell lines PC3 
and DU145.   
 
3.4.3 Differential response to Wnts in cells of holo/meroclones and cells of 
paraclones 
 
A further aim study was to characterise PC3 colonies according to their response to 
Wnt signalling. This is the first study to investigate the free [Ca2+]i release in cells of 
holo/meroclones and paraclones in response to Wnt 5A and Wnt 9B ligands. These 
two Wnts were selected as they are typical Wnt ligands of the non-canonical Wnt / 
Ca2+ pathway (Sheldahl et al., 1999) and canonical Wnt pathways (Dong et al., 
2006) respectively, as described in section 1.4. 
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Analysis of cells within the 2 different colony types demonstrated that as shown in 
Table 11 and Figure 16, whilst all cells of holo/meroclones demonstrated an [Ca2+]i 
response to Wnt 5A and to Wnt 9B, 11 of 58 cells analysed within paraclones did not 
respond to Wnt 5A and 11 of 51 cells analysed within paraclones did not respond to 
Wnt 9B. This observation occurred consistently in all 3 experimental repeats. Cells 
within holo/meroclones were more likely to respond to Wnt 5A (n=103), than cells 
within paraclones (p<0.05). Holo/meroclones were also more likely than paraclones 
to respond to Wnt 9B (n=110) (Davda et al., 2015).   
 
As shown in Table 11 and Figure 16, a secondary response to Wnts 5A was 
observed in 8 of 52 cells within holo/meroclones and 5 of 58 cells of paraclones. A 
secondary response to Wnt 9B was observed in 22 of 52 cells within 
holo/meroclones and 8 of 51 cells of paraclones. Cells of holo/meroclones were 
therefore more likely than cells of paraclones to demonstrate a secondary response 
(n= 213, p<0.05) to Wnt 5A or Wnt 9B. This phenomenon may be a characteristic of 
putative stem-like cells with an increased amount of Ca2+ released in response to 
Wnt ligands. 
 
These findings support my initial hypothesis that cells of holo/meroclones are more 
stem cell like, and the hypothesis that these more stem cell-like cells would be more 
response to Wnt ligand stimulation, which could be demonstrated by an [Ca2+]i  
response. Cells of holo/meroclones may have more receptors able to interact and be 
activated by ligand exposure or may have more significant downstream signalling by 
Wnt mediators. Cells within paraclones may be more heterogenous in their response 
to Wnt 5A and 9B. Alternatively, cells within paraclones may in fact demonstrate a 
uniform response to these Wnt ligands but there may have been an artefactual effect 
leading to these results. For example, a cell not fully within the plane of focus may 
have appeared to not have demonstrated a response. Although this may particularly 
have been a possibility in cells of paraclones, which by definition are more dispersed 
over a larger area from each other, when selecting cells for analysis cells were 
chosen across an individual colony in both colony types i.e. centrally and peripherally 
but within focus.   
 
140 
 
An interesting secondary observation relates to appearance of two calcium peaks in 
some experiments (e.g. Fig 15 B). It could be speculated that in these stem-like 
colonies, there is a bimodal response due to activation of different [Ca2+]i response.  
The secondary response may also be attributable to extracellular calcium entry into 
the cell through store-operated Ca(2+) entry (SOCE).  As discussed, Ca2+ levels in 
the cytosol are controlled bSOCE, mediated by store-operated channels (SOCs) 
(Flourakis et al., 2010; Williams et al., 2001). Findings reported above have shown 
that ORAI-1 (a calcium selective ion channel and component of SOCE) is expressed 
in both PC3 colony types. However, a detailed and systematic analysis of this 
phenomenon is needed and was not within the scope of this project. 
 
 
Free intracellular calcium is involved in key functions including modulation of enzyme 
activity and gene regulation, proliferation and migration (Bading, 2013; M L Villereal 
and Palfrey, 1989; Melchionda et al., 2016; Monteith et al., 2012). Dwell time of 
released free intracellular calcium is a key determinant of how much and for how 
long free calcium is available in the cytosol for such processes. Analyses were 
performed on the differences in [Ca2+]i response to Wnt 5A and Wnt 9B between 
cells of holo/meroclones and cells of paraclones which responded (as summarised in 
Table 12). When comparing response to Wnt 5A by colony type, significant 
differences between cells of holo/meroclones and cells of paraclones were observed. 
Both rise time and dwell times for paraclones were longer than holo/meroclones 
(section 3.3.3 Table 12, Fig 16). In addition, durations of both primary and total 
response were longer than in cells of paraclones than holo/meroclones p<0.05. As 
[Ca2+]i is involved in key cellular functions cells, a potential explanation for these 
findings is that holo/meroclones are more stem cell-like and therefore cells in 
holo/meroclones induce a different pattern of [Ca2+]i  response to Wnt ligand 
stimulation than cells of paraclones. This is consistent with the proposed theory that 
cells of holo/meroclones behave differently to cells of paraclones on Wnt activation.  
 
Cells in holo/meroclones induce a faster elevation of [Ca2+]i  in response to Wnt 
signalling, whilst the response seen in cells of paraclones is slower. This slower 
response in cells of paraclones may possibly be due to less activation either by 
reduced FZ activation or downstream by β-catenin or other mediators.  
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When comparing the same cell type to Wnts, both cells of holo/meroclones and cells 
of paraclones had a shorter rise time following treatment with Wnt 5A than with Wnt 
9B p<0.05 (Table 12). The short rise time following treatment with Wnt5A is 
consistent with previous findings in whole populations of PC3 cells which were not 
clonal (Thrasivoulou et al., 2013). In cells of holo/meroclones, the durations of dwell 
time and total response following treatment were shorter with Wnt 5A than following 
treatment with Wnt 9B p<0.05 (Table 12). Similarly, in cells of paraclones, the 
duration of the total response following treatment with Wnt 5A was shorter than 
following treatment with Wnt 9B p=0<05. Similarly, in whole populations of PC3 cells, 
Thrasivoulou et al found a short dwell time following treatment with Wnt 5A 
compared with treatment with Wnt 9B (dwell time <15 seconds vs >30 seconds 
p<0.05) (Thrasivoulou et al., 2013). It could be speculated that the one of the 
determinants of cellular characteristic or function (e.g. stemness vs differentiation) 
could be the result of release, and availability of free [Ca2+]i and also of the Wnt 
ligand availability (e.g. Wnt 5A or Wnt 9B). For example, shorter dwell time in 
holo/meroclones in response to Wnt 5A in this study and in whole populations of 
PC3 cells may indicate that availability of Wnt 5A ligand is usually tightly regulated. 
 
3.4.4 Expression and co-localisation of β-catenin in different colony types 
 
This is the first study to investigate the effect of Wnts on β-catenin expression in cells 
of PC3 colonies. The effect of Wnts on β-catenin expression has been investigated 
in a population of cells not in colonies (Thrasivoulou et al., 2013). In work by 
Thrasivoulou et al., (2013), there was little or no expression of β-catenin in the 
nucleus of PC3 control cells, as most of the β-catenin is considered to be 
sequestered in the cytosol. However, expression was increased, particularly in the 
nucleus, in cells treated with Wnts 5A, 9B, and 10B (Thrasivoulou et al., 2013). 
Thrasivoulou et al., (2013) confirmed the visual appearances nuclear co-localization 
with objective quantification and additionally found that inhibition of Wnt induced 
[Ca2+]i release also reduced nuclear translocation of β-catenin.  
 
In my study expression of β-catenin was visually observed in cells of both 
holo/meroclone and paraclone colony types (Davda et al., 2015). This is in contrast 
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with other studies reporting β-catenin protein expression to be absent in paraclone 
PC3 colonies and present in holoclone PC3 colonies (Li et al., 2008). Although cells 
of both colony types expressed β-catenin in the absence of Wnt ligand treatment, 
staining appeared relatively increased throughout the cells following treatment with 
Wnt 5A and following treatment with Wnt 9B in both colony types. Visually there 
appeared to be increased expression β-catenin on Wnt 5A and Wnt 9B activation 
and nuclear and peri-nuclear punctate staining. The findings suggest nuclear 
translocation of β-catenin on Wnt activation in PC3 holo/meroclone and paraclone 
colonies. Further work to objectively demonstrate this would be to perform image 
deconvolution and quantitative analyses of nuclear co-localisation of β-catenin using 
colocalization co-efficients. This could be performed on single imaged slices rather 
than the Z-stacks presented above.  
 
 
3.5 Chapter 3 Conclusions  
 
This chapter investigated colony formation from single cell culture of PC3 cells and 
aimed to characterise the colonies formed by subjective parameters and 
characterise differences in their response to Wnts. PC3 cells cultured in a clonogenic 
assay form 2 colony types: holo/meroclones and paraclones. There are differences 
in these 2 types of colonies which can be described by parameters of colony 
diameter and cell density. Both colony types respond to Wnt 5A and Wnt 9B as 
determined by [Ca2+]i response. However, there are differences in Wnt induced 
increase in [Ca2+]i between the 2 colony types: a greater proportion of cells in 
holo/meroclones respond to Wnts 5A and 9B, a greater proportion demonstrate a 
secondary elevation in [Ca2+]i, and there is a shorter rise time compared to cells in 
paraclones. These differences between holo/meroclones and paraclones are 
possibly attributable to cells in the former being more stem cell like.   
 
This study shows for the first time that Wnt mediated [Ca2+]i release occur in 
response to both Wnt 5A and Wnt 9B in both colony types. Both colony types also 
expressed β-catenin and both colony types expressed increased expression β-
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catenin on Wnt activation on visual interpretation of the images. The images suggest 
nuclear translocation of β-catenin on Wnt activation, with strong punctate staining 
observed in the nucleus and around it, in cells of both colony types.  
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Chapter 4: Expression of ion channels in prostate 
cancer cell lines and PC3 colonies 
 
4.1 Introduction 
 
All colonies formed from single cells of PC3 cells respond to Wnt ligands (5A and 
9B) by inducing free [Ca2+]i release, confirming previous observations that both 
canonical and non-canonical ligands can induce calcium release in mammalian cells 
(Thrasivoulou et al., 2013). There is also visual evidence that there is translocation of 
β-catenin in response to Wnt signal activation particularly in holo/meroclones (see 
above). Thrasivoulou et al (Thrasivoulou et al., 2013) further demonstrated it is 
possible to inhibit at least one component of the calcium release with thapsigargin, 
indicating the involvement of store operated calcium entry (SOCE) (Flourakis et al., 
2010; Williams et al., 2001).  
 
Such elevations in free [Ca2+]i are important in cell signalling and mediate key 
processes such proliferation, metabolism and gene transcription (Berridge, 1995; 
Berridge, 2005; Berridge et al., 2003; Clapham, 2007). In addition, the Ahmed 
laboratory has also shown a number of known compounds that regulate cell 
membrane potential (membrane potential regulating compounds, MPRCs) also 
modulate Wnt induced calcium release (New British Patent Application no. 
1318659.8 and US-2016-16-0271157-A1). Further to this, they have demonstrated 
that some MPRCs also activate [Ca2+]i stores (Petrou et al., 2017). The wide range 
of effects of ion channels and the Wnt induced calcium response suggests that ion 
channels may be involved in the Wnt signalling pathway. At the time of conducting 
this project the identity of the specific membrane ion channel that may be involved in 
the Wnt signalling regulation was not known. It was decided therefore to lay some 
foundation work by investigating the expression of a large number of ion channels 
that have been previously described in cancer in the literature (Table 13). 
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Ca2+ levels in the cytosol are controlled bSOCE, mediated by store-operated 
channels (SOCs) (Flourakis et al., 2010; Williams et al., 2001). Calcium release-
activated calcium channel protein 1 (ORAI-1) is a calcium selective ion channel and 
component of SOCE in prostate cancer cell line LNCaP where influx of Ca2+ leads to 
apoptosis, whilst downregulation of ORAI-1, and SOCE function, reduces apoptosis 
(Flourakis et al., 2010). 
 
Over the past decade there has been interest in expression of ion channel genes in 
cancer, their relevance in malignancy and potential effects of their manipulation in 
clinical practice. The expression of ion channel families has been studied in a 
number of tumour types including prostate cancer, breast cancer, melanoma, 
cervical cancer, ovarian cancer and astrocytoma.  Table 13 below gives a summary 
of the important findings to date regarding ion channels and solid cancers.  
 
In addition to the role of ion transporters in the cell membrane in cancer, described 
above, recent observations pertinent to this thesis, have been made in our 
laboratory, very recently. These indicate that various compounds that are known to 
act on a variety of ion channels, receptors and transporters, may be able to regulate 
Wnt signalling (Ahmed A., International Patent Application PCT/GB2014/053138; 
British patent application No. 1318659.8; USPTO 2016/0271157A1).  
 
Table 13. Expression of ion channel genes in solid cancers. 
 
    
Ion 
channel 
gene  
 
Summary of 
channel function 
 
Experimental 
model 
 
 
 
Mechanism 
ORAI-1  ORAI-1 Calcium release-
activated calcium 
channel protein 1 
(ORAI-1) is a 
calcium selective 
ion channel and 
component of the 
Prostate cancer 
cell lines 
Thapsigargin 
triggers Ca2+-
dependent 
apoptosis. Knocking 
down ORAI with si 
ORAI results in 
resistance to 
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ICRAC system: 
calcium release 
activated calcium 
currents. The ion 
channel is 
activated when 
internal calcium 
stores are low. 
STIM 1 protein 
detects low 
concentration of 
calcium in the 
endoplasmic 
reticulum. 
thapsigargin induced 
apoptosis, 
chemotherapy 
induced apoptosis 
following treatment 
with strong alkylating 
agents, and 
resistance to a 
physiological model 
of apoptosis 
(Flourakis et al., 
2010). 
Breast cell lines 
 
Breast cancer 
tissue  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Breast cancer cell 
lines have elevated 
levels of ORAI-1 
whilst STIM1 and 
STIM2 are not 
overexpressed. 
ORAI-1 siRNA 
reduces store-
operated calcium 
entry. Further 
analysis of STIM1 
and STIM2 
expression found 
that from 
transcriptional data 
from almost 300 
breast cancers, 
poorer prognostic 
histology sub-type 
was associated with 
the presence of  high 
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STIM1 : low STIM2 
ratio (McAndrew et 
al., 2011). 
Kv 1.3 KCNA3 Potassium 
channel, voltage 
gated shaker 
related subfamily 
A, member 3 
Human 
osteosarcoma 
cell line; mouse 
melanoma cell 
line 
 
 
 
 
 
 
 
 
Potassium 
membrane-
permeable Kv 1.3 
inhibitors psora-4, 
PAP-1 and 
clofazimine target 
mitochondrial Kv 1.3 
channels. These 
inhibitors induced 
apoptosis in mouse 
melanoma cell line 
B16F10 and human 
sarcoma cell line 
SAOS-2, both of 
which were 
demonstrated to 
express Kv 1.3. The 
same effect was not 
observed in HEK293 
cells, understood to 
highly express Kv 
channels.  
Downregulation of 
Kv 1.3 via siRNA 
removed the 
inhibitors‟ effects 
(Leanza et al., 
2012).  
Melanoma 
mouse model 
In an orthotopic 
melanoma B16F10 
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mouse model, 
clofazimine 
administered 
intraperitoneally 
markedly reduced 
tumour size when 
animals were 
sacrificed at day 16. 
Examination of the 
internal organs of 
the mice 
demonstrated no 
obvious other 
pathology on 
comparison to non-
treated mice 
(Leanza et al., 
2012).  
EAG1 / Kv 
10.1 / h-
eag1 
 
KCNH1 ether à go-
go (Eag1) 
potassium 
channel 
Human 
colorectal cancer 
tissue and 
control benign 
tissue 
 
 
 
 
 
 
 
In normal tissues, 
EAG mRNA is 
specifically 
expressed in the 
brain.  
Analysis of Eag1 
protein in human 
colorectal cancer 
tissue and benign 
tissue found that 
mRNA and protein 
was present in the 
majority of malignant 
samples, but not 
detected in benign 
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tissue. Eag1 protein 
expression was 
associated with 
clinical tumour stage 
(Ding et al., 2007). 
Primary culture 
of cervical tissue 
 
 
Eag1 gene and 
protein expression 
was found in all 
cervical cancer 
primary cultures 
derived from human 
biopsies, whilst 
expression was 
present in 1/3 of 
benign tissues 
(Farias et al., 2004). 
KCa 2.3 / 
SK 3  
 
 
KCNN3 SK channels or 
Small 
conductance 
calcium-activated 
potassium 
channels are a 
subfamily 
of Ca2+-
activated 
K+ channels 
Breast cancer 
cell lines  
SK2 was expressed 
in all breast cancer 
cell lines tested, 
whilst SK3 was only 
expressed in one 
cell line. SK2 was 
found in both benign 
and malignant breast 
cancer tissue whilst 
SK3 was only in 
cancerous tissue. 
SK3 expression 
increased migration 
in cell lines, whilst 
proliferation was not 
affected (Potier et 
al., 2006).  
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KCa 3.1 / 
SK4  
 
 
 
 
KCNN4 Intermediate 
conductance 
Ca2+ activated 
K(+) channel 
Glioma cell lines. 
 
 
Glioma mouse 
model  
Using data from the 
National Cancer 
Institute database, 
KCa 3.1 was 
upregulated in 32% 
of patient cancers; 
KCa 3.1 expression 
was associated with 
reduction in survival. 
 
KCa 3.1, if present, 
enhances cell 
migration. Several 
glioma lines tested 
with a migration 
assay found that cell 
lines with high KCa 
3.1 expression had 
reduced migration 
upon treatment with 
channel inhibitor. 
Cell lines with low 
KCa 3.1 expression 
demonstrated no 
change in migration 
following inhibition. 
Loss of KCa 3.1 
function also 
inhibited invasion. 
Further to this, 
tumour invasion was 
reduced when KCa 
3.1 was inhibited in 
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SCID mice (Turner 
et al., 2014). 
KCa 1.1 KCNMA1 
 
 
 
Pore forming α-
subunit of 
BKCa channels 
(Large 
conductance 
calcium-activated 
potassium 
channels) 
Breast cancer 
cell lines  
Breast cancer cell 
lines from brain 
metastases have a 
higher expression of 
KCNMA1 than those 
cell lines from other 
metastatic sites. 
BKCa channels are 
active in breast 
cancer cell lines and 
their inhibition 
reduces invasion 
and migration 
(Khaitan et al., 
2009). 
TASK3 KCNK 9 Potassium 
channel, 
subfamily K, 
Colorectal 
cancer  
 
 
 
Analysis of 124 
colorectal cancers 
found expression of 
KCNK9 in 46% of 
tumours (Kim et al., 
2004). 
Ovarian cancer 
tissue and 
ovarian cancer 
cell lines 
TASK-3 is 
expressed in ovarian 
cancer cell line, as 
well as normal 
ovarian tissue and 
ovarian cancer 
tissue. Using a 
tissue array, 
expression was 
found in almost all 
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tumours and 
increased staining 
was associated with 
improved prognosis. 
Inhibition of TASK-3 
in 2 cell lines 
resulted in reduced 
cell proliferation and 
apoptosis (Innamaa 
et al., 2013b). 
TREK-1 
and 
TREK-2  
KCNK 2 
and 
KCNK10  
Potassium 
channel, 
subfamily K 
Ovarian cancer 
tissue and 
ovarian cancer 
cell lines  
TREK-1 and TREK-2 
are expressed in 
ovarian cancer cell 
lines, benign ovarian 
tissue and the 
majority of ovarian 
cancer tissue. A 
TREK-1 inhibitor 
reduced cell 
proliferation, in a 
dose dependent 
manner, and 
increased apoptosis 
(Innamaa et al., 
2013). 
hERG / Kv 
11.1 
KCNH2 Human ether-a-
go-go-related 
gene 
K+ channels 
human 
embryonic 
kidney cells 
Glioblastoma cell 
line 
Doxazosin is an 
inhibitor of hERG 
and reduces hERG 
current in human 
embryonic kidney 
(HEK) cells. 
Doxazosin induces 
apoptosis in 2 
153 
 
human glioblastoma 
cell lines. 
Knockdown 
hERG via si RNA 
also reduces cell 
viability of a 
glioblastoma cell line 
(Staudacher et al., 
2014). 
Ear 2 / Kv 
10.2 
KCNH 5 Potassium 
channel, voltage 
gated eag related 
subfamily H, 
member 5. 
Mouse and 
human 
medulloblastoma 
tissue  
Analysis of a mouse 
medulloblastoma 
model found mRNA 
of Eag 2 elevated 
and Eag 1 reduced 
in tumour compared 
with normal 
cerebellum. Eag 2 
expression was also 
elevated in the 
majority of tissue 
samples from 
primary and 
recurrent human 
tumours, compared 
with control tissue.  
Further to this, Eag2 
knockdown reduced 
growth of 
medulloblastoma 
and tumourigenicity 
in a mouse model 
(Huang et al., 2012). 
Kir 4.1 KCNJ10 Inwardly- Human Analysis of human 
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channel 
subunit 
rectifying K+ 
channel 
astrocytoma 
tissue 
astrocytomas found 
Kir 4.1 mRNA and 
protein to be 
expressed. 
Increased 
expression was 
associated with 
pathologic tumour 
grade (Tan et al., 
2008). 
 
 
Based upon this literature review, several classes of ion channels which may be 
important in cancer cell signalling were chosen for further investigation in this project 
with a view that these might be useful targets to regulate the activity of Wnt signalling 
(Petrou et al., 2017). Table 14 summarises the ion channels which are investigated 
in this project.  The expression of ion channel families has been studied in a number 
of tumour types including prostate cancer.  Key families of ion channels associated 
with malignancy have been identified in the literatures. Both Wnt 5A and Wnt 9B 
produce a [Ca2+]i response in a population of PC3 cells, and in cells cultured in a 
colony forming assay in holo/meroclones and in paraclones. The aim of this study 
was to characterise ion channel expression in prostate cancer cell lines and cells of 
PC3 colonies. 
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Table 14. Summary of ion channel genes known to be associated with malignancy and 
characterised further in this study. 
 
Family Genes  
  
KCNJ KCNJ1 var1, KCNJ2, KCNJ3 var1, KCNJ4 var1, KCNJ5, 
KCNJ6, KCNJ8, KCNJ9, KCNJ10, KCNJ11, KCNJ12, 
KCNJ13 var1, KCNJ14, KCNJ15, KCNJ16   
KCNA KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, 
KCNA7, KCNA10  
KCNK KCNK1, KCNK2 var1, KCNK3, KCNK4, KCNK5, KCNK6, 
KCNK 7 var C, KCNK9 var1, KCNK10 var1, KCNK12, 
KCNK13, KCNK15, KCNK16 var1, KCNK17 var1, KCNK 18 
ORAI ORAI1, ORAI2 var1, ORAI2 var2, ORAI3  
STIM STIM1 var1, STIM1 var2, STIM2 var1, STIM2 var2 
KCNH KCNH1 var1, KCNH2 var1, KCNH2var2, KCNH5 var1  
KCNMA KCNMA1 var1  
KCNN3 KCNN3 var1, KCNN4  
CACNA CACNA1C var2  
   
 
A number of MPRCs are commonly and safely routinely used in clinical practice, 
mainly for cardiovascular conditions. Such MPRCs include amlodipine and 
isradipine. These MPRCs, as well as cadmium chloride were chosen as a selection 
of MPRC to test their effects on cancer cell line proliferation. Rather than specific 
MPRCs, broad-channel blockers, and known regulators of the cell membrane 
potential were selected for use in this project. Table 15 below describes several 
calcium channel blockers, their physiological effect and clinical indications. 
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Table 15. Calcium channel blockers, their physiological effect and clinical indications. 
Calcium channel blockers have been in widespread clinical use for decades for therapeutic 
use in cardiovascular disease as summarised below. 
 
 
Calcium channel blocker 
 
 
Physiological effect and clinical indication 
Isradipine Similar effects to those of nifedipine. 
Clinical indications: Hypertension (RSPGB, 2015). 
Amlodipine  
 
No effect on myocardial contraction and can be 
used in cardiac failure. Improves coronary 
vasospasm. 
Clinical indications: Angina; hypertension (RSPGB, 
2015). 
Nifedipine Relaxation of vascular smooth muscle leading to 
dilatation of coronary and peripheral arteries. 
Compared with verapamil, there is greater effect on 
vasculature and it is not an anti-arrhythmic. 
Infrequently causes heart failure. 
Clinical indications: Hypertension; angina (RSPGB, 
2015). 
Nimodipine Similar to nifedipine but primary effect on coronary 
artery smooth muscle. 
Clinical indications: Prevention of vascular spasm 
following aneurysmal subarachnoid haemorrhage 
(RSPGB, 2015). 
Verapamil Reduces cardiac output, slows the heart rate, and 
may impair atrioventricular conduction. 
Clinical indications: Angina; hypertension; 
arrhythmias (RSPGB, 2015). 
Diltiazem 
 
Less negative inotropic effect than verapamil and 
significant myocardial depression occurs rarely. 
Clinical indications: Angina; hypertension (RSPGB, 
2015). 
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Nicorandil  Promotes potassium efflux leading to inhibition of 
voltage gated calcium channels. Acts a vasodilator 
and is used in the treatment of angina (RSPGB, 
2015).   
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Experimental Aims 
The aim of this chapter is to investigate ion channel gene expression in prostate 
cancer cell lines and ion channel protein expression. A further aim is that if channels 
are identified, to perform provisional work on the inhibition by MPRCs. 
 
4.1.1. Hypothesis 
 
Ion channel genes are expressed in prostate cancer cell lines.  
 
Ion channels are expressed in both cells of PC3 holo/meroclones and cells of PC3 
paraclones.  
 
4.1.2 Objectives 
 
The following objectives test the hypothesis:  
 
1. To characterise ion channel expression in prostate cancer cell lines by gene 
expression. 
 
2. To confirm ion channel protein expression, for some channels that are 
putative targets of MPRCs in cells of PC3 holo/meroclones and cells of PC3 
paraclones.  
 
A further objective was to establish cell growth conditions ± MPRCs to assess 
if inhibition of MPRCs affects proliferation of cancer cells in whole populations 
of the PC3 prostate cancer cell line. 
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4.2 Materials and methods 
 
4.2.1 Ion channel genes  
 
Primer sequences were designed for ion channel genes identified as being 
overexpressed in cancer. The method of primer sequence design was as outlined in 
section 2.6, using sequence of interest information from the NCBI website 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/date of accession 6th March 2014). 
Each primer sequence was allocated a PCR reaction number, as indicated in Table 
16.  
 
For gene expression in whole populations, prostate cancer cell lines PC3, DU145 
and LNCaP were cultured in T75 flasks. Cells were harvested, and RNA extraction 
performed using RNeasy kit as outlined in section 2.6. RNA was quantified for each 
cell line and reverse transcription was performed as outlined in section 2.6. RNA was 
synthesised to cDNA using a Qiagen Omniscript RT kit as per the 10/2010 handbook 
protocol: http://www.qiagen.com/us/products/catalog/assay-technologies/end-point-
pcr-and-rt-pcr-reagents/omniscript-rt-kit/. For sufficient yield of cDNA for subsequent 
PCR, constituents were scaled up x 2 so that 4µg template RNA was used and made 
up to a volume of 24 µl with RNase free water as indicated in table 4. Once the 
protocol was completed, the cDNA was frozen at -20C if for later use in PCR. 
PCR was performed using Qiagen Taq PCR Master Mix kit and following the 
protocol handbook 10/2010. http://www.qiagen.com/us/products/catalog/assay-
technologies/end-point-pcr-and-rt-pcr-reagents/taq-pcr-master-mix-kit. Prior to 
commencing PCR cDNA was thawed on ice and quantified using a spectrometer 
giving a concentration in µg/ml. 0.5 µg template cDNA was used in all PCR reactions 
per reaction tube. The volume of cDNA required for 0.5 µg was calculated and the 
volume of RNase free water to make a cDNA solution up to 12 µl was calculated as 
indicated in table 5. Reaction tubes were placed in a thermal cycler programmed as 
indicated in table 6. Following amplification, PCR product samples were stored at 
4°C until agarose gel electrophoresis. 
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Table 16. Oligonucleotide sequences designed for PCR of ion channel genes, and expected 
size for each product. 
 
 
PCR 
reaction 
number  
 
Oligonucleotide sequence (5' to 3') 
 
Oligonucleotide 
name 
 
Expected 
size  
    
1 GTGGACATCTGGACAACGGT KCNJ1 var1 F 418 
 CTCCCCGTTTGCTGATCACT KCNJ1 var1 R  
2 CCGCTACAGCATCGTCTCTT KCNJ2 F  446 
 TTGGGCATTCATCCGTGACA KCNJ2 R  
3 GGCATTGTGGAAACAACTGGG KCNJ3 var1 F 508 
 AATCAGCCACAGACTGGCTC KCNJ3 var1 R  
4 GCTCTTTTTCGGCCTCCTCT KCNJ4 var1F 620 
 CCTTGCCCATGCCATAAAGC KCNJ4 var1 R  
5 AGATCAGCCAGCCCAAGAAG  KCNJ5 F 799 
 CCCCCAAACAGCACACTCAA  KCNJ5 R  
6 CAGCACCCCATCCCTTAGTG KCNJ6 F 684 
 TGTAACTGCCACACCCACAT  KCNJ6 R  
7 ATCTCAGCAACTGACCTGGC  KCNJ8 F 690 
 CCCACCCCTGCACATAACTT  KCNJ8 R  
8 CACGGGAATGACATGCCAAG KCNJ9 F 534 
 TCCCTGAAATCAGGACCCCT  KCNJ9 R  
9 CACACCTGCCATCTCACTGT  KCNJ10 F 497 
 GCATGGCTGAGGCCTTCTAA  KCNJ10 R  
10 TGTGCCCATTGTAGCTGAGG  KCNJ11 F 559 
 AGAGTGTGGCTGGTCAATCG  KCNJ11 R  
11 CCTACAGACGGGAGTCAGAGA  KCNJ12 F 680 
 GCTCGTGAGCTCGATGAAGT KCNJ12 R  
12 CTCTGTTGACCCGAGGTTCC KCNJ13 F 592 
 CACCCAGGGAGCTAGGTTTG  KCNJ13 R  
13 AGTCTAGTTTCCCCGGCTCT KCNJ14 F 510 
161 
 
 GCTTCTCACCCTGGTCAACA KCNJ14 R  
14 CCCTGGAATCCCAGACAACC  KCNJ15 F 796 
 AGGGTTAAACCTGGATGGCG  KCNJ15 R  
15 CAAGGCGAGACGAAGGTCAT KCNJ16 F 479 
 GCCTCCTTCCTGCCTTCATT  KCNJ16 R  
16 CGGTGATGTCTGGGGAGAACG KCNA1 F 598 
 GTGCCCGTGAAGTCCTTGT KCNA1 R  
17 ACATGCATGGTAGTGGGGTG KCNA2 F 579 
 PCCCCAATGGTAGTCGGAACC KCNA2 R  
18 TCGCAGGACTCATTCGAAGC KCNA3 F 556 
 TGGTCACTGGGTGCATATCG KCNA3 R  
19 GCCTGAAGAGGCCAGTCAAT KCNA4 F 640 
 CGGAATACTCGGACCAGACG KCNA4 R  
20 TGCCATGACCGTCAGAGGAG KCNA5 F 467 
 TGCGGTCGAAGAAGTACTCG KCNA5 R  
21 GGAGGGAGAGCAACAGGATG KCNA6 F 562 
 ACCTCGACCATCTACACGGA KCNA6 R   
22 TTCCCGGACACTCTGCTAGG KCNA7 F 743 
 CGGATGACTCTCAGGATGGC KCNA7 R  
23 GACTTCGACTCAACCAGCCC KCNA10 F 646 
 CCCTATCCTCCCGGAACTCT KCNA10 R  
24 CAACTCGGTCAAGGAGTCCC ORAI1 F 381 
 TCCTGTAAGCGGGCAAACTC ORAI1 R  
25 ACCTCTAACCACCACTCGGT ORAI2 F 495 
 GATGATGGTGGACACCAGGG ORAI2 R  
26 GAGTGACCACGAGTACCCAC ORAI3 F 554 
 AGGAGCGGTAGAAATGCAGG ORAI3 R  
27 GTTCTGAAGGCTACGGGACC STIM1 F 574 
 GATGGTGTGTCTGGGTCTGG STIM1 R  
28 CAACTGCCGCCTCCTCTC STIM2 F 535 
 GGGCGTGTTAGAGGTCCAAA STIM2 R  
31 ATGCTTCCAGTCGGAATGTGT KCNJ1 var1 F 528 
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 TGGCCCCACACATGAAAGAA KCNJ1 var 1 R  
32 CAAATGGCTTTGGGAACGGG KCNJ2 var1 F 433 
 ATGATGCAGCCCACGATTGA KCNJ2 var1 R  
33 GCATTGTGGAAACAACTGGG KCNJ3 var1 F 438 
 AGTTGCCCGGAACTGAACTT KCNJ3 var1 R  
34 GCTCTTTTTCGGCCTCCTCT KCNJ4 var1 F 597 
 CTGTCCTCGTCGATCTCGTG KCNJ4 var1 R  
35 AAGAGAGCGGAGACCCTCAT KCNJ5 F 543 
 CCGGCCTTCCCTCTTCATTT KCNJ5 R  
36 CTGGACCGCATCTTTCTGGT KCNJ12 F 521 
 TCTGACTCCCGTCTGTAGGG KCNJ12 R   
37 GGAGGATGGTCACCAAGGAT KCNJ13 var1 F 424 
 TTCGCCACAAAAGCACCTGT KCNJ13 var1 R   
38 GGACACTCTGCTAGGGGACC KCNA7 var1 F 546 
 ATACACAGCGTCTCCACCAC KCNA7 var1 R  
39 ACCTGGAACTGGTCACCTCT ORAI2 var1 F 565 
 AGGGAGCGGTAGAAGTGGAT ORAI2 var1 R  
40 ACCTGGAACTGGTCACCTCT ORAI2 var2 F 565 
 AGGGAGCGGTAGAAGTGGAT ORAI2 var2 R  
41 TGTGCACCTCTTTGCACTCA ORAI3 F 524 
 GTTCCTGCTTGTAGCGGTCT ORAI3 R  
42 GACAAGCCGGGTATCTCTGC STIM1 var1 F 470 
 TGTCAGGCAGTTTCTCCACC STIM1 var1 R  
43 CACATGAGGTGGAGGTGCAA STIM1 var2 F 498 
 CGGAATGGGTCAAATCCCTCT STIM1 var2 R  
44 TTTGGACCTCTAACACGCCC STIM2 var1 F 548 
 GCAGCAACCTCATCTTTAGCA STIM2 var1 R  
45 CGACTTTTTCGCTGGCAACA STIM2 var2 F 493 
 CTGTGTCTGGCACTTCCCAT STIM2 var2 R  
51 GAACTGGGACTTCACCTCCG KCNK1 F 409 
 GCCTTCCCCAGGCACATAAT KCNK1 R  
52 AACCCACGAGCAAAAAGGGA  KCNK2 var1  F 485 
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 TCTGTGCGTGGTGAGATGTT KCNK2 var1 R  
53 TCATCGTGTGCACCTTCACCTA KCNK3 F 527 
 GAAGGTCCAGTGCTCGTAGTG KCNK3 R  
54 TTTATGCGCTGGTGGGGATT KCNK4 F 417 
 ACACTACTCGCAGCCAGTTC  KCNK4 R  
55 GAGGTGTGAGTCTGCGGAAG KCNK5 F 593 
 GGAGTAGACTACCAGGGGCA KCNK5 R  
56 AGTGACCGTCTGCTTTCTGG KCNK6 F 402 
 TACCTGGGGATGGAAGCGTA KCNK6 R  
57  CTTCCAGGCAGAGCATAGGG   KCNK 7 var C F 594 
 GCTGTTAGGTGGCTGGACTT KCNK 7 varC R  
58 CCATAGGTTATGGGCACGCT  KCNK9 var1  F 488 
 CCGCTCATCCTCACTGTTCA KCNK9 var1 R  
59  TTTCTTTCCTTGGTGGCCGT   KCNK10 var1  F 404 
 CCTATTGGACTGACTCCCGC  KCNK10 var1 R  
60 GCTGGGACCATCCTGTTCTT KCNK12 F 417 
 CGAGTAAATGCAGCACACGC  KCNK12 R  
61 GGGTGTTCCAGCACCATCTT KCNK13 F 531 
 GCGTGATCGCAAGAGTCCT  KCNK13 R  
62 CTCGAGTCCGAGGCGGAAAG KCNK15 F 593 
 AGGAAGCTGAAGGCCACGTA KCNK15 R  
63 AGAGCCTTTCCAAACACCCC KCNK16 var1 F 419 
 GAAGCGTCTAGGCTGTGTG KCNK16 var1 R  
64 GAGCTGTTGCAGAACTTCACG KCNK17 var1 F 524 
 TGGGAGGGGTTCATTCCAATC KCNK17 var1 R  
65 TGGCTACATCTACCCCGTCA KCNK 18 F 474 
 TCCACCTGCTGTCCAACTTC KCNK 18 R  
66 GCGTGCAAAAAGGCGAGAAT KCNH1 var1 F 450 
 AGGCACTAACCTCATCCACG KCNH1 var1 R  
67 GTTCATCATCGCCAACGCTC KCNH2 var1 F 570 
 ATGGCTGTCACTTCGTCCAG  KCNH2 var1 R  
68 ACTTCACCTTCAGCAGCCTC KCNH2var2 F 591 
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 AGGGCATTTCCAGTCCAGTG KCNH2 var2 R  
69 GCACTGACGTACTGTGACCT KCNH5 var1 F 458 
 AGTTCCATGGCATCACGGTT KCNH5 var1 R  
70 AGAACTGTACCTCACGCAGC KCNMA1 var1 F 421 
 AAACTCATAGGGCGGGTTGG KCNMA1 var1 R  
71 CACACGTGAAGTCCAGCTCT KCNN3 var1 F 435 
 CTTTCACAGACACGGACGGT KCNN3 var1 R  
72 CTCATCGTGGCCTTTCATGC KCNN4 F 479 
 GTGGCATTAACAGCCTGCCT KCNN4 R  
73 GGCCCCATCTACAACTACCG CACNA1C var2 F 436 
 AACCCTTGGGTTTGAAGGCA CACNA1C var2 
R 
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4.2.2 Immunostaining for ion channel proteins 
 
Following PCR experiments, ORAI-3 and KCNK-1 protein ion channel expression 
was investigated by immunocytochemistry. Whole cell populations of PC3 cells were 
grown on 8-well chamber slides (Nunc Lab-Tek Chamber Slide System). Cells at day 
5 of culture were trypsinised, counted and plated at a concentration of 500 cells in 
each well with 200 µL of medium. After 3 days of culture, the cells were fixed with 
4% PFA and immunocytochemistry was performed as outlined in Chapter 2.  
 
ORAI-3 and KCNK-1 antibodies for immunocytochemistry were available 
commercially. As the primary antibodies, anti-ORAI-3 Ab (Sigma product number 
HPA015022) and anti- KCNK1 (abcam; sigmaaldrich) were used at dilutions of 1:50-
1:200 and 1:200-1:500, respectively, as recommended by the manufacturer. Primary 
antibody dilutions and concentrations are as indicated in Tables 17 and 18 below. 
Negative control experiments, in which no primary antibody was added, were used to 
determine non-specific reaction. Experiments with no primary antibody were used as 
a negative control. 
 
An optimisation process was performed, as summarised in Tables 17 and 18 and 
Figures 29 and 30 to establish basic specificity and concentration dependence of 
antigen-antibody interactions (Burry, 2000; sigmaaldrich, 2017). The secondary 
antibody used was goat anti-rabbit IgG-FITC (Southern Biotech- 4030-02) at a 
dilution of 1:500. 
 
 
Table 17. Concentrations of primary antibody anti-ORAI-3 tested in optimisation process for 
immunocytochemistry. 
 
 Dilution 
  
Concentration 1 Anti-ORAI-3    1:50 (4 µg/ml) 
Concentration 2 Anti-ORAI-3   1:100 (2 µg/ml) 
Concentration 3 Anti-ORAI-3   1:200 (1 µg/ml) 
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Table 18. Concentrations of primary antibody anti-KCNK1 tested in optimisation process for 
immunocytochemistry. 
 
 Dilution 
  
Negative control with no 1° antibody 0 µg/ml 
Concentration 1 anti-KCNK1 1:200 (1 µg/ml) 
Concentration 2 anti-KCNK1 1:350 (0.57 µg/ml) 
Concentration 3 anti-KCNK1 1:500 (0.4 µg/ml) 
 
 
 
 
4.2.3 Assessment of MPRCs on proliferation of cancer cell lines in whole 
populations of cells  
 
A number of MPRCs are commonly and safely routinely used in clinical practice, 
mainly for cardiovascular conditions (see section 3.1). Such MPRCs include 
amlodipine, nicorandil and isradipine. These MPRCs, as well as cadmium chloride 
were chosen as a selection of MPRC to test their effects on cancer cell line 
proliferation. Rather than specific MPRCs, broad-channel blockers, and known 
regulators of the cell membrane potential were chosen for this preliminary 
investigation on PC3 proliferation in whole populations.  
 
Table 19 below shows the molecular formula, mass, 2-dimensional structure and 
concentration used in experiments for amlodipine (Sigma-Aldrich A5606), cadmium 
chloride (Sigma-Aldrich 202908), nicorandil (Sigma-Aldrich N3539) and isradipine 
(Sigma-Aldrich I6658). Dose-response was analysed for isradipine at concentrations 
of 5 µM, 10 µM and 100 µM. 
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Table 19. MPRCs used in cell proliferation experiments and their molecular formula, mass, structure and concentrations tested in proliferation 
experiments. 
Drug 
 
Molecular Formula Molecular mass (g/mol) 2-Dimensional structure Concentration 
tested 
 
Amlodipine 
 
 
C20H25ClN2O5 
(PubChem, 2017) 
 
408.9 
 
 
(PubChem, 2017) 
 
530 nM 
 
Cadmium chloride 
 
 
CdCl2 
(PubChem, 2017) 
 
183.3 
 
 
(PubChem, 2017) 
 
1 mM 
 
Isradipine 
 
C19H21N3O5 
(PubChem, 2017) 
 
371.4 
 
 
(PubChem, 2017) 
 
5 µM, 10 µM 
and 100 µM 
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Experiments were performed in whole populations of PC3 cells (not on colonies) as 
initial work to potentially form the foundation for future studies on holo/meroclones 
and paraclones.  
 
PC3 prostate cancer cells were cultured in T80 flasks, as described in Chapter 
sections 2.1.  Cells were trypsinised, counted and subjected to serial dilution to 
50,000 cells/ml. Then, 50,000 cells were pipetted into each well of a 6-well plate 
(Nunc), with 2 ml RPMI with supplements (see section 2.1. The plates were placed in 
a 37oC, CO2 incubator in an IncuCyte™ (Essen Bioscience) live cell imaging system, 
which acquired images every 4 hours for later analysis of confluence. After 24 hours, 
the plates were removed, treated with MPRCs and control plates received vehicle 
only, phosphate buffered saline or dimethylsulfoxide, DMSO. Control wells were 
treated with the same volume of DMSO control used in the experiment wells. Plates 
were placed back in an IncuCyte™ and experiments were terminated once the 
control wells had reached confluence (>90% growth in the vessel), or after a 
maximum or 144 hours (6 days). Experiments were performed in triplicate. 
 
Statistical analyses were performed on numerical cell confluence data obtained from 
the IncuCyte™ at the time intervals specified above. An independent t-test was used 
to assess if there were differences in cell proliferation between the control 
experiments (no MPRC) and experimental arms. IPSS software was used for 
statistical analysis.  
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4.3 Results 
 
4.3.1 Characterisation of ion channel gene expression in 3 prostate cancer 
cell lines 
 
4.3.1.1 Ion channel genes expressed on RT-PCR  
 
Numerous ion channel genes are expressed in the prostate cancer cell lines PC3, 
LNCaP and DU145. PCR was performed on 3 cell passages for each of the cell lines 
PC3, LNCaP and DU145. Figure 27 (A-D) below shows representative agarose gel 
electrophoresis images from PC3 cell PCR reactions for the expression of channel 
genes. Experiments were performed in RNA isolated from three different passages 
of the cell lines. 
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Figure 27. Agarose gel electrophoresis images from PC3 cell PCR reactions. 
0.5 µg template cDNA was used in all PCR reactions per reaction tube. The volume of cDNA 
required for 0.5 µg was calculated and made up to a volume of 12 µl with RNase free water. A 
reaction mixture of Taq PCR mastermix solution, Primer A (forward) 8.4 µM, Primer A (reverse) 
8.4 µM, RNase-free water + Template DNA 0.5 µg was made up to a total volume of 30 µl. 
Agarose gel 1.1% was made up using 150 ml TAEx1 with 1.65g agarose and 10 µl 0.5 μg/ml 
ethidium bromide (Sigma-Aldrich) for visualisation. 10 µl of each PCR product was pipetted 
into wells with 1 μl 10x Blue Juice loading dye (Sigma-Aldrich). 2 µl of 1K base pair DNA ladder 
(ThermoFisher Scientific 10787-018) was also pipetted into a well in each column with <1 μl 
10x Blue Juice loading dye. Gel electrophoresis was performed using a current was applied at 
110V for 70 min followed by the gel imaging under UV light. Presence of product bands at the 
expected sizes is indicative of expression of that specific gene.  
 
Figure (A) shows 1kb plus DNA ladder with labelled base pairs (bp) size bands on ladder and 
PCR products 1–15 with expected size of respective products (bp). Left to right the products 
are: (1) KCNJ1 (418); (2) KCNJ2 (446); (3) KCNJ3 (508); (4) KCNJ4 (620); (5)KCNJ5 (799); 
(6)KCNJ6 (684); (7)KCNJ8 (690); (8)KCNJ9 (534); (9)KCNJ10 (497); (10)KCNJ11 (559);  
(11)KCNJ12 (680); (12)KCNJ13 (592); (13)KCNJ14 (510); (14)KCNJ15 (796); (15)KCNJ16 (479). 
 
 
 
 
(A) 
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Figure (B) shows 1kb plus DNA ladder with labelled base pairs (bp) size bands on ladder and 
PCR products 16–30 with expected size of respective products (bp). Left to right the products 
are: (16) KCNA1 var 1 (598); (17) KCNA2 (579); (18) KCNA3 var 1 (556); (19) KCNA4 var 1 (640); 
(20) KCNA5 (467); (21) KCNA6 (562); (22) KCNA7 (743); (23) KCNA10 (646); (24) ORAI1 (381); 
(25) ORAI2 (495); (26) ORAI3 (554); (27) STIM1 (574); (28) STIM2 (535); (29) GAPDH + DNA (568); 
(30) GAPDH no DNA. 
 
(B)  
 
 
 
 
 
 
Figure C shows 1kb plus DNA ladder with labelled base pairs (bp) size bands on ladder and 
PCR products 31–45 and 66-69 with expected size of respective products (bp). Left to right the 
products are: (31) KCNJ1 var1 (528); (32) KCNJ2 var1 (433); (33) KCNJ3 var1 (438); (34) KCNJ4 
var1 (597);  (35) KCNJ5 (543); (36) KCNJ12 (521); (37) KCNJ13 var1 (424); (38) KCNA7 var1 
(546); (39) ORAI2 var1 (565); (40) ORAI2 var2 (565); (41) ORAI3 (524); (42) STIM1 var1 (470); (43) 
STIM1 var2 (498); (44) STIM2 var1 (548); (45) STIM2 var2 (493); (66) KCNH1 var1 (450); (67) 
KCNH2 var1 (570); (68) KCNH2 var2 (591); (69) KCNH5 var1 (458). 
 
(C) 
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Figure D shows 1kb plus DNA ladder with labelled base pairs (bp) size bands on ladder and 
PCR products 51–65 and 70-75 with expected size of respective products (bp). Left to right the 
products are: (51) KCNK1 (409); (52) KCNK2 var1 (485); (53) KCNK3 (527); (54) KCNK4 (417); 
(55) KCNK5 (593); (56) KCNK6 (402); (57) KCNK 7 var C (594); (58) KCNK9 var1 (488); (59) 
KCNK10 var1 (404); (60) KCNK12 (417); (61) KCNK13 (531); (62) KCNK15 (593); (63) KCNK16 
var1 (419); (64) KCNK17 var1 (524); (65) KCNK 18 (474); (70) KCNMA1 var1 (421); (71) KCNN3 
var1 (435); (72) KCNN4 (479); (73) CACNA1C var2 (436); (74) GAPDH + DNA (568); (75) GAPDH 
no DNA. 
 
(D) 
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The results of PCR gene expression are summarised in Tables 20 and 21.  
 
Table 20. Gene expression detected in the three cell lines PC3, DU145 and LNCaP, performed 
in triplicate in 3 cell passages.  
* Denotes appropriate band size detected on agarose gel electrophoresis following PCR; + 
denotes gene confirmed on sequencing.  
 
Gene 
 
 
Reaction 
number 
 
Band 
Size 
 
 
PC3 
 
 
DU145 
 
 
LNCaP 
 
      
KCNJ1 1 418 
  
 
KCNJ2 2 446 
 
 
KCNJ3 3 508 
 
  
KCNJ4 4 620 
  
 
KCNJ5 5 799 
  
 
KCNJ6 6 684 
  
 
KCNJ8 7 690 * + 
 
 
KCNJ9 8 534 
  
 
KCNJ10 9 497 * + 
 
 
KCNJ11 10 559 
 
* +  
KCNJ12 11 680 * 
 
 
KCNJ13 12 592 
 
* * + 
KCNJ14 13 510 
 
* * 
KCNJ15 14 796 
  
 
KCNJ16 15 479 
  
 
KCNA1 var 1 16 598 
  
 
KCNA2 17 579 
  
 
KCNA3 var 1 18 556 
 
 
KCNA4 var 1 19 640 
 
  
KCNA5 20 467 
 
  
KCNA6 21 562 
  
* + 
KCNA7 22 743  
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KCNA10 23 646 
 
  
ORAI1 24 381 * + *  
ORAI2 25 495    
ORAI3 26 554    
STIM1 27 574    
STIM2 28 535    
GAPDH + DNA 29 568 * * * 
GAPDH no DNA 30     
KCNJ1 var1 31 528    
KCNJ2 var1  32 433 
Band not 
expected size   
KCNJ3 var1 33 438 
  
* + 
KCNJ4 var1 34 597 
Band not 
expected size   
KCNJ5 35 543 
 
  
KCNJ12 36 521 * 
 
* + 
KCNJ13 var1 37 424  * 
KCNA7 var1 38 546 
Band not 
expected size   
ORAI2 var1 39 565 * * * + 
ORAI2 var2 40 565 * *  
ORAI3 41 524 * * * 
STIM1 var1 42 470 
 
  
STIM1 var2 43 498 * * * 
STIM2 var1 44 548 * * * + 
STIM2 var2 45 493 * * * + 
KCNK1 51 409 * * * + 
KCNK2 var1  F 52 485 
 
*  
KCNK3 53 527    
KCNK4 54 417 
 
  
KCNK5 55 593   
KCNK6 56 402    
KCNK 7 var C 57 594    
KCNK9 var1 58 488    
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KCNK10 var1 59 404    
KCNK12 60 417    
KCNK13 61 531 * * * + 
KCNK15 62 593  *  
KCNK16 var1 63 419    
KCNK17 var1 64 524    
KCNK 18 65 474 
 
 * + 
KCNH1 var1 66 450 
 
  
KCNH2 var1 67 570 
  
 
KCNH2 var2 68 591 
  
 
KCNH5 var1 69 458 
  
 
KCNMA1 var1 70 421 * * * + 
KCNN3 var1 71 435 * * * + 
KCNN4 72 479 
  
 
CACNA1C var2 73 436 
  
 
GAPDH + DNA 74 568 * * * 
GAPDH no DNA 75 
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Table 21. Summary of identified ion channel genes detected in 3 prostate cancer cell lines. 
 * Denotes predicted band size detected on agarose gel electrophoresis following PCR. 
 
 
Gene PC 3 
 
 
DU 145 
 
LNCaP 
 
    
KCNJ3 var1   * 
KCNJ8 * 
  KCNJ10 * 
  KCNJ11 
 
* 
 KCNJ12 * 
  KCNJ12 * 
 
* 
KCNJ13 
 
* * 
KCNJ14 * * 
KCNA6 
  
* 
KCNA7 * 
 ORAI1 * * 
 ORAI2 var1 * * 
 ORAI2 var2 * * 
 ORAI3 * * * 
STIM1 var2 * * * 
STIM2 var1 * * * 
STIM2 var2 * * * 
KCNK1 * * * 
KCNK13 * * * 
KCNK15  * 
 KCNK 18 
 
 * 
KCNMA1 var1 * * * 
KCNN3 var1 * * * 
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4.3.1.2 Validation of the PCR products 
 
A number of ion channel genes were expressed in all 3 cell lines PC3, LNCaP and 
DU145. A PCR product of the predicted size is only an indication of the presence of 
the gene of interest in the sample (Bevan et al., 1992). To validate these results, 
some of the PCR products were sequenced using commercial sequencing facilities. 
DNA extraction from agarose gel was performed for these genes, and the purified 
DNA was sequenced by Beckman Coulter Genomics. Finch TV software was used 
to review the results. The NCBI website (http://www.ncbi.nlm.nih.gov/) was used to 
cross-reference the DNA sequence found against the gene it represented. Table 22 
below lists these genes expressed in all 3 cell lines and confirmed on sequencing. 
 
Table 22. Ion channel genes expressed in all 3 cell lines PC3, LNCaP and DU145 and confirmed 
on sequencing. 
 
ORAI1  
ORAI2 var1  
ORAI3  
STIM1 var2  
STIM2 var1  
 STIM2 var2  
 KCNK1  
KCNK13  
KCNMA1 var1  
KCNN3 var1  
 
 
Assessment of gene expression in cells of PC3 colonies holo/meroclones and 
paraclones would be of interest. However, due to time constraints it was not possible 
to assess gene expression by colony type. 
 
After PCR and sequencing, I also sought to analyse the expression of selected ion 
channel proteins to validate the PCR results. 
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4.3.2 Ion channel protein expression of KCNK-1 and ORAI-3 in PC3 colonies 
 
As detailed in section 4.3.1.1, characterisation of gene expression found a number of 
ion channels to be expressed in all 3 prostate cancer cell lines. KCNK-1 and ORAI-3 
are 2 such genes. Expression of KCNK-1 and ORAI-3 proteins in PC3 colonies was 
also investigated by immunocytochemistry. In addition to the commercial availability 
of these antibodies, KCNK1 and ORAI-3 were chosen for further investigation as 
both genes were expressed in all 3 prostate cancer cell lines PC3, LNCaP and DU 
145. KCNK family have been found to be expressed in colorectal cancer (Kim et al., 
2004) and have been implicated, indirectly, in the proliferation of ovarian cancer 
tissue (Innamaa et al., 2013). The ORAI family of genes have been found to be 
involved with resistance to apoptosis in prostate cancer cell lines apoptosis 
(Flourakis et al., 2010) and a more aggressive phenotype in breast cancer cell lines 
(McAndrew et al., 2011). 
 
Optimisation of primary antibodies was performed, as described in the Methods 
section of Chapter 4. Results are shown in Figures 28 and 29. Negative controls for 
immunostaining were performed using no primary antibody. Figures 28A and 29A 
show negative controls demonstrated no staining. Concentration of KNCK-1 primary 
antibody 1:200 (1 µg/ml) is shown in figure 28B and was selected for further 
immunocytochemistry as staining could be seen most clearly using this 
concentration. Similarly, staining for ORAI-3 was visualised most clearly using 
concentration of Anti-ORAI-3 1:50 (4 µg/ml) as shown in figure 29B. 
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Figure 28. Immunocytochemistry and optimisation of primary antibody demonstrating 
expression of KNCK-1 in PC3 cells.  
 
KNCK-1 was detected with a FITC conjugated secondary antibody (green) and counter stained 
with DAPI (blue) and merge images are presented. (A) Negative control (no primary antibody); 
(B) Primary antibody concentration 1:200 (1 µg/ml); (C) Primary antibody concentration 1:350 
(0.57 µg/ml). (D) Primary antibody concentration 1:500 (0.4 µg/ml); Excitation and emission 495 
nm and 525 nm respectively. There is no non-specific staining in the negative control (A). 
Staining is seen using various primary antibody concentrations as shown with clear staining 
in all PC3 cells (B). Cells were grown in eight-well chamber slides, fixed, and stained for 
KNCK-1 using protocols described in section 1.2.2. Z-stacks obtained using an Olympus 
confocal system are shown. Representative images of at least 10 repeats are shown. Scale bar 
A-D: 45 μm.  
 
 
 
 
  
 
      
    
        
D C 
B A 
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Figure 29. Immunocytochemistry and optimisation of primary antibody demonstrating 
expression of ORAI-3 in PC3 cells. 
ORAI-3 was detected with a FITC conjugated secondary antibody (green) and counter stained 
with DAPI (blue) and merge images are presented. (A) Negative control; (B) Primary antibody 
concentration 1:50 (4 µg/ml); (C) Primary antibody concentration 1:100 (2 µg/ml); (D) Primary 
antibody concentration 1:200 (1 µg/ml). Excitation and emission wavelengths 495 nm and 525 
nm respectively. There is no non-specific staining in the negative control (A). Staining is seen 
using various primary antibody concentrations as shown with clear staining in all PC3 cells 
(B). Cells were grown in eight-well chamber slides, fixed, and stained for ORAI-3 using 
protocols described in section 1.2. Z-stacks obtained using an Olympus confocal system are 
shown. Representative images of at least 10 repeats are shown. Scale bar A-D: 45μm. 
 
 
 
 
Immunostaining for expression of KCNK-1 in PC3 holo/meroclone and paraclone 
cells was performed. Figures 30 and 31 show a representative holo/meroclone and 
paraclone respectively. All imaged cells in both colony types express KCNK-1.  
 
Immunostaining for expression of ORAI-3 in PC3 holo/meroclone and paraclone 
cells was performed. Figure 32 and 33 show a representative holo/meroclone and 
paraclone respectively. All imaged cells in both colony types express ORAI-3. 
  
 
    
     
C D 
A B 
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Figure 30. Immunocytochemistry showing expression of KCNK-1 (green) in PC3 cells of a 
holo/meroclone colony. 
Primary antibody mouse monoclonal to KCNK-1 concentration 1:200 detected with a 
flurophore secondary antibody (goat anti-rabbit IgG-FITC 1:500, green) and counter stained 
with DAPI (blue). A-C show the same whole colony: A shows DAPI staining, B signal observed 
for flurophore secondary antibody, C shows A+B merge. D,E,F,G,H,I,J,K,L show higher 
magnification of cells within this colony. D,G,J show DAPI staining, E,H,K show signal 
observed for flurophore secondary antibody; F,J,L show respective merge images. KCNK-1 is 
expressed in all cells of holo/meroclones. Cells were grown in eight-well chamber slides, fixed, 
and stained for KCNK-1 using protocols described in section 1.2.2. Excitation and emission 
wavelengths 495 nm and 525 nm respectively. Z-stacks obtained using an Olympus confocal 
system are shown. Representative images of at least 10 repeats are shown. Scale bar A: 180 
µm; B-D: 15 μm. 
DAPI     KCNK-1         Merge 
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Figure 31. Immunocytochemistry showing expression of KCNK-1 (green) in PC3 cells of a 
paraclone colony. 
Primary antibody mouse monoclonal to KCNK-1 concentration 1:200 detected with a 
flurophore secondary antibody (goat anti-rabbit IgG-FITC 1:500, green) and counter stained 
with DAPI (blue). A-C show the same whole colony: A shows DAPI staining, B signal observed 
for flurophore secondary antibody, C shows A+B merge. D,E,F,G,H,I,J,K,L show higher 
magnification of cells within this colony. D,G,J show DAPI staining, E,H,K show signal 
observed for flurophore secondary antibody; F,J,L show respective merge images. KCNK-1 is 
expressed in all cells of paraclones. Cells were grown in eight-well chamber slides, fixed, and 
stained for KCNK-1 using protocols described in section 1.2.2. Excitation and emission 
wavelengths 495 nm and 525 nm respectively. Z-stacks obtained using an Olympus confocal 
system are shown. Representative images of at least 10 repeats are shown. Scale bar A: 180 
µm; B-D: 15 μm. 
DAPI       KCNK-1       Merge 
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Figure 32. Immunocytochemistry showing expression of ORAI-3 (green) in PC3 cells of a 
holo/meroclone colony. 
Primary antibody mouse monoclonal to ORAI-3 concentration 1:200 detected with a flurophore 
secondary antibody (goat anti-rabbit IgG-FITC 1:500, green) and counter stained with DAPI 
(blue). A-C show the same whole colony: A shows DAPI staining, B signal observed for 
flurophore secondary antibody, C shows A+B merge. D,E,F,G,H,I,J,K,L show higher 
magnification of cells within this colony. D,G,J show DAPI staining, E,H,K show signal 
observed for flurophore secondary antibody; F,J,L show respective merge images. ORAI-3 is 
expressed in all cells of holo/meroclones. Cells were grown in eight-well chamber slides, fixed, 
and stained for ORAI-3 using protocols described in section 1.2.2. Excitation and emission 
wavelengths 495 nm and 525 nm respectively. Z-stacks obtained using an Olympus confocal 
system are shown. Representative images of at least 10 repeats are shown. Scale bar A: 180 
µm; B-D: 15 μm.  
    DAPI     ORAI-3        Merge 
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Figure 33. Immunocytochemistry showing expression of ORAI-3 (green) in PC3 cells of a 
paraclone colony. 
Primary antibody mouse monoclonal to ORAI-3 concentration 1:200 detected with a flurophore 
secondary antibody (goat anti-rabbit IgG-FITC 1:500, green) and counter stained with DAPI 
(blue). A-C show the same whole colony: A shows DAPI staining, B signal observed for 
flurophore secondary antibody, C shows A+B merge. D,E,F,G,H,I,J,K,L show higher 
magnification of cells within this colony. D,G,J show DAPI staining, E,H,K show signal 
observed for flurophore secondary antibody; F,J,L show respective merge images. ORAI-3 is 
expressed in all cells of paraclones. Cells were grown in eight-well chamber slides, fixed, and 
stained for ORAI-3 using protocols described in section 1.2.2. Excitation and emission 
wavelengths 495 nm and 525 nm respectively. Z-stacks obtained using an Olympus confocal 
system are shown. Representative images of at least 10 repeats are shown. Scale bar A: 180 
µm; B-D: 15 μm. 
  DAPI      ORAI-3         Merge 
    
  
  
   
A B C 
D E F 
I 
L K 
G H 
J 
185 
 
To determine if there was non-specific staining of secondary antibody in PC3 cells, 
which could be affecting these results, negative control experiments without primary 
antibody were performed. Figure 34 below shows in the absence of primary antibody 
there is no non-specific staining in cells of a holo/meroclone (A-F) or cells of a 
paraclone (G-L) for secondary antibody. 
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Figure 34. Immunocytochemistry showing negative controls with lack of flurophore secondary 
antibody signal in absence of primary antibody in a PC3 holo/meroclone and PC3 paraclone. 
No significant flurophore secondary antibody signal (goat anti-rabbit IgG-FITC 1:500, green) is 
seen in absence of primary antibody in PC3 holo/meroclones and PC3 paraclones counter 
stained with DAPI (blue). A-C show a holo/meroclone colony: A shows DAPI staining, B signal 
observed for flurophore secondary antibody, C shows A+B merge. D,E,F show higher 
magnification of cells within this colony for DAPI, flurophore secondary antibody, and merge 
respectively. There is no non-specific staining in the holo/meroclone negative control without 
primary antibody. G,H,I show a paraclone colony: G shows DAPI staining, H signal observed 
for flurophore secondary antibody, I shows A+B merge. J,K,L show higher magnification of 
cells within this colony for DAPI, flurophore secondary antibody, and merge respectively. 
There is no non-specific staining in the paraclone negative control without primary antibody. 
Cells were grown in eight-well chamber slides, fixed, and stained using protocols described in 
section 3.7.2. Excitation and emission wavelengths 495 nm and 525 nm respectively. Z-stacks 
obtained using an Olympus confocal system are shown. Representative images of at least 10 
repeats are shown. Scale bar A-C, G-I: 180 µm; D-F, J-L: 15 µm.   
 
 DAPI     Negative Control      Merge 
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4.3.3 Effect of treatment of MPRCs on proliferation of a population of PC3 
cells 
Experiments were performed to test the effect of MPRCs isradipine, amlodipine and 
cadmium chloride on the proliferation of PC3 cells in a whole population. PC3 cells 
were plated in 6-well plates, as described in Chapter section 4.2.3. Cell confluence 
data obtained from IncucyteTM is presented below.  
 
4.3.3.1 Effect of isradipine on proliferation of PC3 cells 
 
Data on cell proliferation in 6-well plates was obtained by imaging using an 
IncucyteTM live cell imaging system every 4 hours. Imaging was commenced 4 hours 
after plating and continued for 144 hours (6 days). Control wells were treated with 
DMSO and experimental wells were treated with isradipine 100µM, 24 hours after 
plating. A growth curve with and without the drug is shown in Figure 35. Confluence 
was observed to be similar in the control and experimental wells until 24 hours 
(Figure 35), after which time the curves diverge as can be seen by the shift in the 
slope of the growth curve ± drugs (Figure 35). The control arm proliferation 
continued, whilst confluence in the treated wells failed to increase. At 144 hours, 
mean confluence in the control well was 97.9% ± 0.1 (n=3) whilst mean confluence 
in isradipine treated wells was lower at 9.8% ± 0.9 (n=3). Statistical testing using an 
independent t-test for the confluence at the end of assay (144h), demonstrates 
percentage of confluence in the wells treated with isradipine was significantly less 
than that in the control wells (p<0.05). 
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Figure 35. Graph showing the % confluence against time of population of PC3 cells when 
treated with isradipine or DMSO control.  
The increase in % confluence is arrested following treatment with isradipine (100 µM). PC3 
prostate cancer cells were cultured in T80 flasks, trypsinised, counted and subjected to serial 
dilution to 50,000 cells/ml. 1 ml of cell solution (50,000 cells) was pipetted into each well of a 6-
well plate (Nunc), with 2 ml RPMI. The plates were placed in a 37
o
C, CO2 incubator in an 
IncuCyte™ (Essen Bioscience) live cell imaging system, which acquired images every 4 hours 
for later analysis of confluence. After 24 hours, the plates were removed, treated with 
isradipine (control plates received vehicle only), and placed back in IncuCyte™ for further 
imaging. Experiments were terminated after 144 hours (6 days). Experiments were performed 
in triplicate. 
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4.3.3.2 Effect of amlodipine on proliferation of PC3 cells 
 
Similarly, the effect ofanother MPRC, amlodipine on proliferation of a population of 
PC3 cells was assessed. Figure 36 shows the proliferation in 3 control wells and 3 
wells treated with amlodipine 530 nM 24 hours following plating. Proliferation does 
continue in cells treated with amlodipine 540 nM but is slower than that observed in 
control cells. At 60 hours, mean confluence in control wells was 70.8% ± 2.9 (n=3) 
compared with mean confluence 58.9% ± 1.7 (n=3) in amlodipine treated wells 
(p<0.05). By 100 hours there was still a lower level of confluence in the amlopidine 
treated wells (92.6% ± 0.7) (n=3) compared with control wells (96.6% ± 0.5) (n=3) 
p<0.05. It should be noted that very low concentration of the drug was used here as 
part of preliminary, proof of concept experiments. 
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Figure 36. Graph showing the % confluence against time of population of PC3 cells when 
treated with amlodipine or DMSO control.  
The increase in % confluence is arrested following treatment with amlodipine 530 nM. PC3 
prostate cancer cells were cultured in T80 flasks, trypsinised, counted and subjected to serial 
dilution to 50,000 cells/ml.1 ml of cell solution (50,000 cells) was pipetted into each well of a 6-
well plate (Nunc), with 2 ml RPMI. The plates were placed in a 37
o
C, CO2 incubator in an 
IncuCyte™ (Essen Bioscience) live cell imaging system, which acquired images every 4 hours 
for later analysis of confluence. After 24 hours, the plates were removed, treated with 
amlodipine (control plates received vehicle only), and placed back in IncuCyte™ for further 
imaging. Experiments were terminated after 144 hours (6 days). Experiments were performed 
in triplicate. Graph showing the confluence % against time of PC3 cells when treated with 
amlodipine 530 nM or DMSO control. Wells treated with amlodipine have a reduction in % 
confluence compared with control wells p<0.05.   
 
                                                                                                
 
4.3.3.3 Effect of cadmium chloride on proliferation of PC3 cells 
 
The effect on PC3 cell proliferation of cadmium chloride 1 mM was similarly tested 
using IncucyteTM. Figure 37 below shows that treatment of cadmium chloride to wells 
at 24 hours following plating completely stopped proliferation of PC3 cells. Figure 
37shows the consistent results of 3 experimental repeats. Independent t-test for 
significance confimed that at 100 hours following cell plating, there was a significant 
difference in the confluence reached by control wells (mean 90.6% ± 2.0 n=3) and 
those treated with cadmium chloride (mean 5.7% ± 0.4 n=3), p<0.05. 
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Figure 37. Graph showing the % confluence against time of PC3 cells when treated with 
cadmium chloride or DMSO control. 
As shown, proliferation of cells is inhibited following treatment with cadmium chloride 1 mM. 
PC3 prostate cancer cells were cultured in T80 flasks, trypsinised, counted and subjected to 
serial dilution to 50,000 cells/ml. 1 ml of cell solution (50,000 cells) was pipetted into each well 
of a 6-well plate (Nunc), with 2 ml RPMI. The plates were placed in a 37ºC, CO2 incubator in an 
IncuCyte™ (Essen Bioscience) live cell imaging system, which acquired images every 4 hours 
for later analysis of confluence. After 24 hours, the plates were removed, treated with cadmium 
chloride 1mM (control plates received vehicle only), and placed back in IncuCyte™ for further 
imaging. Experiments were terminated after 144 hours (6 days). Experiments were performed 
in triplicate. Graph showing the confluence % against time of PC3 cells when treated with 
cadmium chloride 1 mM or DMSO control. Wells treated with cadmium chloride have a 
reduction in % confluence compared with control wells p<0.05.   
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4.3.3.4 Dose–response effect of isradipine on proliferation of PC3 cells 
 
Following these preliminary experiments further investigation of a possible dose-
response relationship between MPRC concentration and effect on reduction of 
proliferation was explored. Dose response experiments were conducted as they are 
suggestive of a cause an effect relationship between isradipine and reduction in 
proliferation. Further experiments were therefore performed using isradipine, 
comparing 3 differing concentrations: isradipine 5 µM, isradipine 10 µM and 
isradipine 100 µM with DMSO control treated wells. Experiments were performed in 
triplicate. Figure 38 below shows the effect of isradipine at these 3 concentrations on 
PC3 cell proliferation.  The figure demonstrates that at 100 hours, the % confluence 
is reduced when wells are treated with either isradipine 5 µM, 10 µM or 100 µM.  
Following incubation to a longer time to 173 hours, there was no difference in 
confluence between isradipine 5 µM and control wells‟ confluence (p=0.29) (n=3). As 
observed in the initial experiment, cell proliferation is halted following treatment of 
isradipine 100 µM at 24 hours.  These results show that isradipine inhibits cell 
proliferation in a concentration dependent manner with an IC50 between 10 and 100 
µM.  
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Figure 38. Graph showing the confluence % against time of PC3 cells when treated with 
isradipine 100 µM, isradipine 10 µM and isradipine 5 µM or DMSO control. 
Increasing concentration of isradipine reduced proliferation of PC3 cells. 
 
4.4 Discussion  
 
The aim of the work presented in this chapter was to begin the characterisation of 
ion channel expression in prostate cancer cell lines and cells of PC3 colonies 
holo/meroclones and paraclones. As there was significant expression of ion 
channels in all 3 prostate cancer cell lines investigated and in cells of both colony 
types, I then also investigated whether the inhibition of expressed channels, by 
known inhibitors, may affect the proliferation of the PC3 prostate cancer cell line 
using 3 broad MPRCs isradipine, amlodipine and cadmium chloride. 
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4.4.1 Expression of ion channel genes 
 
After conducting a review of the published literature as summarised in Chapter 
section 4.1, ion channel families which have been identified in carcinogenesis and 
cancer proliferation in other tumour types, were selected for investigation in prostate 
cancer cell lines. Their expression level in 3 prostate cancer cell lines (PC3, DU145 
and LNCaP) was determined. The profile of expression differed between them, 
though expression of several ion channel proteins was detected in all 3 cell lines. In 
the cases of PC3 cells expression of KCNJ2 var1 and KCNJ4 var1, bands were seen 
but not of the sizes expected (500 base pairs with expected size 597, 700 base pairs 
with expected size 433 respectively). In PC3 expression of KCNA7 var 1, two bands 
were seen at size 400 and 480 with expected band size of 546. These findings may 
be due to splice variants. However, I have not reported these genes as being 
expressed as they were not sent for sequencing confirmation. Gene expression was 
most diverse in the LNCaP cell line, with 15 out of 65 of the tested genes being 
expressed in this cell line. Several ion channel genes e.g. ORAI1, ORAI2 var1, 
ORAI3, STIM1 var2, STIM2 var1, STIM2 var2, KCNK1, KCNK13, KCNMA1 var1 and 
KCNN3 var1 were expressed in all the 3 cell lines. A limitation of this work was the 
lack of a positive control for each primer set used. This would have indicated if a 
gene was not expressed rather than the primer pair developed not functioning.  
 
Although the gene expression is indicative of the presence of mRNA, however, to be 
functionally relevant the protein must be expressed. Testing the presence of proteins 
for all the genes expressed in the 3 prostate cell lines was not planned at the start of 
this research to be within the scope of this project. This scale of analysis could be 
performed using automated protein expression analysis (Symes, PLOS ONE et al 
2013), which was not planned to be undertaken and would have entailed excessive 
costs. As such, I performed immunocytochemistry protein expression of 2 of these 
genes ORAI and KCNK for assessment in holo/meroclones and paraclones types.  
 
Cells within both holo/meroclones and paraclones expressed ion channel proteins 
ORAI and KCNK.  
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4.4.2 Effect of MPRCs on cell proliferation 
 
Ion channel genes were widely expressed in all the 3 prostate cancer cell lines 
investigated, and in cells of holo/meroclones and paraclones PC3 colonies. Further 
investigation was undertaken to determine whether the inhibitors of ion channel 
functions may affect cell proliferation, as proposed for the MPRCs in the patent by 
Ahmed et al (Ahmed et al., 2016) and as shown previously in vitro studies in other 
prostate, melanoma, glioblastoma and ovarian cancer cell lines, the latter in a dose 
dependent manner (Flourakis et al., 2010; Innamaa et al., 2013; Leanza et al., 2012; 
Staudacher et al., 2014). Rather than specific MPRCs, broad-channel blockers, and 
known regulators of the cell membrane potential were used that are frequently used 
in clinical practice were chosen for this preliminary investigation. Concentrations of 
drugs used were physiological. These were calculated from clinical dose 
concentration data from British National Formulary for the volume of the solutions 
used. Experiments were performed with whole cell populations rather than stem cell 
colonies. Due to time constraints it was not possible to perform experiments in stem 
cell-like cells in this study. However, more recent experiments however have shown 
that some of the MPRCs do inhibit putative prostate stem-like cells from cell lines 
(personal communications; experiments in Ahmed laboratory).  
 
PC3 prostate cancer cells were treated with the MPRCs isradipine, amlodipine, 
cadmium chloride, nicorandil. IncuCyteTM imaging of cells was performed from 
plating to confluence. The compounds isradipine, amlodipine and cadmium chloride 
were found to cause a reduction in the proliferation of cells and the percentage of 
confluence.  
 
A possible dose–response effect on proliferation was briefly explored with isradipine. 
The results suggested that treatment with increasing concentration of isradipine was 
associated with further reduction in the extent of cell proliferation.  
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4.5 Chapter 4 Conclusions  
 
This chapter investigated the expression of several families of ion channel genes in 3 
prostate cancer cell lines and foundational work was performed that can be carried 
on in other projects in the laboratory. With reference to the literature, ion channels 
thought to be potentially expressed and important in prostate cancer were identified. 
This study provides a relatively comprehensive characterisation of ion channel gene 
expression in 3 prostate cancer cell lines for the first time. This work is not only 
relevant for the purposes of the stated objectives of this thesis, but also generally for 
the investigations of the fundamental role the ion channels play in physiology. This 
study demonstrates that these genes are expressed in all the 3 cell lines tested: 
PC3, DU145 and LNCaP. However, the profile of expression differs between the cell 
lines. Such analyses could be useful for researchers interested in specific ion 
channel function in prostate and prostate cell lines. This study demonstrates that 
cells within both holo/meroclones and paraclones of PC3 colonies expressed ion 
channel proteins ORAI and KCNK. 
 
Given these finding, investigation was undertaken to determine whether the inhibition 
of ion channel signalling may affect cell proliferation, albeit in whole populations. The 
exploratory experiments performed in this study found that treatment of PC3 cells 
with broad MPRCs was associated with a reduction in cell proliferation. Whether this 
is directly related the inhibition of Wnt signalling could be explored further. Evidence 
from the laboratory experiments conducted independently of this project in the host 
laboratory indicates that this may indeed be the case. 
 
With regards to the published literature of ion channel and cancer, a range of 
mechanisms have been identified in various tumour types as summarised in Table 
13 (section 4.1). On review of the literature, several studies have investigated the 
effect of MPRCs on cancer cell proliferation or apoptosis in vitro.  
 
TREK-1 and TREK-2 are potassium channels, subtype family K, expressed in 
ovarian cancer cell lines, benign ovarian tissue and the majority of ovarian cancer 
tissue  (Innamaa et al., 2013). In vitro, a TREK-1 inhibitor reduced cell proliferation, 
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in a dose dependent manner, and increased apoptosis (Innamaa et al., 2013). 
Although the assay used differed to my experiments, the results are consistent with 
the effects of broad MPRCs isradipine and cadmium chloride found in my study. 
Innamaa et al proposed further work to investigate the therapeutic potential of TREK-
1 blockers is warranted (Innamaa et al., 2013).  
 
Breast cancer cell lines from brain metastases have a higher expression of ion 
channel KCa1.1(KCNMA1), a pore forming α-subunit of BKCa channels (large 
conductance calcium-activated potassium channels),  than those cell lines from other 
metastatic sites  (Khaitan et al., 2009). Increased BKCa channel activity leads to 
greater invasiveness and migration. The BKCa channel may be a key target of 
downstream Wnt signalling as Wnts induce free [Ca2+]i release in prostate cells 
(Thrasivoulou et al., 2013) which acts as an activator of these ion channels. 
Iberiotoxin is an ion channel inhibitor of large-conductance calcium-activated 
potassium channels. Cell migration was reduced in breast cancer cell lines MCF-7, 
MDA-MB-231 and MDA-MB-361 by blocking KCNMA1 by either treatment of cells 
with siRNA that targeted the KCNMA1 gene or by treatment of cells with iberiotoxin 
(Khaitan et al., 2009). 
  
A further study with results consistent with my work was based upon inhibition of  
Human ether-a-go-go-related gene K+ channel hERG / Kv11.1 in human embryonic 
kidney cells and glioblastoma cell lines (Staudacher et al., 2014). hERG is inhibited 
by  doxazosin (Staudacher et al., 2014). Doxazosin induced apoptosis in 2 human 
glioblastoma cell lines and knockdown hERG via si RNA also reduced cell viability of 
a glioblastoma cell line (Staudacher et al., 2014). 
 
Further work in gliomas using the National Cancer Institute reported that KCa 3.1 
was upregulated in 32% of patient cancers and KCa 3.1 expression was associated 
with reduction in survival (Turner et al., 2014). Work in glioma cell lines and a glioma 
mouse model found cell lines with high KCa 3.1 expression had reduced migration 
upon treatment with a channel inhibitor. Cell lines with low KCa3.1 expression 
demonstrated no change in migration following inhibition. Loss of KCa 3.1 function 
also inhibited invasion. Further to this, tumour invasion was reduced when KCa 3.1 
was inhibited in SCID mice (Turner et al., 2014). 
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In a mouse medulloblastoma model, there was found to be increased mRNA of Eag 
2 (Potassium channel, voltage gated eag related subfamily H, member 5.) and low 
levels of Eag 1 in tumour compared with normal cerebellum (Huang et al., 2012). 
Eag 2 expression was elevated in the majority of both primary and recurrent human 
tumours, compared with control tissue (Huang et al., 2012).  Eag2 knockdown 
reduced growth of medulloblastoma and tumourigenicity in a mouse model (Huang 
et al., 2012). 
 
Inhibition of the Kv 1.3 Potassium channel, voltage gated shaker related subfamily A, 
member 3 in a human osteosarcoma cell line and mouse melanoma cell line has 
investigated using Kv 1.3 inhibitors psora-4, PAP-1 and clofazimine (Leanza et al., 
2012).  These inhibitors induced apoptosis in mouse melanoma cell line B16F10 and 
human sarcoma cell line SAOS-2, both of which were demonstrated to express Kv 
1.3. Downregulation of Kv1.3 via siRNA removed the inhibitors‟ effects (Leanza et 
al., 2012). Further to this, in an orthotopic melanoma B16F10 mouse model, 
clofazimine administered intraperitoneally markedly reduced tumour size when 
animals were sacrificed at day 16. Examination of the internal organs of the mice 
demonstrated no obvious other pathology on comparison to non-treated mice 
(Leanza et al., 2012).  
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Chapter 5: Discussion and conclusions 
 
5.1 Summary of findings 
 
 Colonies formed from single PC3 cells can be classified into 2 different 
classes - holo/meroclones and paraclones - by their morphological 
appearances unlike 3 distinct colony types reported previously. 
 
 Colonies formed from single PC3 cells can also be classified into 
holo/meroclones and paraclones by objective characteristics such as cell 
density.  
 
 Colonies of both types respond to 2 classes of Wnt ligands - Wnt 5A and 9B - 
with an intracellular calcium response.  
 
 Calcium response is likely to be a key mediator of Wnt signalling in both 
colony types and in response to both Wnt 5A and Wnt 9B.  
 
 There are differences in Wnt induced increase in [Ca2+]i between the 2 colony 
types. In particular, a greater proportion of cells in holo/meroclones respond to 
Wnts 5A and 9B, a greater proportion demonstrate a secondary elevation in 
[Ca2+]i, and there is a shorter rise time compared to cells in paraclones. These 
differences between holo/meroclones and paraclones are possibly attributable 
to cells in the former being more stem cell like.   
 
 β-catenin is expressed in cells of both colony types with and without Wnt 
activation.  
 
 β-catenin translocation appears to occur in response to Wnt 5A and Wnt 9B 
activation in cells of both holo/meroclones and paraclones. 
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 In the literature, ion channels have been shown to be expressed in a range of 
solid cancers and inhibition of such channels have reduced cell proliferation in 
ovarian cancer, glioblastoma, osteosarcoma and melanoma cell lines.  
 
 Prostate cancer cell lines express a number of ion channels genes from a 
range of families. Investigated ion channels proteins are expressed in cells of 
both PC3 holo/meroclones and PC3 paraclones. 
 
 MPRCs tested reduce proliferation of PC3 cells. Isradipine suppresses whole 
cell population growth, drastically. 
 
 Further investigation of the effects of MPRCs on cell proliferation in cells of 
holo/meroclones and cells of paraclones is of interest. 
 
 If MPRCs can inhibit the proliferation of holo/meroclones or a subpopulation of 
cells driving a cancer in vivo, this mechanism could lead to novel therapies 
using ion channel inhibition as strategy to treat prostate cancer.  
 
5.2 Wnt signalling in PC3 colonies 
 
As discussed in Chapter 1.6, Wnt signalling plays a key role in the self-renewal of 
stem cells and in the human body, the crypts of the small intestine provide an 
example of this maintenance of stem cells and production of differentiated cell types 
(Barker et al., 2012; Potten and Loeffler, 1990). Dysregulated Wnt signalling occurs 
in cancer, most notably in colorectal cancer (Kinzler et al., 1991; Nishisho et al., 
1991). 
 
Cells plated at clonal density are reported to form colonies (Barrandon and Green, 
1987), and cells of holoclones possess cancer stem cell-like characteristics (Li et al., 
2008; Pfeiffer and Schalken, 2010; Zhang and Waxman, 2010), including the ability 
to induce tumour in a xenograft model (Li et al., 2008; Locke et al., 2005; Pfeiffer and 
Schalken, 2010). 
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Unlike 3 distinct colony types reported previously (Li et al., 2008), my study found 
that PC3 cells form 2 colony types, namely holo/meroclones and paraclones. 
However, the colonies reported by Li et al were only morphologically described and 
not objectively characterised to be distinct, as shown in this work. My study 
investigated Wnt signalling in holo/meroclones and paraclones in PC3 cells. My 
research found both holo/meroclones and paraclones express β-catenin. This differs 
from the findings of Li et al showing that paraclones lack the expression of β-catenin. 
However, in my work, the colonies were fixed and stained at an earlier time point as 
compared to that reported by Li et al (2 weeks); this may explain the difference 
observed. In my study, β-catenin was expressed in both colony types after treatment 
with Wnt 5A and Wnt 9B. These findings indicate that the Wnt pathway involving β-
catenin is active in both colony types and that β-catenin Wnt signalling is active after 
treatment with both Wnt 9B and Wnt 5A. 
  
There are no published studies investigating a calcium response in Wnt signalling in 
different colony types in any cell line.  Cells within holo/meroclones demonstrate an 
increase in [Ca2+]i on exposure to both Wnt5A and Wnt 9B. All cells analysed 
demonstrated such a response. These findings are consistent with my initial 
hypothesis that cells of holo/meroclones being more stem cell-like would be more 
response to Wnt ligand stimulation, demonstrated by an [Ca2+]i response. Cells of 
holo/meroclones may have more receptors able to interact and be activated by 
ligand exposure, or may have more significant downstream signalling by Wnt 
mediators. Cells of paraclones also demonstrate a calcium response to Wnt5A and 
Wnt 9B but a proportion of cells do not. Cells within paraclones may be more 
heterogenous in their response to Wnt 5A and 9B.  
 
Cells of paraclones may be more heterogeneous in their expression of Wnt signalling 
target genes. The expression of Wnt target genes in cells of holo/meroclones and 
cells of paraclones, and any differential expression between cells was not 
investigated in this study. As this study has shown that cells of both holo/meroclones 
and cells of paraclones respond to Wnt signalling, an analysis of Wnt target genes in 
different colony types would be of interest.  
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5.3 Ion channels and cancer  
 
Over the past decade there has been interest in expression of ion channel genes in 
cancer, their relevance in malignancy and potential effects of their manipulation in 
clinical practice. The expression of ion channel families has been studied in a 
number of solid cancers, including breast cancer, melanoma, cervical cancer, 
ovarian cancer and astrocytoma.  
 
As discussed in Chapter 4.4.3, several in vitro studies using cancer cell lines have 
demonstrated that specific inhibition of ion channels TREK-1 and TREK-2, 
K+ channel hERG and Kv 1.3 Potassium channel resulted in reduced cell 
proliferation (Innamaa et al., 2013),(Staudacher et al., 2014) (Leanza et al., 2012). 
Little in vivo work has been performed investigating the effect of MPRCs on cancer 
cell proliferation. One study utilised an orthotopic melanoma B16F10 mouse model, 
to test clofazimine administered intraperitoneally (Leanza et al., 2012). Clofazimine 
markedly reduced tumour size when animals were sacrificed at day 16. Examination 
of the internal organs of the mice demonstrated no obvious other pathology 
compared to control non-treated mice (Leanza et al., 2012).  
 
 
 
5.4 Ion channels in prostate cancer cell lines and cancer stem 
cells  
 
The expression of a number of ion channel families has been investigated and 
characterised in this study. Expression of ion channels in cells of different colony 
types - PC3 holo/meroclones and paraclones has been demonstrated.  
 
This work adds to the literature on the limited body of work on ion channel signalling 
in prostate cancer. One study has investigated whether PC3 cells have a differing 
physiological profile of potassium channel as compared to LNCaP cells. Patch clamp 
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testing with characterisation of effects of external calcium levels and compounds was 
performed on PC3 and LNCaP cell lines. Different profiles were observed with 
LNCaP cells demonstrating greater voltage-gated potassium current density. Unlike 
LNCaP cells, a proportion of potassium channels in PC3 cells were Ca2+-sensitive 
and, therefore, more excitable (Laniado et al., 2001). A subsequent study further 
investigated the expression of a subunit of voltage-gated Na(+) channels thought to 
be important in prostate cancer metastases. When PC3 and LNCaP cell lines were 
tested for expression of the subunits by PCR, expression was found to be greater in 
the former than in the less aggressive LNCaP cell line (Diss et al., 2001).  
 
In my study, some variation was noted in the ion channel genes expressed in the 3 
cell lines tested. In contrast to the finidngs of Diss et al, the results of this study 
showed that the LNCaP cell line expressed the greatest number of the ion channel 
genes tested. The selection of families tested in this study was based upon a 
literature review of the classes of ion channels that have been detected in other 
cancer solid types and those that have been found to have functional significance, 
for example, with regard to the prognosis or associated with inhibition of 
proloiferation in vitro.  
 
The discovery that Wnt signalling is electrogenic and could be inhibited by MPRCs is 
a new discovery (Ahmed et al., 2016). Since the termination of this project a clear 
link between ion channels and Wnt signalling has been established (Ahmed, A 
personal communication). In that context the characterisation of multiple ion channel 
genes could be very helpful in progressing this emerging field. This would be of 
particular importance if this work is further explored in prostate cancer stem cells.  
 
There is limited published work on ion chanels in cancer stem-like cells. This project 
investigated the expression of ion channel genes in PC3 colonies. Cells of colonies 
described to be more cancer stem cell-like (holo/meroclones) expressed ion channel 
proteins as did cells of paraclones. A clear difference in expression was not 
demonstrated in cells of different colonies.  Conversely, a study on glioblastoma cells 
found that a differential pattern in ion channel gene expression exists in cells which 
are more cancer stem cell-like. Benign neural and glial tissue does not express the 
ion channel KCa3.1, whilst the glioblastoma cell line U87MG does. In addition, levels 
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of  KCa3.1 mRNA and protein are increased in a stem cell-like sub-population of 
U87MG cells, as compared to the parent population (Ruggieri et al., 2012). 
 
The findings of this study suggest that ion channels may play an important role in 
signalling in prostate cancer cell lines in cells of both holo/meroclones and cells of 
paraclones. Ion channel signalling may be important in prostate cancer and its 
inhibition may provide a mechanism via which proliferation of prostate cancer cells 
may be reduced. There has been limited data on ion channel inhibition in prostate 
cancer. One study investigating the expression of voltage-gated potassium channels 
detected the expression of Kv1.3 on immunostaining of all prostate cancer and 
benign specimens tested. This study demonstrated that the potassium channel 
agonists minoxidil,1-ethyl-2-benzimidazolinone (EBIO) and diazoxide increased PC3 
cell proliferation. Conversely, treatment with potassium channel-blockers 
dequalinium, amiodarone and glibenclamide, resulted in reduced proliferation and 
apoptosis of PC3 cells (Abdul and Hoosein, 2002). 
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5.5 MPRCs as a therapy 
 
If effective in reducing proliferation of populations of cancer cells, the potential lack of 
toxicity of MPRCs makes them an attractive therapeutic strategy compared to 
conventional cancer treatments such as chemotherapy which have many side 
effects. Ion channel blockers are a class of compounds in widespread clinical use. 
The expression of ion channel families has been studied in a number of solid 
cancers, including breast cancer, melanoma, cervical cancer, ovarian cancer and 
glioma. Several studies have demonstrated cell proliferation can be reduced in vitro 
by the inhibition of ion channels found to be active or over-expressed in that 
particular cancer. Examples include inhibition of  TREK-1 inhibitor in an ovarian 
cancer cell line (Innamaa et al., 2013); inhibition of KCNMA1 in breast cancer cell 
lines by either treatment of cells with siRNA that targeted the KCNMA1 gene or by 
treatment of cells with iberiotoxin (Khaitan et al., 2009); inhibition of  Human ether-a-
go-go-related gene K+ channel hERG / Kv11.1 in glioblastoma cell lines using either 
doxazocin or via si RNA also reduced cell viability of a glioblastoma cell line 
(Staudacher et al., 2014); inhibition of KCa3.1 in glioma cell lines (Turner et al., 
2014); inhibition of  Eag2 in medulloblastoma (Huang et al., 2012); inhibition of Kv 
1.3 in a human osteosarcoma cell line and mouse melanoma cell line (Leanza et al., 
2012).   
 
 
 
5.6 Further research  
 
In this study I have shown effects on [Ca2+]i on Wnt signalling in PCR colonies and 
MPRC inhibition of cell proliferation. There are several strands of interest in further 
investigating the possible differential response of cells in holo/meroclones and cells 
of paraclones to Wnts and in particular, in investigation of the effects of MPRCs on 
Wnt signalling directly in colonies.  
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Cells of paraclones may be more heterogeneous in their expression of Wnt signalling 
target genes. The expression of Wnt target genes in cells of holo/meroclones and 
cells of paraclones, and any differential expression were not investigated in this 
study. As this study has shown that cells of both holo/meroclones and cells of 
paraclones respond to Wnt signalling, an analysis of Wnt target genes in different 
colony types would be of interest.  
 
Further work may involve investigating the effect of Wnt signalling in cells of colonies   
treated with MPRCs. Any differences in [Ca2+]i response, or Wnt target gene 
expression between cells of different colony types could be investigated.  One would 
hypothesise that treatment with MPRCs would inhibit the [Ca2+]i response seen in 
this study observed when cells within colonies were treated with Wnt 5A and Wnt 9B. 
Inhibition of Wnt signalling by MPRCs may supress Wnt target gene expression. 
Such work would strengthen the proposed relationship between Wnt signalling, 
[Ca2+]i response and inhibition of cell proliferation by MPRCs proposed in this study.  
 
Initial, exploratory experiments performed in this study found MPRCs currently used 
in clinical practice reduced the proliferation of PC3 cells. Further research on the 
specific and any differential effects of MPRCs on cells of holo/meroclones and cells 
of paraclones, and effects on proliferation is of interest. It is possible that a profile of 
ion channel expression in cells of holo/meroclones is associated with malignant 
proliferation, invasion and metastases, and it may be possible to target this profile of 
channels with specific inhibitors. These concepts and profiling require further 
investigations both in vitro and in vivo. MPRCs may provide a targeted, relatively 
well-tolerated therapy for men with prostate or other cancers. MPRCs with a 
relatively low toxicity profile compared with chemotherapy would therefore be 
attractive for further study.   
 
 
  
207 
 
5.7 Conclusions 
 
Although significant advances have been made in the management of prostate 
cancer over the past decade, there is a lack of targeted therapies. There is a 
particular need to improve treatments for use in advanced, castrate-resistant 
disease. The effects on the PC3 castrate resistant cell line are highly important since 
novel treatment strategies are required for this population of men who currently have 
limited treatment options available to them. 
 
In this study, PC3 colonies were characterised into 2 types: holo/meroclones and 
paraclones. I also show, for the first time, that Wnt signalling is active in both colony 
types was observed in response to 2 Wnts ligands: 5A and 9B.  
 
Ion channel signalling may be regulator of the Wnt pathway and several other 
cellular processes. It is known that Wnt signalling is important in prostate cancer. 
The body of work to date suggests that ion channels are expressed in various 
cancers, but there is little in the literature regarding prostate cancer. This study, for 
the first time, characterises the expression of ion channels in 3 prostate cancer cell 
lines and ORAI3 and KCNK protein expression in cells of both holo/meroclones and 
paraclones. Inhibition of ion channels with a selection of MPRCs resulted in reduced 
PC3 cell proliferation. Targeting a profile of ion channels may provide a mechanism 
against prostate cancer cell proliferation. This may lead to the development of a new, 
novel therapy with limited toxicity for the treatment of prostate and other cancers.  
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